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ABSTRACT 
 
 
 Global nutrient restriction or excess can influence umbilical hemodynamics in sheep fetuses 
(Chapter 2). We hypothesized that a specific component of the diet, namely maternal metabolizable protein 
(MP), would alter placental function. When MP restriction during late gestation occurs, we hypothesized that 
there would be a decrease in the sensitivity to bradykinin (BK) of the placental vascular arteries. In 
experiment 1, ewes received one of three isocaloric dietary treatments during late gestation: MP60: 60% of 
MP requirements; MP80: 80% of MP requirements; and MP100: 100% of the MP requirements on a dry 
matter basis from day 100 to 130 of gestation. In experiment 1, fetal and placental mass were not affected 
by dietary treatment; however, placental function was altered by a maternal diet low in protein.  Ewes not 
meeting MP requirements during late gestation had fetal placental arteries that were more sensitive to BK-
induced vasorelaxation; therefore we reject our hypothesis for experiment 1.  In order to understand the 
mechanism of BK-induced vasodilation in the placental arteries, experiment 2 was designed.  We 
hypothesized that MP level would alter the mechanism of BK-induced vasorelaxation in placental arteries.  
In experiment 2, ewes received one of three isocaloric dietary treatments during late gestation: MP60: 60% 
of MP requirements; MP100: 100% of the MP requirements; and MP140: 140% of MP requirements from 
day 100 to 130 of gestation.  Maternal protein level during gestation did not impact the mechanism of BK-
induced vasodilation; therefore we reject our hypothesis for experiment 2. However, the maternal and fetal 
placental vessels responded to BK through different mechanisms.  In maternal placental arteries, pathways 
involving endothelium-derived hyperpolarizing factors (EDHF) and nitric oxide (NO) were responsible for 
BK-induced vasodilation, while the prostacyclin (PGI2) pathway did not greatly contribute to BK-induced 
vasodilation.  The fetal placental arteries responded to BK through a mechanism that does not involve 
EDHF, NO, or PGI2, indicating that BK-induced vasorelaxation of the fetal placental arteries may be 
mediated through an unclassified EDHF-like pathway.  It is important to realize the maternal and fetal 
placental arteries may respond to BK-induced vasodilation through different pathways when considering 
possible therapeutics for compromised pregnancies.  
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CHAPTER 1.  LITERATURE REVIEW 
Introduction 
Developmental programming is the theory that a maternal insult or stimulus during any period of 
development, both in utero and during the neonatal period, can impair or enhance bodily systems and 
processes of the offspring, and that these impairments or enhancements early in life can have lasting 
effects on the offspring, even into adulthood (Godfrey and Barker, 2000).   Epidemiologic evidence has 
identified maternal nutrition during pregnancy as a factor that affects fetal growth (Barker et al., 1993), 
and poor fetal development has been linked to several disorders including cardiovascular disease and 
hypertension in adult life (Barker et al., 1990; Barker et al., 1993).  
Maternal nutrition may impact blood flow across the placenta, and adequate blood flow to the 
developing fetus is one of the most important factors for successful fetal development.  Increasing uterine 
blood flow during the last half of gestation is critical for oxygen and nutrient delivery to the exponentially 
growing fetus, and alterations in placental blood flow or vasculature may compromise the growth of the 
developing fetus (Ford, 1995; Meschia, 1983; Redmer et al., 2004; Reynolds et al., 2005; Reynolds et al., 
2006; Vonnahme et al., 2013).    In normal pregnancies, uterine and umbilical blood flows increase 
exponentially throughout gestation (Reynolds et al., 1995); however, in models of intrauterine growth 
restriction (IUGR) caused by maternal undernutrition or overnutrition, blood flow to the fetus is reduced 
(Chandler et al., 1985; Wallace et al., 2001; Carr et al., 2012; Lemley et al., 2012).   
An important question to consider is if these alterations to the health of the offspring, placenta, 
and placental blood flow are due to an overall caloric restriction or to restriction of a specific component in 
the diet.  Evidence in rodent models suggests that maternal dietary protein level plays an important role in 
the health of the offspring.  For example, maternal restriction of dietary protein results in offspring with 
glucose intolerance (Dahri et al., 1991; Langley et al., 1994), insulin resistance (Dahri et al., 1991), 
elevated blood pressure (Langley and Jackson, 1994; Ozaki et al., 2001), and vascular dysfunction (Itoh 
et al., 2002; Koumentaki et al., 2002; Torrens et al., 2002; Brawley et al., 2003).   
While much has been learned about the role of maternal protein level and offspring health in 
rodents, this data cannot be directly applied to ruminants, and no data exist on the effects of maternal 
protein levels during gestation on the vascular function of the placenta in sheep.  Because placental blood 
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flow is so important for normal fetal growth, and because maternal protein levels have been shown to 
alter vascular function, it is important to study how maternal protein level might impact the vascular 
function of the placental arteries.   
This literature review will discuss: 1) developmental programming and the importance of protein 
in the maternal diet; 2) provide a brief overview on ovine placental development and the effect of maternal 
protein intake on placental development in ruminants; 3) detail the current literature available on the 
effects of maternal protein level during gestation on placental, fetal, and birth weight as well as 
hypertension in the offspring in both rodents and ruminants; 4) detail the effects of maternal protein level 
during gestation on the vascular function of maternal and offspring arteries; 5) provide a brief introduction 
to the kallikrein-kinin system and the likely importance of kallikrein and bradykinin in reproduction; 6) 
provide a brief overview on the role of arginine and nitric oxide in fetal growth and development; 7) 
discuss the use of non-invasive Doppler ultrasonography to measure the effects of maternal nutrition 
during late gestation on fetal and placental measurements and umbilical artery hemodynamics in sheep; 
8) conclude with a statement of the problem that this dissertation will address.   
This literature review will focus on studies involving ovine models; however, because of the 
limited data regarding maternal protein intake on vascular function in sheep, studies involving other 
species will be included as necessary.   Following the literature review, four studies are reported.  First, a 
study on the effects of maternal under- and over-nutrition on umbilical hemodynamics is presented.  
Following this are three studies on the effects of maternal metabolizable protein intake on fetal and 
placental measurements, blood flow to the fetus, amino acid concentrations in maternal and fetal 
circulation, and vascular function of the maternal and fetal placental arteries.  This dissertation will then 
conclude with a general discussion and future directions.  
 
Developmental programming and maternal protein level during gestation 
Developmental programming is the idea that a maternal insult or stimulus during critical periods of 
development, both in utero and during the neonatal period, can impair bodily systems and processes of 
the offspring, and that these impairments early in life can have lasting effects on the offspring, even into 
adulthood (Godfrey and Barker, 2000).  Data from epidemiologic studies suggests a link between 
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maternal nutrition during pregnancy and cardiovascular disease and hypertension of the offspring later in 
life (Barker et al., 1993; Barker and Clark, 1997). 
Intrauterine growth restriction (IUGR) is often a result of suboptimal maternal nutrition during 
gestation.  About 5% of human infants born in the United States suffer from IUGR (Marsal, 2002) and 
about 8% of human infants suffer from IUGR in other developed countries (Mandruzzato, et al., 2008), 
which can result in fetal and infant mortality and morbidity (Bernstein et al., 2000).   Intrauterine growth 
restriction is also a major concern for the livestock industry since growth restriction during gestation 
causes negative impacts later in life on animal performance, including postnatal growth, body 
composition, and reproductive performance (reviewed in Wu et al., 2006).  While IUGR is a significant 
problem for both humans and livestock species, the development of effective therapeutic options has not 
been possible because of the lack of knowledge about the mechanisms of IUGR.  In order to investigate 
these mechanisms, extensive studies with multiple tissue collections need to be conducted, which is why 
developing animal models of IUGR is important for understanding exactly how IUGR is caused and how 
IUGR can lead to last health effects later in life.  
Several ovine models exist that demonstrate the role of maternal undernutrition during gestation 
on placental and fetal growth (Charlton and Johengen, 1985; Holst et al., 1986, 1992; Faichney and 
White, 1987; McCrabb et al., 1991, 1992a, 1992b; Heasman et al, 1998; Bloomfield et al., 2000; 
Vonnahme et al., 2003; Scheaffer et al., 2004; McMullen et al., 2005; Lekatz et al., 2010a, 2010b; Lemley 
et al., 2012).  An important question to consider is if these alterations to placental and fetal growth are 
due to an overall caloric restriction or to a specific component in the diet.  Evidence in rodent models 
suggests that maternal dietary protein level plays an important role.  The role of maternal protein intake 
during gestation on placental mass, fetal mass, birth weight, blood pressure, and vascular function will be 
discussed in greater detail later in this chapter, but briefly, maternal protein restriction can cause 
alterations to placental mass, fetal mass (Langley et al., 1996a, 1996b; Rees et al., 1999; Koumentaki et 
al., 2002), and birth weight (Langley et al., 1996a, 1996b) in rats.  Further, maternal protein restriction can 
result in hypertension in the offspring (Brawley et al., 2003; Musha et al., 2006; Torrens et al., 2006) and 
decreased arterial sensitivity to endothelium-dependent vasorelaxants (Itoh et al., 2002; Koumentaki et 
al., 2002; Torrens et al., 2002; Brawley et al., 2003; Torrens et al., 2006).  These data in rodents support 
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the theory that maternal protein restriction is one such insult that can alter the placenta and “program” the 
cardiovascular health of the offspring.   
A review by Wu et al. (2004) suggests that maternal protein levels, particularly arginine levels, are 
important to placental and fetal growth.  Figure 1.1 (adapted from Wu et al., 2004) briefly illustrates the 
hypothesized mechanism of how arginine affects fetal growth and development.  When a dam is nutrient 
restricted, there will be less arginine that crosses the placenta and into fetal circulation (Casanello and 
Sobrevia, 2002).  Further, arginine is a common precursor for nitric oxide (NO; Flynn et al., 2002), and 
IUGR is associated with impaired nitric oxide synthesis (Hata et al., 1998) and endothelial nitric oxide 
synthase (eNOS) activity (Casanello and Sobrevia, 2002).  An overview of nitric oxide and its role in 
pregnancy is discussed later in this chapter, but briefly, nitric oxide aids in regulating placental 
angiogenesis, blood flow, and thus, the transfer of nutrients and oxygen from mother to fetus (Hefler et 
al., 2001; Bird et al., 2003), which ultimately impacts placental and fetal growth.  
Because of the importance of arginine and nitric oxide to placental blood flow and nutrient transfer to the 
fetus, it stands to reason that a maternal diet that is low in protein may lead to negative effects on the 
placental and IUGR. Epidemiological studies in humans and animal studies in sheep link maternal 
undernutrition to alterations in placental mass, fetal growth, and birth weight.  Studies in rodents suggest 
that maternal protein may play an important role in the growth and development of the fetus as well as in 
the health of the offspring later in life.  Further, it has been hypothesized that maternal protein level, 
specifically arginine levels may alter placental function and blood flow to the fetus, which ultimately can 
lead to growth restriction and health issues later in life.  Clearly, maternal protein level is important, but 
data regarding maternal protein intake during gestation are largely lacking in sheep.  Therefore, studies 
utilizing an ovine model of maternal protein level are needed in order to understand how maternal protein 
during gestation may alter placental function. 
 
Ovine placental development and the effect of maternal protein intake on placental development 
in ruminants 
The ovine placenta is classified as cotyledonary and epitheliochorial (Senger, 2005).  The 
endometrium of the sheep placenta contains two distinct areas, the aglandular caruncular region and the 
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highly glandular intercaruncular region (Ramsey, 1982).  The caruncles, which are raised areas of the 
uterine endometrium, serve as the site for the implantation and placentation (Wimsatt, 1950; Amoroso, 
1951).  Placentation in the ovine involves the fusion of placental cotyledons with endometrial caruncles to 
form placentomes, which provide the site of exchange between the mother and developing fetus.  
Early gestation is a critical time for the success of the pregnancy; however, because the focus of 
this dissertation is on late gestation, the many changes to the placenta that take place early in gestation 
will not be reviewed in this literature review.  The ovine placenta grows rapidly early in pregnancy and 
then growth ceases during mid-gestation (Barcroft and Kennedy, 1939; Alexander, 1964; Stegeman, 
1974). Placentome formation begins in the fourth week of gestation (Stegeman, 1974; Stevens, 1975).  
The number of placentomes in the gravid uterus vary, but 60 to 100 placentomes is normal (Alexander, 
1964; Wimsatt, 1950).  The total weight of the placentomes reaches a maximum between days 63 and 90 
of gestation (Alexander, 1964; Stegeman, 1974).  In the later stages of gestation, the total placentome 
weight decreases, mainly due to a decrease in the water content of the villi (Barcroft and Barron, 1946), 
which gradually disappears throughout gestation. 
Few studies exist that examine the role of maternal protein intake in placental development in the 
ruminant.  In a study by Amanlou et al. (2011), delivered placenta weight was heavier in ewes that were 
fed 114% of metabolizable protein requirements compared with ewes that were receiving 100% of 
metabolizable requirements during late gestation; however, there is no easily explainable reason why 
these results were observed since maximal placental weight is normally achieved by late gestation 
(Barcroft and Kennedy, 1939; Alexander, 1964; Stegeman, 1974).  Sullivan et al. (2009) observed 
increased placental weight in heifers restricted to 75% of crude protein requirements during early 
gestation compared with heifers consuming 250% of crude protein requirements; however, Sullivan et al. 
(2009) also observed a decrease in placental weight compared to controls when the 75% crude protein 
diet was fed to a different breed of heifers, which suggests that breed may be a factor when considering 
how maternal protein intake affects placental development.  Although differences in placental weight were 
observed between the 75% and 250% crude protein diets, there were no differences in cotyledonary 
weight, cotyledonary surface area, placental efficiency, or the number of caruncles (Sullivan et al., 2009).    
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Figure 1.1.  Schematic of the hypothesized mechanism of how maternal undernutrition, 
specifically maternal arginine restriction, impacts nitric oxide synthesis and, therefore, 
placental angiogenesis and placental blood, which can lead to reduced fetal growth and 
development.  Adapted from Wu et al., 2004.  
 7 
 
 
 Studies designed to investigate how maternal protein intake during late gestation affects placental 
function in sheep, including vasoreactivity of placental arteries, nutrient transport across the placenta, and 
vascularity of the caruncular and cotyledonary tissues, are lacking. These studies would provide 
additional information on the role of maternal protein level on the placental development and function 
during late gestation when fetal growth is most rapid.   
 
The effects of maternal protein level in the diet during gestation on 
placental, fetal, and birth weight and hypertension in the offspring 
This section of the literature review will detail studies involving the effects of maternal protein 
level in the diet during gestation on placental, fetal, and birth weight in animal models.  Because most 
research in this area has been done in rodents, studies utilizing rats will be discussed first followed by 
literature which exists for ruminants.  Data regarding hypertension in the offspring is included when blood 
pressure of the offspring was measured.    
 
Studies in rats 
 Because rodents provide genetic consistency in laboratory trials and have short gestation periods 
and a short average life span, researchers often use rodents as an experimental model.  Rodents allow 
for research across multiple generations and throughout life, making them an attractive model for 
developmental programming experiments.   There are quite a few rodent studies involving maternal 
protein level during gestation; for an overview of the select studies involving the effects of maternal 
protein level during gestation on placental and fetal measurements in rodents discussed in this literature 
review, please refer to Table 1.1.  
 Galler and Tonkiss (1991) were one of the first to investigate the effects of maternal protein level 
on the birth weight of pups in the rat.  Male and female rats were fed diets containing either 25% or 6% of 
casein (by body weight) for 5 weeks before males and females on the same diet were mated.  Pregnant 
female rats continued on their diet throughout gestation.  The offspring from dams on the 6% casein diet 
were lighter at birth compared with offspring from the 25% dams (Galler and Tonkiss, 1991).   According 
to the NRC (1995), the protein requirements for pregnant rats is 15% protein (by body weight); therefore, 
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Galler and Tonkiss did not truly have a control group, rather the study compared protein excess with 
protein restriction.  Despite this, Galler and Tonkiss (1991) were one of the first to link maternal protein 
restriction with decreased birth weight.   
 As mentioned, the NRC (1995) recommends 15% protein (by weight) for pregnant rats; however, 
this is the minimum requirement, and from the rat studies covered in this literature review, it appears that 
a diet containing 18% protein is normal.  It may be important to note that most of the studies reviewed in 
this chapter fed the 18% or 9% protein diets prior to mating.  Since the NRC (1995) recommends 5% 
protein for maintenance in rats, these rats (especially ones on the 18% protein diet) were receiving 
excess protein during the periconceptional period. 
Langley-Evans et al. (1994) conducted one of the first studies to investigate the association 
between maternal nutrition, fetal growth, and the later development of hypertension in the rat.  Fourteen 
days prior to mating, rats were fed either a control (containing 18% casein by weight) or a restricted (9% 
casein by weight) diet. Diets continued through gestation (22 days).  Maternal blood pressure was 
measured throughout pregnancy, pups were weighed at birth, and blood pressure in the offspring was 
measured at 4 weeks of age (Langley-Evan et al., 1994).  Maternal blood pressure was unaffected by the 
low protein diet.  Pups born to dams on the restricted protein diet weighed less at birth and had a higher 
blood pressure at 4 weeks of age compared to control offspring (Langley-Evans, et al., 1994).  Next, to 
evaluate how a low protein diet might affect blood pressure in adult rats not exposed to protein restriction 
in utero, Langley et al. (1994) fed adult male and female rats either a control (containing 18% casein by 
weight) or a restricted (9% casein by weight) diet for 14 days, and found no differences in systolic blood 
pressure.  This was one of the first studies to associate fetal exposure to maternal low protein diets with 
hypertension in offspring in rats.   
After this study, Langley and Jackson (1994) designed a study to investigate differing levels of 
maternal protein in the diet.  Female rats were fed diets containing either 18, 12, 9, or 6% of protein by 
weight from 14 days before breeding until delivery and found pups from the 6% group weighed less at 
birth than pups from any other treatment group.  Further, the offspring from the 6% protein dams were 
lighter than offspring from the 18% protein dams from week 1 until week 21 of life.  Mean offspring 
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Table 1.1.  An overview of select studies in rats that include maternal protein restriction during gestation and the effects on 
placental weight, fetal weight, and birth weight.  
Authors  Treatments1  
Timing of 
treatments  
Day(s) of 
assessment  
Placental 
weight  
Fetal 
weight  
Birth 
weight 
Brawley et al., 
2003 
 18% casein (C) 
vs. 9% (R) 
casein 
 Day 0 to birth  Birth  N/A2  N/A  NS3 
Guzman et al., 
2006 
 20% casein (C) 
vs. 10% 
caseing (R) 
 Day 0 to birth  Birth  N/A  N/A  ↓ R 
Itoh et al., 2002  18% casein (C) 
vs. 9% (R) 
casein 
 Day 0 to 19  Day 19  NS  NS  N/A 
Koumentaki et al., 
2002 
 18% casein (C) 
vs. 9% (R) 
casein 
 Day 0 to 18  Day 18  ↓ R  ↓ R  N/A 
Langley et al., 
1996a 
 18% casein (C) 
vs. 9% (R) 
casein 
 Day -14 to day 
12, 14, 16, 18, 
20, or birth 
 Day 12, 14, 
16, 18, 20, 
birth 
 12: NS 14: 
↑ R 
16: NS 
18: NS 
20: ↑ R 
Birth: N/A 
 12: NS 
14: ↑ R 
16: NS 
18: NS 
20: ↑ R 
 
 ↓ R 
Langley et al., 
1996b 
 18% casein (C) 
vs. 9% (R) 
casein 
 Day -14 to 20, or 
birth 
 Day 20, birth  20: ↑ R 
Birth: N/A 
 
20: ↑ R 
 
 ↓ R 
Musha et al., 2006  18% casein (C) 
vs. 9% (R) 
casein 
 Day 0 to birth  Day 175 of 
age 
 N/A  N/A  NS 
Rees et al., 1999  18% casein (C) 
vs. 9% (R) 
casein 
 Day -14 to 19 or 
20 
 Day 19, 20  19: NS 
21: ↓ R 
 
19: ↑ R 
21: ↓ R 
 
 N/A 
Torrens et al., 
2002 
 18% casein (C) 
vs. 9% (R) 
casein 
 Day 0 to birth  Birth and day 
19 of female 
offspring 
 Birth: N/A 
19 
(offspring): 
NS  
 NS  NS 
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Table 1.1. An overview of select studies in rats that include maternal protein restriction during gestation and the effects on 
placental weight, fetal weight, and birth weight (continued).  
Authors  Treatments1  
Timing of 
treatments  
Day(s) of 
assessment  
Placental 
weight  
Fetal 
weight  
Birth 
weight 
Torrens et al., 
2006 
 18% casein (C) 
vs. 9% (R) 
casein 
 Day 0 to 19 or 
birth 
 Day 19, birth  19: NS 
Birth: N/A 
 NS 
 
 NS 
1Dietary treatments were diets formulated to provide either 18% protein (based on dam weight; C = control) or 9% protein (based 
on dam weight; R = restricted). 
2N/A = not applicable; this measurement was not taken in the corresponding study 
3NS = P > 0.05 
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systolic blood pressure of the dietary groups was observed to be inversely related to average 
maternal protein intake.  The authors acknowledged that the diets used were not isoenergetic and 
stated the 6 and 9% protein diets were likely deficient in energy as well as protein (Langley and 
Jackson, 1994).   
 The need for isocaloric diets when investigating maternal protein restriction and 
hypertension in the offspring was demonstrated by Langley-Evans (2000).   Pregnant rats were 
assigned to either a control protein diet or to a restricted protein diet.  Further, each diet (control 
and restricted protein) was provided from one of two commercial operations and differed in fat 
content.  Therefore the four diets were control protein-high fat, control protein-control fat, low 
protein-high fat, and low protein-control fat.  Langley-Evans (2000) observed that offspring from 
the low protein dams were lighter at birth compared to offspring from dams fed control protein, 
regardless of fat level.  However, hypertension was only observed in the low protein offspring 
compared with controls when dams were fed a high fat diet.  Langley-Evans (2000) concluded 
that maternal protein level may influence birth weight, but fat content in the diet seems to 
contribute to hypertension in the offspring, and therefore, care should be taken to balance diets 
isocalorically and to make sure content of fat is similar between treatments.  
 Based upon the data of Langley and Jackson (1994), Langley-Evans et al. (1996a) chose 
to investigate an 18% protein diet (control) compared with a 9% protein diet (restricted), but care 
was taken to balance the diets calorically.  The purpose of this study (Langley et al., 1996a) was 
to study how a protein restricted diet during gestation affects fetal growth throughout pregnancy.  
In this study (Langley et al., 1996a), the diets were fed from 14 days prior to breeding until day 
12, 14, 16, 18, 20 of gestation or until birth, and placental and fetal/pup measurements were 
obtained at each time point.  On days 14 and 20 of gestation, placental weight was greater in the 
restricted rats compared with the controls.  The restricted fetuses were heavier compared to the 
controls at days 14, 18, and 20 of gestation, but had lower birth weights (average length of 
gestation = 22 days), which indicates that the fetuses from protein restricted dams did not 
experience the same growth rate during the last two days of gestation as fetuses from the control 
dams.  Indeed, the data show fetuses in the control group increased body mass by 90% during 
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the last two days of gestation whereas fetuses in the restricted group only increased body mass 
by 70% during the same time period (Langley-Evans et al., 1996a).  Further, total organ mass 
growth during the last two days of gestation was blunted in the fetuses from the restricted dams 
compared with fetuses from the control dams (Langley-Evans et al., 1996a).   The reduction in 
body mass in the restricted offspring observed at birth was no longer present at 4 weeks of age.  
In fact, offspring from the protein restricted dams were heavier than control offspring at 4 weeks 
of age, and this increase in mass could not be explained by increases in liver, lung, heart, or brain 
mass.   The blood pressure of the restricted offspring was higher at 4 weeks of age compared 
with the control offspring (Langley-Evans et al., 1996a).  This was the first study in rats to show 
that protein restriction in the maternal diet may lead to increased growth throughout early and mid 
gestation, but this rate of growth is not sustained during rapid exponential growth of the fetus 
before delivery.  Further, despite being lighter at birth, by 4 weeks of age, offspring of protein-
restricted dams were heavier and were hypertensive compared to control offspring (Langley-
Evans et al., 1996a).  
 The fetal growth observation was repeated by Rees et al. (1999) who fed female rats the 
same experimental diets as the Langley-Evans studies (i.e. 18% vs. 9% casein) from 14 days 
before mating until either day 19 or 21 of gestation.  Maternal protein restriction increased fetal 
weight at day 19 of gestation, but by day 21 of gestation, fetuses from restricted dams weighed 
less compared to the controls.  The data indicate the control fetuses experienced a 123% 
increase in mass from day 19 to 21 of gestation compared with only a 78% increase in mass in 
the restricted fetuses over the same time period (Rees et al., 1999).   In this experiment (Rees et 
al., 1999), placental weight was not different between the two groups at day 19 of gestation, but 
by day 21, placental mass was decreased in the restricted animals.   
 Langley-Evans et al. (1996b) again reported that a 9% casein diet from 14 days prior to 
breeding through day 20 or delivery resulted in increased placental and fetal mass at day 20 of 
gestation, but reduced birth weight compared with control animals.  At 7 weeks of age, offspring 
blood pressure was elevated in the restricted group compared with the control group (Langley-
Evans et al., 1996b).  
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 While maternal protein restriction increased fetal weight compared to controls at days 18, 
29, and 20 in some studies (Langley-Evans et al., 1996a, 1996b; Rees et al., 1999), Koumentaki 
et al. (2002) observed decreased fetal and placental weight at day 18 of gestation in protein 
restricted animals compared with controls.  The authors acknowledge that the protein restricted 
fetuses in this study (Koumentaki et al., 2002) experienced reduced mass earlier than fetuses 
from previously published data (Langley-Evans et al., 1996a, 1996b; Rees et al., 1999), but did 
not offer a hypothesis as to why this was observed.  Itoh et al. (2002) and Torrens et al. (2006) 
did not see any differences at day 19 of gestation in fetal or placental mass in dams that were 
protein restricted throughout gestation.  Langley-Evans et al. (1996a, 1996b) and Rees et al. 
(1999) utilized 56, 136, and 38 dams, respectively, while Koumentaki (2002), Itoh (2002), and 
Torrens et al. (2006) utilized 20, 21, and 34 dams, respectively.  Perhaps if a larger sample size 
were studied, the fetal weight data would have been similar to the previously reported studies.  
 Brawley et al. (2003), Musha et al. (2006), and Torrens et al. (2006) all fed pregnant rats 
either 18% or 9% casein from day 0 of gestation until delivery.  Birth weight was not affected by 
maternal protein level in any of the studies (Brawley et al., 2003; Musha et al., 2006; Torrens et 
al., 2006), but blood pressure was elevated in all offspring from protein restricted dams at 15 
weeks of age (Torrens et al., 2006), male offspring from protein restricted dams at day 130 of age 
(Brawley et al., 2003) and in female offspring from protein restricted dams at day 175 of age 
(Musha et al., 2006).  
 Guzmán et al. (2006) fed rats either a 20% or a 10% casein diet from day 0 of gestation 
through weaning at day 21 of age.  Female offspring from the protein restricted dams were lighter 
at birth compared with female offspring from control dams.  This body weight difference persisted 
through weaning (day 21 of age) and into early adulthood (d 70 of age), but was no longer 
present in late adulthood (22 months of age).  
 The studies regarding the effects of maternal protein restriction on placental, fetal, and 
birth weight and offspring hypertension presented in this literature review indicate that when 
maternal protein intake is restricted, fetuses may experience faster growth up until day 20 of 
gestation, but during the last two days of pregnancy, which coincides with rapid, exponential fetal 
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growth in the rat, protein-restricted fetuses do not experience as great of growth as control 
fetuses; however, this pattern was not observed in all studies discussed.  None of the studies 
discussed found that maternal protein restriction increases birth weight in offspring; birth weight 
was either not affected or was decreased with maternal protein restriction.  Also, some of the 
studies discussed highlighted the importance for isocaloric dietary treatments with similar levels 
of all components except protein.  
 
Studies in ruminants 
 There are a limited number of studies investigating the effects of maternal protein levels 
in the diet on placental and fetal growth and offspring weight in ruminants, and data regarding 
maternal protein intake during gestation on vascular function is nonexistent.  In beef cattle, dam 
body weight and body condition score have been improved by late gestation crude protein 
supplementation (Anthony et al., 1986; Stalker et al., 2006; Funston et al., 2010), and these 
improvements may also enhance fetal growth and development.   However, serial fetal 
measurements following maternal protein restriction during late gestation in cattle do not currently 
exist to my knowledge.  
 Micke et al. (2010) fed pregnant heifers a diet that was high in both metabolizable energy 
and crude protein or a diet that was low in both metabolizable energy and crude protein for the 
first trimester of pregnancy.  During the second trimester, half of the heifers on each diet were 
switched to the opposite diet, resulting in four dietary treatments: HH (high metabolizable energy 
and high crude protein for both the first and second trimester), HL (high metabolizable energy and 
high crude protein for the first trimester followed by low metabolizable energy and low crude 
protein for the second trimester), LH (low  metabolizable energy and low crude protein for the first 
semester followed by high metabolizable energy and high crude protein for the second semester), 
and LL (low  metabolizable energy and low crude protein for the first trimester followed by low  
metabolizable energy and low crude protein for the second trimester).  All heifers received similar 
diets during late gestation (Micke et al., 2010).  Fetuses from heifers on the low metabolizable 
energy and low crude protein diet during the first trimester had a decreased curved crown rump 
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length at day 39 of gestation compared to fetuses from heifers receiving the high metabolizable 
energy and high crude protein diet, but this was not observed at day 68 or 95 of gestation (Micke 
et al., 2010).  At day 95 of gestation, the umbilical cord diameter was decreased in the low 
metabolizable energy and low crude protein heifers compared with the high metabolizable energy 
and high crude protein heifers (Micke et al., 2010), suggesting that perhaps umbilical blood flow 
and nutrient delivery to the fetus were blunted in the low group.  Calf birth weight was lower in 
heifers that were on the low metabolizable energy and low crude protein diet throughout the first 
and second trimesters compared with calves from heifers on the high metabolizable energy and 
high crude protein diet throughout the first and second trimesters (Micke et al., 2010).  While this 
data is interesting, it is complicated by the fact that both metabolizable energy and crude protein 
levels were studied.  Further, these dietary treatments were administered during the first two 
trimesters of gestation and not during the last third of gestation when fetal growth is most rapid.  
So while the data of Micke et al. (2010) does provide some insight into the effects of maternal 
protein levels on fetal growth in ruminants, further studies are needed to better investigate the 
role of maternal protein in ruminant fetal development.   
 The majority of studies involving crude protein supplementation during late gestation in 
cattle have found that calf birth weight is not significantly altered by crude protein 
supplementation.  Anthony et al. (1986), Bohnert et al. (2002), Stalker et al. (2006), Martin et al. 
(2007), Larson et al. (2009), and Funston et al. (2010) all reported similar calf weights between 
control and crude protein supplemented dams during late gestation.  
 There are even fewer studies investigating maternal protein level during late gestation in 
the ewe.  Ocak et al. (2005) fed pregnant ewes a control diet or a diet that was formulated to 
provide similar energy but 1.4 times the crude protein requirements from day 85 of gestation to 
lambing.  Lamb birth weight was significantly increased in ewes receiving the high protein diet 
compared with ewes on the control diet (Ocak et al., 2005).  In a study by Amanlou et al. (2011) 
investigating the effect of metabolizable protein supplementation, pregnant ewes were fed one of 
three isocaloric diets for the three weeks prior to lambing: a control diet, formulated to meet 
protein requirements, a moderate protein supplementation diet, formulated to provide a 14% 
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increase in protein requirements, or a high protein supplementation diet, formulated to provide a 
24% increase in protein requirements.  Maternal protein level did not alter lamb birth weight 
(Amanlou et al., 2011).  Delivered placental weight was similar between ewes on the control and 
high protein diets and the delivered placenta from ewes on the moderate protein diet were 
heavier than placentas from the controls and high protein ewes (Amanlou et al., 2011).  
Studies utilizing ruminants for the investigation of the role of maternal protein intake 
during late gestation are largely lacking, and the existing studies vary in design, diet formulation, 
and type of protein studied.  Because of the significance of maternal protein intake on placental 
and fetal measurements, offspring hypertension, and vascular function in rodents (discussed 
below), additional studies are warranted in ruminants. 
 
The effects of maternal protein level during gestation on vascular  
function in maternal and offspring arteries 
Pregnancy is a unique ephemeral state with dramatic alterations in many physiological 
systems, including the vascular system (reviewed in Magness, 1998).  During normal pregnancy 
these physiological changes are important for normal placental and fetal development to produce 
healthy offspring.  There are numerous alterations to ensure adequate blood and thus supply of 
nutrients reaches the developing fetus including dramatic reductions in systemic vascular 
resistance and increases in cardiac output, heart rate, stroke volume, and blood volume; as 
peripheral resistance falls, blood pressure is maintained by a rise in cardiac output (Ford, 1982; 
Rosenfeld, 1984; Magness and Zheng, 1996, Magness, 1998). Compared to all other vascular 
beds, the uteroplacental vascular bed undergoes the most dramatic cardiovascular alterations 
during gestation.   
Endothelial cells are involved in the control of vascular tone through the release of nitric 
oxide (Furchgott and Zawadzki, 1980; Ignarro et al., 1981), prostacyclin (Moncada et al., 1976), 
and endothelium-derived hyperpolarizing factor (Nagao and Vanhoutte, 1993).   Vascular defects 
to the maternal and offspring vasculature beds such as endothelial dysfunction may be caused by 
maternal protein restriction during gestation.  This section of the literature review will address 
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studies that investigate the effects of maternal protein restriction during gestation on vascular 
function both in the dams and in the offspring, and will be limited to the effects on endothelium-
dependent vasorelaxants.  When experiments to study the mechanisms contributing to 
endothelium-dependent vasorelaxants were performed, these results will be included as well.  
Because, currently, the effects of maternal protein level on vascular function are largely lacking 
for ruminant species, this literature review will cover studies in rats, where detailed experiments 
have been conducted on this subject.  For an overview of the select studies involving the effects 
of maternal protein level on vascular function in rats, please refer to Table 1.2.  
Koumentaki et al. (2002) hypothesized that initial vasodilation in pregnant rats is likely to involve 
much of the systemic circulation and that peripheral vasodilatation would be reduced in rats fed a 
low-protein diet during pregnancy.  To test this hypothesis, twenty pregnant rats were fed either a 
diet containing 18% casein (by body weight) or a diet containing 9% casein (by body weight) from 
day 0 until day 18 of gestation.  At this time, cumulative concentration-response curves to the 
endothelium-dependent vasorelaxant acetylcholine (ACh) were obtained in the mesenteric artery 
of the pregnant dams.  The sensitivity of mesenteric arteries to ACh was attenuated in dams fed 
the protein restricted diet compared with the control diet, which supports the original hypothesis.  
To investigate which pathway might be responsible for this endothelium-dependent relaxation, 
dose response curves to ACh were repeated following incubation with a combination of N-nitro-L-
arginine methyl ester (NLA) and indomethacin (INDO), which inhibit nitric oxide synthase and 
cyclooxygenase, respectively.  The maximal response to ACh following incubation with the 
inhibitors was not different from the ACh dose response curve without inhibitors in the control 
animals, suggesting that vasodilation of the mesenteric arteries in the control animals is occurring 
through a pathway not involving nitric oxide or prostacyclin.  However, in the protein restricted 
animals, the maximal response to ACh was blunted by 48% following incubation with the 
inhibitors, which indicates in the restricted animals, one or both of the nitric oxide and prostacyclin 
pathways is mediating mesenteric arterial vasodilation in response to ACh (Koumentaki et al., 
2002).   
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Next, a study was designed to investigate if maternal protein restriction during gestation 
altered the vasoreactivity of the uterine artery (Itoh et al., 2002).  Similar to Koumentaki et al. 
(2002), pregnant rats were fed either the 18% protein diet or the 9% protein diet from day 0 until 
day 18 of gestation.  Uterine arteries were collected and used for dose response curves to ACh.  
In this study (Itoh et al., 2002), maternal protein restriction did not blunt the sensitivity to ACh 
compared to the control animals.  In order to determine if the mechanism driving ACh-induced 
vasorelaxation in the uterine artery involved the nitric oxide pathway, the dose response curve 
was repeated after incubation with NLA, and in both the treatment groups, the maximal response 
to ACh was reduced, which indicates nitric oxide is partly responsible for ACh-induced 
vasodilation of the uterine artery (Itoh et al., 2002).  Itoh et al. (2002) also studied the vasodilatory 
effects of VEGF on the uterine artery and found that VEGF did induce vasodilation of the uterine 
artery in both treatment groups, but that the sensitivity and maximal response to VEGF was 
decreased in the protein restricted group.  The VEGF dose response curves were repeated in the 
presence of NLA, INDO and the combination of the two.  In the 18% casein group, the maximal 
response to VEGF was significantly reduced by INDO alone and further reduced by the 
combination of NLA and INDO, but in the 9% casein group, the maximal response to VEGF was 
reduced by INDO, but was not further reduced by the combination of NLA and INDO (Itoh et al., 
2002). These results indicate that in control fed animals, both the nitric oxide and prostacyclin 
pathways are important for VEGF-mediated vasorelaxation of the uterine artery, but in the protein 
restricted group, the prostacyclin pathway appears to mediate VEGF-mediate relaxation more so 
than the nitric oxide pathway.   
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Table 1.2.  An overview of select studies in rats that include maternal protein restriction during gestation and the effects on vascular 
function of either maternal or offspring arteries.  
Authors  Treatments1  
Timing of 
treatments  
Day(s) of 
assessment  
Vessel(s) 
analyzed  
Endothelium-
dependent 
vasodilator(s)  Summary of results 
Brawley et al., 
2003 
 18% casein (C) 
vs. 9% (R) 
casein 
 Day 0 to 
birth 
 DRC2: Day 87, 
164 of age 
 
BP: Day 130 
of age 
 OMA3  ACh4 
BK5 
 
ACh: ↓ R at days 
87 and 164 
BK ↓ R at days 87 
and 164 
 
BP6: ↑ R 
 
Itoh et al., 2002  18% casein (C) 
vs. 9% (R) 
casein 
 Day 0 to 
19 
 Day 19  UA7 
OMA 
 ACh 
VEGF8 
 UA: ACh: NS9  
      VEGF: ↓ R  
 
OMA: ACh: N/A10 
          VEGF: NS  
 
Koumentaki et 
al., 2002 
 18% casein (C) 
vs. 9% (R) 
casein 
 Day 0 to 
18 
 
 
 Day 18  MMA11  ACh  ACh: ↓ R 
Koumentaki et 
al., 2002 
 18% casein (C) 
vs. 9% (R) 
casein 
 Virgin 
rats, fed 
for 18 
days 
 18 days after 
diets initiated 
 MMA  ACh  ACh: ↓ R 
 
 
 
 
Musha et al., 
2006 
 18% casein (C) 
vs. 9% (R) 
casein 
 Day 0 to 
birth 
 DRC: Day 175 
of age 
 
BP: Day 175 
of age 
 OMA  ACh 
BK 
 ACh: NS 
BK: NS 
 
BP: ↑ R 
 
 
Torrens et al., 
2002 
 18% casein (C) 
vs. 9% (R) 
casein 
 Day 0 to 
birth 
 Day 19 of 
female 
offspring 
 MMA  ACh  ACh: ↓ R 
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Table 1.2.  An overview of select studies in rats that include maternal protein restriction during gestation and the effects on vascular 
function of either maternal or offspring arteries (continued).  
Authors  Treatments1  
Timing of 
treatments  
Day(s) of 
assessment  
Vessel(s) 
analyzed  
Endothelium-
dependent 
vasodilator(s)  Summary of results 
Torrens et al., 
2006 
 18% casein (C) 
vs. 9% (R) 
casein 
 Day 0 to 
19 or birth 
 DRC: Day 19, 
birth 
 
BP: Day 105 
of age 
 UA 
OMA 
 ACh 
VEGF 
 
 
UA: ACh: ↓ R  
 
OMA: ACh: NS  
          VEGF: ↓ R  
 
BP: ↑ R 
1Dietary treatments were diets formulated to provide either 18% protein (based on dam weight; C = control) or 9% protein (based on 
dam weight; R = restricted). 
2DRC = dose response curve  
3OMA = offspring mesenteric artery 
4ACh = acetylcholine  
5BK = bradykinin 
6BP = blood pressure 
7UA = uterine artery  
8VEGF = vascular endothelial growth factor 
9NS = P > 0.05 
10N/A = not applicable; this measurement was not taken in the corresponding study 
11MMA = maternal mesenteric artery 
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Because maternal protein restriction in pregnant rats has consistently resulted in 
hypertension in the offspring (Langley-Evans et al., 1994; 1996a; 1996c; Gardner et al., 1997), 
Brawley et al. (2003), Torrens et al. (2002; 2006), and Musha et al. (2006) began investigations of 
vascular function on the offspring from protein restricted dams.  In order to test the hypothesis that 
exposure to a protein-restricted diet in utero may induce vascular defects in the resistance arteries 
of adult offspring (which may play a part in the maintenance of the elevated systolic blood 
pressure observed in offspring of this rodent model), pregnant rats were fed a diet containing 
either 18% casein or 9% casein from day 0 to delivery (Brawley et al., 2003).   Male offspring from 
this study had increased blood pressure when exposed to low protein in utero compared with male 
offspring from control fed dams (Brawley et al., 2003).  The mesenteric arteries from male 
offspring from these mothers were then analyzed at day 87 or day 164 of age for the response to 
the endothelium-dependent vasorelaxants ACh and bradykinin (BK).   At day 87 of age, the overall 
sensitivity of mesenteric arteries to ACh was attenuated in the male offspring from protein 
restricted dams, but the maximal response was similar between the males from control and protein 
restricted dams.  Also at day 87 of age, the overall sensitivity and the maximal response of 
mesenteric arteries was blunted in males from protein restricted animals compared with offspring 
from control mothers (Brawley et al., 2003).  By day 164 of age, both the sensitivity and the 
maximal response of the mesenteric arteries to ACh and BK were attenuated in male offspring 
from protein restricted mothers (Brawley et al., 2003).  Brawley et al. (2003) was the first to show 
that mesenteric arterial function in response to endothelium-dependent vasorelaxants is impaired 
in rats exposed in utero to maternal low protein diets; therefore, dietary protein restriction in 
pregnancy induces vascular defects in isolated arteries, which results in hypertension of the 
offspring (Brawley et al., 2003).  
Because male offspring subjected to low protein in utero were hypertensive and had 
impaired vascular function (Brawley et al., 2003), Torrens et al. (2002) hypothesized that female 
offspring exposed to low protein in utero would have impaired vascular function during pregnancy 
despite protein restriction outside of the uterus.  To test this hypothesis, pregnant rats were fed 
diets with either 18% casein or 9% casein from day 0 until delivery.  Birth weight of the female 
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dams did not differ (Torrens et al., 2002) and the female offspring received a control diet 
throughout life.  Female offspring were mated, and on day 19 of gestation the mesenteric arteries 
of the now pregnant female offspring were collected, and the dose response curve to ACh was 
obtained.  Mesenteric arteries from pregnant female offspring exposed to low protein in utero were 
less sensitive to ACh than mesenteric arteries from female offspring of control dams (Torrens et 
al., 2006).  These results were the first to associate low protein in utero to impaired vascular 
function in pregnant female offspring (Torrens et al., 2002), and indicate that protein restriction 
during gestation does program the cardiovascular health of female offspring later in life.   
The effect of in utero protein restriction due to maternal diet on the vascular function of 
mesenteric arteries in response to ACh and BK was also investigated in nonpregnant female 
offspring (Musha et al., 2006).  Dams were fed a diet containing either 18% casein or 9% casein 
from day 0 until delivery and female offspring were raised on a control diet throughout life.  By day 
175 of age, blood pressure was increased in female offspring subjected to low protein during fetal 
development compared with control offspring (Musha et al., 2006).  In this study, the mesenteric 
arterial response at day 175 of age to both ACh and BK was not different between female 
offspring from control and protein restricted dams (Musha et al., 2006).  Musha et al. (2006) 
recorded female offspring blood pressure from day 50 to day 175 of life, and blood pressures were 
similar between females from control dams and protein restricted dams until day 175 of age.  
Perhaps differences in the endothelium-dependent relaxant dose response curves were not 
observed at day 175 of age because these female offspring were just beginning to develop 
hypertension compared to the control offspring.  
Another study by Torrens et al. (2006) investigated the effect of maternal protein 
restriction on both the uterine artery of pregnant dams and of the mesenteric arteries of male 
offspring.  Pregnant rats were again fed a diet with either 18% casein or 9% casein from day 0 
until either day 19 of gestation or delivery.  At day 19, maternal uterine arteries were collected for 
vasoactive studies in response to both ACh and VEGF.  The sensitivity of the uterine artery to ACh 
did not differ between controls and protein restricted animals (Torrens et al., 2006), but the 
maximal response of the uterine artery to VEGF was attenuated in the protein restricted dams 
  
23
compared with controls (Torrens et al., 2006).  In order to investigate the mechanism of VEGF-
induced relaxation in the uterine artery, vessels were incubated with NLA, INDO or the 
combination of the two.  In the presence of NLA, uterine arteries reached maximal relaxation, 
indicating that nitric oxide is not responsible for VEGF-induced relaxation of uterine arteries in 
either dietary treatment group.  Rather, Torrens et al. (2006) reports that prostacyclin is likely 
responsible for VEGF-induced relaxation of the uterine artery since incubation with INDO blunted 
uterine arterial response to VEGF.  The addition of NLA to INDO did not change the uterine artery 
response compared to INDO alone, again confirming that prostacyclin contributes to VEGF-
induced relaxation in the uterine artery more so than nitric oxide (Torrens et al., 2006).   
In the offspring from this study (Torrens et al., 2006), mesenteric arterial response at 15 
weeks of age to ACh was attenuated in males exposed to amaternal low protein diet in utero 
compared to males exposed to the control maternal diet in utero.  The offspring mesenteric 
arteries were only subjected to a combination of NLA and INDO rather than the two inhibitors 
separately.  Inhibition of both nitric oxide synthase and cyclooxygenase significantly impaired the 
mesenteric arterial response to ACh in males exposed to the maternal control diet in utero, but 
inhibition of these pathways in males subjected to protein restriction in utero had no effect on the 
mesenteric arterial response to ACh (Torrens et al., 2006).  This suggests that when exposed to a 
maternal diet low in protein during fetal development, the mesenteric arteries of offspring are 
programmed to respond to endothelium-dependent relaxants via a pathway independent of nitric 
oxide or prostacyclin.   
Overall, these studies indicate that maternal protein restriction during pregnancy impairs 
the vascular function of both maternal and offspring arteries in response to endothelium-
dependent vasorelaxants.  When attempting to determine the mechanism of endothelium-
dependent vasorelaxation, the overall results are conflicting.  It appears in some cases maternal 
dietary protein intake influences the mechanism of endothelium-dependent vasodilation and not in 
others.  Further, the data indicate that endothelium-dependent responses in the vessels analyzed 
(maternal mesenteric, uterine artery, offspring mesenteric) may be mediated by different 
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mechanisms.  Further studies are needed to better understand how endothelium-dependent 
vasorelaxants are eliciting vascular responses.  
 
The kallikrein-kinin system 
The scientific interest in the kallikrein-kinin system (KKS) can partly be explained by the 
duality and the complexity of this system.  The KKS includes two kininogens [high molecular 
weight kininogen (HK) and low molecular weight kininogen (LK)], two kallikreins (plasma kallikrein 
and tissue kallikrein), two main kinins [bradykinin and kallidin), two receptors (bradykinin receptor 
1 (BKR1) and bradykinin receptor 2 (BKR2)], and two kinin-forming systems (plasma kallikrein-
kinin system and tissue kallikrein-kinin forming system).  The duality of the KKS extends to the 
pharmacological activities of the system: the kinins of the KKS can result in either vasoconstriction 
or vasodilation.  The complexity of the KKS is evident by the presence of the different constituents 
in plasma and numerous tissues throughout the body.  Further, the KKS has multiple relationships 
with other important physiologic pathways such as the renin-angiotensin and coagulation 
pathways.   For the purpose of this literature, most components of the KKS will only be briefly 
described, and the focus will mainly be on the kinin bradykinin.  
Briefly, the KKS represents a cascade, that when activated, triggers the release of active 
kinins from kininogens by kallikrein enzymes.  These kinins then exert their pharmacological 
activities by binding to specific receptors before being metabolized by various peptidases 
(reviewed in Moreau et al., 2005).  
 
Kininogens  
 High molecular weight kininogen (HK) and low molecular weight kininogen (LK) are the 
precursors of kinins, and are encoded by the same gene but then undergo alternate splicing 
(Kitamura et al., 1985; Takagaki et al., 1985).   The HK circulates in human plasma as an 88- to 
120-kDa single-chain glycoprotein at a concentration of 70 to 90 µg/mL (Adam et al., 1985).  The 
LK ranges from 50 to 68 kDa and circulates in human plasma at a concentration of 170 and 220 
µg/mL (Muller-Esterl et al., 1982; Adam et al., 1985).   
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The kinin-forming systems 
 A simplified illustration of the kinin-forming system is shown in Figure 1.2.  There are two 
main pathways by which kinins are generated.  The plasma kallikrein-kinin system is the more 
complex pathway, and initiates activation of the intrinsic coagulation pathway.  This pathway 
involves HK as the substrate for plasma kallikrein to release bradykinin.  Plasma kallikrein is 
encoded by a single gene and is synthesized in the liver (Asakai et al., 1897; Yu et al., 1998).  It is 
secreted as inactive prekallikrein, which binds to HK (Mandle et al., 1976; Reddigari and Kaplan, 
1989; reviewed in Bhoola et al., 1992).  Contact of plasma with a negatively charged surface leads 
to the binding and autoactivation of factor XIII to factor XIa, activation of prekallikrein to kallikrein, 
and cleavage of HK by kallikrein to release bradykinin (Mori et al., 1981; Kaplan et al, 1997).   
Another mechanism for the initiation and activation of the KKS involves binding of HK to the 
surface of cells such as leukocytes, platelets, and endothelial cells (Zhao et al., 2001).   Binding of 
HK to endothelial cells activates prekallikrein to kallikrein and release of bradykinin from HK 
(Nishikawa et al., 1992; Motta et al., 1998; Lin et al., 2000; Zhao et al., 2001).  
 Tissue kallikreins are members of a large multigene family (Diamandis et al., 2000), of 
which only one gene, KLK1, encodes for an enzyme capable of releasing a vasoactive kinin 
(Clements, 1997; Margolius, 1998; Diamandis et al., 2000).  For the purposes of this review, the 
term “tissue kallikrein” will refer to the product of KLK1, the kallikrein with the ability to release 
active kinins from kininogen precursors.  Tissue kallikrein is widely distributed in a number of 
tissues including the kidney, central nervous system, pancreas, gut, salivary glands, spleen, 
adrenal glands, and blood vessels (reviewed in Bhoola et al., 1992; Mahabeer and Bhoola, 2000).  
Tissue kallikrein is synthesized as a prokallikrein, and trypsin, plasmin, activated plasminogen 
(Yamade &Erdös, 1982), and plasma kallikrein (Takada et al., 1985) have all been shown to 
cleave prokallikrein to the active tissue kallikrein in vitro.  Tissue kallikrein releases the vasoactive 
kallidin from LK, and although LK is considered the main substrate of tissue kallikrein, this enzyme 
is also capable of cleaving HK to release bradykinin (reviewed in Mahabeer and Bhoola, 2000).  
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Kinin receptors 
 There are two G-protein-coupled receptors that mediate the cellular effects of the kinins, 
the BKR1 and BKR2 receptors (Leeb-Lundberg et al., 2005).  Because both BKR1 and BKR2 are 
G-protein-coupled receptors, they are similar in structure with a single polypeptide chain that 
spans the membrane seven times, with the amino  
 
 
 
 
Kininogen 
Kallikrein 
Bradykinin 
EDHF PGI2 NO 
Vasodilation 
Figure 1.2.  A simplified illustration of the kallikrein-kinin system pathway.  
Kininogen is cleaved by the enzyme kallikrein to form bradykinin, a potent 
vasodilator.  Bradykinin elicits vasodilation through one of three classic 
pathways: endothelial-derived hyperpolarizing factor (EDHF), prostacyclin 
(PGI2), or nitric oxide (NO).  
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terminus being extracellular and the carboxyterminus being intracellular.  Despite the similar 
structure, the two proteins are expressed very differently.  Numerous studies have consistently 
shown BKR2 is present in most tissues, particularly in endothelial cells and smooth muscle cells, 
but BKR1 is not expressed in significant levels in normal tissues, rather BKR1 is inducible and 
expression of BKR1 is up-regulated following tissue injury (reviewed in Marceau et al., 1998; 
Christiansen et al., 2004; reviewed in Marceau and Regoli, 2004; Souza et al., 2004; reviewed in 
Moreau et al., 2005).   
 
General pharmacology of bradykinin 
 Bradykinin is a nonapeptide, biologically active, naturally occurring vasoagent (Regoli and 
Barabé, 1980).  Circulating levels of bradykinin are difficult to measure accurately since sampled 
blood contains the necessary components to generate and destroy these peptides in vitro and also 
because bradykinin is an autocoid that is only active close to its site of formation (Blais et al., 
2000).  The vasoresponses elicited by bradykinin are determined by the stimulation of endothelial 
cells from which secondary messengers are released under the influence of Ca2+-sensitive 
cascades to influence the vascular smooth muscle.  Upon bradykinin binding to BKR2, signal 
transduction activates several secondary messenger systems.  Activation of adenylyl cyclase or 
guanylyl cyclase is a transduction mechanism that leads to the production of cAMP and cGMP, 
which is a known vasodilatory mechanism in vascular smooth muscle.  Bradykinin-induced release 
of nitric oxide from the endothelial cells, and the subsequent rise of cGMP in smooth muscle cells, 
leading to vasorelaxation has been documented in a number of systems.  Bradykinin also can lead 
to the release of prostacyclin from the endothelium cells, which will result in an increase in cAMP 
in smooth muscle cells, also leading to vasorelaxation.  Other mechanisms of endothelium-
dependent vasorelaxation have been documented including endothelium-dependent 
hyperpolarization of smooth muscle cells (Batenburg et al., 2004; reviewed in Marceau and Regoli, 
2004; reviewed in Moreau et al., 2005).   
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The role of kallikrein and bradykinin in reproduction 
 Because tissue kallikrein mRNA expression was greatest during the proestrus stage of the 
estrous cycle in the rat (Corthorn and Valdés, 1994), Corthorn et al. (1997) hypothesized that 
kallikrein was stimulated by estrogen.  In order to test this hypothesis, Corthorn et al. (1997) 
ovariectomized rats and assigned them to either a control group (no estrogen) or to a treated 
group that received subcutaneous doses of estrogen or progesterone.  Uteri were collected at 
different days of supplementation and used for a tissue kallikrein assay.  Tissue kallikrein 
expression was increased with estrogen supplementation but not with progesterone, thus Corthorn 
et al. (1997) concluded that estrogen stimulates kallikrein expression in the uterus, which explains 
the increases in kallikrein mRNA observed during high levels of estrogen during the estrous cycle 
(Corthorn and Valdés, 1994).  Further, because uterine kallikrein expression was similar between 
the control and progesterone groups, Corthorn et al. (1997) concluded that progesterone does not 
stimulate kallikrein expression. 
 If kallikrein is stimulated by estrogen, and its expression is increased during the estrous 
cycle (Corthorn et al., 1997) as well as early pregnancy (Valdés et al., 1993), and if kallikrein 
releases the vasoactive peptide bradykinin (reviewed in Bhoola et al., 1992), it stands to reason 
that both kallikrein and bradykinin are important in pregnancy in rats.  Further, because bradykinin 
is a potent vasodilator (reviewed in Bhoola et al., 1992), and because increasing blood flow is 
necessary for successful nutrient transfer to the fetus (Ford, 1995; Meschia, 1983; Redmer et al., 
2004; Reynolds et al., 2005; Reynolds et al., 2006), it is reasonable to assume that kallikrein and 
bradykinin are factors contributing to the necessary increases in blood flow during gestation.  
Moreover, both tissue kallikrein and BKR2 have been localized to luminal and glandular epithelial 
cells in the rat (Valdés et al., 1993; Valdés et al., 1996; Corthorn and Valdés, 1997; Figueroa et 
al., 2001) and human uterus (Clements et al., 1994; Clements and Mukhtar, 1997; Figueroa et al., 
1997), indicating a role for bradykinin in reproduction.  Valdés et al. (2001) further addressed the 
role of kallikrein and bradykinin during gestation by evaluating the temporospatial pattern of 
kallikrein and BKR2 in the human uterus in early and late pregnancy and found kallikrein and 
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BKR2 in the luminal and glandular epithelium, decidual cells, trophoblast invading arteries, 
endothelium, and vascular and myometrial  smooth muscle. Valdés et al. (2001) pointed out these 
are sites that compose the fetomaternal interface and intervene in the contact and attachment of 
the embryo, in placental development, and in parturition, and, therefore, concluded that the 
kallikrein-kinin system and bradykinin likely play a role in embryo attachment, implantation, 
placentation, and maintenance of placental blood flow through processes likely involving 
vasodilation, increased vasopermeability, and stimulation of cell proliferation.   
 
The role of arginine and nitric oxide in fetal growth and development 
The focus of this dissertation centers on maternal protein intake during late gestation on 
placental vascular function.  Because Wu et al. (2004) hypothesized that arginine and nitric oxide, 
which is synthesized from arginine, aid in fetal growth and development, it can be hypothesized 
that a maternal diet low in protein (and therefore arginine) may impact fetal growth and 
development through mechanisms involving nitric oxide.  Further, this dissertation addresses the 
action of bradykinin in placental arteries, and the nitric oxide pathway is one way bradykinin elicits 
vasodilation.  Therefore, this section of the literature will address the topic of arginine and nitric 
oxide in fetal development in sheep.  
 Arginine is a precursor for nitric oxide via nitric oxide synthase (Flynn et al., 2002).  Nitric 
oxide is a major endothelium-derived vasorelaxant and is important for regulating placental-fetal 
blood flows, and, therefore, nutrient transport to the fetus (Bird et al., 2003).   Preventing nitric 
oxide synthesis, either by nitric oxide synthase inhibitors or by endothelial nitric oxide synthase 
knockout models in mice, results in IUGR (Hefler et al., 2001).  Further, feeding arginine-free diets 
to pregnant rats or inhibiting nitric oxide synthesis resulted in increased fetal resorptions, IUGR, 
increased perinatal mortality, and decreased number of live fetuses (Greenberg et al., 1997), but 
when dietary arginine is supplemented to pregnant rats, fetal growth restriction is reversed 
(Vosatka et al., 1998).  The results of Greenberg et al. (1997) indicate that endogenous synthesis 
of arginine is insufficient for pregnant dams, and arginine must be provided from diets to insure 
optimal fetal survival and growth.  
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The effects of a low protein diet during gestation on arginine concentrations and nitric 
oxide synthesis in ruminants has not been investigated, but feeding a low protein diet from mating 
until day 40 or 60 of gestation in pigs resulted in decreased arginine concentrations in fetal plasma 
and allantoic fluid (Wu et al., 1998a) and decreased placental nitric oxide synthase activity (Wu et 
al., 1998b).  In sheep, a 50% global restriction of NRC requirements between day 28 and 78 of 
gestation decreased arginine concentrations in maternal plasma, fetal plasma, and allantoic fluid 
at day 78 in sheep (Kwon et al., 2004) while a 40% global restriction of NRC requirements 
between days 50 and 130 of gestation resulted in decreased arginine in maternal plasma in sheep 
at day 130 of gestation (Lekatz et al., 2011).  Further, global maternal nutrient restriction in sheep 
from day 0 until day 70 of gestation increased arterial blood pressure in the ovine fetus and 
impaired nitric oxide-dependent vasodilation of fetal femoral arteries at day 127 of gestation 
(Ozaki, et al., 2000). 
 These studies indicate that maternal arginine intake during pregnancy is important for the 
growth and development of the fetus.  Maternal diets lacking in arginine may impair fetal 
development or vascular function through mechanisms involving nitric oxide. 
 
         Using Doppler ultrasound to measure the effects of maternal 
 nutrition during late gestation on fetal and placental biometry and umbilical artery 
hemodynamics in sheep 
Historically, animal research has relied on multiple tissue collections in order to gather 
cross-sectional data of fetal and placental growth throughout gestation; however, a major limitation 
of this method is that each time point is derived from a different cohort of pregnancies, which may 
contribute variation to the experimental design.  By contrast, ultrasonography offers a noninvasive 
means of assessing fetal growth longitudinally within a single cohort of pregnancies.   
In clinical practice, umbilical artery Doppler waveform analysis is the primary tool for 
diagnosing and monitoring fetuses with IUGR (Baschat, 2010).  Umbilical artery Doppler 
measurements provide a noninvasive method for evaluating umbilical blood flow and impedance 
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to blood flow, and UA indicies correlate well with directly measured blood flow and vascular 
resistance in normal sheep pregnancy (Maulik et al., 1989; Nimrod et al., 1989; Acharya et al., 
2004). 
The pulsatility index (PI) and resistance index (RI) are pulsed-wave Doppler 
measurements of downstream resistance in arteries.  These indices normally decline as gestation 
progresses and correlate positively with measured umbilical vascular resistance and negatively 
with umbilical blood flow (Newnham et al., 1987; Wallace et al., 2001; Acharya et al., 2004).   
Doppler ultrasonography also allows for measurement of placentomes, fetal biparietal diameter, 
and fetal abdominal girth.  
Very few studies have used noninvasive Doppler ultrasonography to measure umbilical 
artery PI and RI in sheep IUGR models induced by maternal under- or over-nutrition.   For the 
purpose of this literature review, only two studies involving maternal nutrition during late gestation 
in sheep will be discussed. Although limited, the data available are in agreement that fetal growth 
measurements increase with advancing gestation, placentome size peaks around d 80 of 
gestation, and umbilical artery PI and RI decrease throughout gestation in normal pregnancies 
(Carr et al., 2012; Lemley et al., 2012).  
In a well-established model of IUGR in an overnourished model (reviewed in Wallace et 
al., 2006), pregnant adolescent ewes received either a control diet, formulated to meet nutritional 
requirements or a high diet, formulated to exceed nutritional requirements from embryo transfer to 
day 131 of gestation.  Noninvasive Doppler techniques were used to measure umbilical artery 
hemodynamics, fetal growth, and placental growth beginning on day 83 of gestation and 
continuing weekly until day 126 of gestation (Carr et al., 2012).   By day 83 of gestation (baseline 
ultrasound measurements), the overnourished ewes already had decreased placentome size, and 
the placentomes remained smaller than those in control ewes for the remainder of the study.  
Placentome size in both the control and the overnourished ewes decreased throughout gestation 
(Carr et al., 2012).  Fetal measurements, including biparietal distance and abdominal girth were 
significantly reduced in the overfed ewes compared with the controls, and in both groups, fetal 
measurements increased as gestation advanced (Carr et al., 2012).  Umbilical artery RI and PI 
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were increased in the overnourished ewes by day 83 of gestation, and while these indices 
decreased in both the controls and the overfed ewes as gestation progressed, they remained 
increased in the overfed ewes compared with the control ewes (Carr et al., 2012).  
In another established model of IUGR (Lekatz et al., 2010a, 2010b; Meyer et al., 2010a, 
2010b), Lemley et al. (2012) fed pregnant ewes either a control diet, formulated to meet 
requirements or a restricted diet, formulated to provided 60% of requirements from day 50 until 
day 130 of gestation.  In this experiment, noninvasive Doppler ultrasonography measurements 
were obtained on day 50 and repeated every ten days until day 110 of gestation.  Measurements 
obtained included placentome size, fetal biparietal distance, fetal abdominal girth, umbilical artery 
RI and PI, and umbilical artery blood flow.   Placentome size peaked around day 80 of gestation 
and decreased slightly afterwards.  Reductions in fetal abdominal girth in the restricted ewes were 
not observed until day 110 of gestation, and nutritional plane did not impact biparietal distance in 
Lemley et al. (2012), but abdominal and biparietal distance increased as gestation advanced in 
both the control and restricted ewes.  The umbilical artery RI and PI peaked prior to day 80 of 
gestation and decreased as gestation progressed in both treatment groups. Umbilical blood flow 
was decreased by day 80 of gestation in the restricted ewes and remained lower than umbilical 
blood flow in control animals throughout gestation(Lemley et al., 2012).    
In both Carr et al. (2012) and Lemley et al. (2012), placentome diameter peaked by day 80 
of gestation and RI and PI also peaked by day 80 of gestation before decreasing throughout the 
remainder of gestation.  After attainment of maximal size, ovine placentome enhance their 
vascular development (Borowicz et al., 2007).  Perhaps this increase in vascularity allows for the 
decrease in resistance indices as gestation advances (Newnham, et al., 1987; Wallace, et al., 
2001; Acharya et al., 2004).   Because differences in PI and RI are observed before differences in 
fetal size (Carr et al., 2012; Lemley et al., 2012) using these Doppler-derived indices may serve as 
an easy and noninvasive method to recognize compromised pregnancies earlier in gestation.   
 In conclusion, maternal nutritional plane appears to impact umbilical artery indices in 
sheep. More studies are needed to determine how monitoring umbilical resistance could help 
improve fetal outcomes. 
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Statement of the problem 
Developmental programming is of interest to reproductive physiologists since stimuli or 
impairments early in life can alter fetal growth and development as well as the function of 
physiologic systems later in life (Godfrey and Barker, 2000).   Epidemiologic evidence has 
identified poor maternal nutrition during pregnancy as a cause of intrauterine growth restriction 
(IUGR; Barker et al., 1993), and IUGR is a concern for both the human population and the 
livestock industry (Bernstein et al., 2000; Marsal, 2002; Wu et al., 2006; Mandruzzato, et al., 
2008).  While IUGR is a significant problem for both humans and livestock species, the 
development of effective therapeutic options has not been possible because of the lack of 
knowledge about the mechanisms of IUGR.   
Animal models of poor nutrition have linked IUGR to inadequate blood flow to the fetus 
(Chandler et al., 1985; Wallace et al., 2001; Carr et al., 2012; Lemley et al., 2012).  Because of the 
importance of placental blood flow to the developing fetus, it is not surprising that inadequate 
blood flow across the placenta is involved with IUGR.   
Most of the available animal studies investigating IUGR involve global under- or over-
nutrition during pregnancy; therefore, the question if the observed effects of maternal nutrition on 
fetal growth and development are due to overall nutrient levels or to levels of a specific component 
in the diet arises.  Evidence in rodent models suggests that maternal protein level during gestation 
plays an important role in the health of the offspring; however, this data cannot be directly applied 
to ruminants, and data regarding maternal protein intake in ruminants is largely lacking.   
Because rodent data indicates that maternal protein level may alter vascular function, 
particularly endothelium-dependent vasoresponses, and because bradykinin, which is dependent 
on functional endothelium, appears to be important for mediating blood flow during pregnancy, it is 
necessary to examine the role of maternal protein intake on vascular function of the placenta, 
including vasoactive pathways involving bradykinin.  Such studies, which are currently nonexistent 
in sheep, will provide novel insight into the role of maternal protein intake and IUGR in sheep. 
Furthermore, these studies may provide insight to possible therapeutics for compromised 
pregnancies.  
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The first study (Chapter 2) in this dissertation hypothesizes that maternal global under- or 
over-nutrition during gestation will result in altered umbilical hemodynamics.   The next study 
(Chapter 3) hypothesizes that maternal protein restriction will result in reduced amino acid 
concentration in fetal circulation, and the possible reduction in circulating arginine will reduce 
blood flow to the fetus.  Thereafter, in Chapter 4, we hypothesize that maternal protein restriction 
will impair placental vascular function, particularly in response to bradykinin.  Finally, in Chapter 5, 
the hypothesis was that placental arterial vasodilation is mediated at least partly through the nitric 
oxide pathway, and that maternal protein level may impact the pathways mediating bradykinin-
induced vasodilation in the placental arteries.  
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CHAPTER 2.  IMPACTS OF MATERNAL NUTRITIONAL PLANE ON UMBILICAL ARTERY 
HEMODYNAMICS AND FETAL AND PLACENTOME GROWTH IN SHEEP 
 
 
Abstract 
The present study aimed to examine the impact of maternal nutritional plane on umbilical 
hemodynamics.  Ewes (n = 15) were assigned to 1 of 3 dietary treatments [control (CON; 100% of 
NRC requirements), restricted (RES; 60% of CON), or overfed (OVR; 140% of CON)] beginning on 
day 40 of gestation.  Umbilical artery hemodynamics, fetal growth, and placentome growth were 
measured on days 40, 45, 52, 80, 94, and 108 of gestation by Doppler ultrasonography.  The 
percentage change in umbilical artery pulsatility and resistance indices remained steady through 
day 80 of gestation, and then decreased (P ≤ 0.03) by day 108 of gestation.  Moreover, plane of 
nutrition affected (P = 0.03) the percentage change from day 40 in pulsatility index, with RES ewes 
having a greater (P = 0.03) change compared to CON (16.66 vs. -15.57 ± 7.54%) with OVR being 
intermediate (3.19 ± 7.54%).  Fetal biparietal and abdominal diameters increased (P = 0.01) 
throughout gestation, and fetal heart rate decreased (P = 0.01) from day 52 to 108 of gestation.  
Placentome diameter increased (P = 0.01) through day 80 of gestation, was similar (P = 0.64) at 
day 80 and 94 of gestation, and then decreased (P = 0.01) by day 108 of gestation.  Maternal 
plane of nutrition can impact umbilical resistance indices, and ultimately may impact blood flow to 
the fetus.  
 
Keywords:  Maternal nutrition, pulsatility index, resistance index, sheep, umbilical artery 
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Introduction 
Adequate blood flow to the fetus is critical for normal growth and development during 
gestation.  In normal pregnancies, uterine and umbilical blood flows increase exponentially 
throughout gestation (Reynolds et al., 1995); however, in models of intrauterine growth restriction 
(IUGR) caused by maternal undernutrition or overnutrition, blood flow to the fetus is reduced 
(Chandler et al., 1985; Leury et al., 1990; Wallace et al., 2001; Carr et al., 2012; Lemley et al., 
2012). 
The pulsatility index (PI) and resistance index (RI) are pulsed-wave Doppler 
measurements of downstream resistance in arteries.  These indices normally decline as gestation 
progresses and correlate positively with measured umbilical vascular resistance and negatively 
with umbilical blood flow (Newnham et al., 1987; Wallace et al., 2001; Acharya et al., 2004).   Few 
studies have looked at umbilical artery PI and RI in sheep IUGR models, but Galan et al. (1998; 
2005) and Carr et al. (2012) concluded that these indices are increased in the umbilical artery of 
compromised pregnancies.  
We have demonstrated that first parity ewes fed 40% more, or 40% less, than adequately 
fed ewes, have lambs that are growth restricted at or near term (Lekatz et al., 2010a; Lekatz et al., 
2010b; Meyer et al., 2010a, Lemley et al., 2012).  We hypothesized the plane of nutrition will alter 
the umbilical artery PI and RI, which could have severe implications on blood flow to the fetus.   
 
Materials and methods 
 The NDSU Animal Care and Use Committee approved all animal procedures for this study 
(#A0617). Nulliparous, Rambouillet ewes with similar (P = 0.73) body weight (52.6 ± 1.71 kg) 
carrying singleton fetuses (n = 15) were individually housed and on day 40 of gestation ewes were 
assigned randomly to 1 of 3 nutritional plane treatments supplying 60% (RES, n = 5), 100% (CON, 
n = 5) or 140% (OVR, n = 5) of global nutritional requirements  (NRC, 1985; Meyer et al., 2010b). 
Ewes had free access to water and a trace mineralized salt block (Roto Salt Company, Penn Yan, 
NY). Diets were fed once daily at 0800 h in a complete pelleted ration. Ewes were weighed on day 
40 of gestation and then every 7 or 14 days until day 130 at which time ewes were weighed for a 
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final ewe weight.  Ewe body condition score was assigned (1 to 5 scale; 1 = emaciated, 5 = obese) 
by two trained technicians on days 40, 68, 96, 124, and 130, and the two body condition scores 
were averaged for each day.  Diets were adjusted for body weight every 14 days.   
Umbilical artery hemodynamics were assessed using a duplex B-mode (brightness mode; 
Figure 2.1) and D-mode (Doppler spectrum) program of the color Doppler ultrasound instrument 
(model SSD-3500; Aloka America, Wallingford, CT) fitted with a 7.5-MHz finger transducer (Aloka 
UST-672) as previously described (Lemley et al., 2012).  Ultrasonography evaluations took place 
on days 40, 45, 52, 80, 94, and 108 of gestation.  All dams were scanned transabdominally.   
 
 
Figure 2.1.  An image of umbilical cord hemodynamics with pulsatility index (PI) and 
resistance index (RI) measurements present on the left hand side.  The umbilical cord was 
located, the angle of insonation was determined, and wave forms of the cardiac cycle were 
recorded.  Measurements for at least 3 waveforms were averaged to determine PI and RI.  
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Briefly, for each ultrasound examination dams were placed into an elevated crate, wool 
from the abdomen and rear flanks was removed, skin cleaned with soapy water, and sufficient 
Aquasonic transmission gel (Parker Laboratories, Fairfield, NJ) was applied to the probe. Three 
similar cardiac cycle waveforms were obtained and averaged per ewe within a gestation day. 
Cardiac cycle waveforms were plotted in D-mode by velocity (cm/s; y-axis) and time (s; x-axis). 
Fetal heart rate (beats/min), pulsatility index (PI), and resistance index (RI) were calculated using 
preset functions on the instrument (Figure 2.1). Abbreviations for equations are: peak systolic 
velocity (PSV), end-diastolic velocity (EDV), and mean velocity (MnV).  Equations are as follows:  
PI = [PSV (cm/s) – EDV (cm/s)] / MnV (cm/s); RI = [PSV (cm/s) – EDV (cm/s)] / PSV (cm/s).  
Percentage change in PI and RI were calculated as: [(value on any day – day 40 value) / day 40 
value] × 100.  
Placental and fetal growth parameters were assessed using B-mode. Fetal abdominal 
diameter was recorded at the base of the rib cage and above the entry point of the umbilicus 
(Figure 2.2). Fetal biparietal distance was also determined (Figure 2.3). Average placentome 
diameter was determined by randomly selecting ten placentomes and recording diameter at the 
largest position.   
The effects of nutritional plane and day of gestation on ewe body weight, the percentage 
change from day 40 in ewe body weight, ewe body condition score the percentage change from 
day 40 in ewe body condition score, the percentage change from day 40 in umbilical artery PI and 
RI, fetal abdominal diameter, biparietal diameter, heart rate, and average placentome diameter 
were analyzed with the MIXED procedure of SAS (SAS software version 9.2; SAS Institute, Cary, 
NC) using repeated-measures ANOVA (d 40 to 108 of gestation), and if the F test was significant, 
means were separated using the PDIFF option of the LSMEANS statement. The model included 
nutritional plane, day of gestation, and their interaction.  Least squares means and SEM are 
reported.  
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Figure 2.2.  An image of a day 70 fetus. The blue line indicates the fetal abdominal 
width that was obtained by measuring across the body at the umbilicus. Left of the 
blue line, the outline of the kidney is apparent. 
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Results 
There was a nutritional plane by day of gestation interaction (P = 0.01) for ewe body 
weight (Figure 2.4A), the percentage change from day 40 in ewe body weight (Figure 2.4B), ewe 
body condition score (Figure 2.4C), and the percentage change from day 40 in ewe body condition 
score (Figure 2.4D).  Final ewe body weight was less (P = 0.01) in the RES ewes compared with 
the CON and OVR ewes, which did not differ (50.0 vs. 59.7 and 63.8 ± 2.81 kg for RES, CON, and 
OVR, respectively).  The percentage change from day 40 to 130 in ewe body weight was different 
(P = 0.01) among all three groups (-3.66, 9.63, and 25.0 ± 2.16% for RES, CON, and OVR, 
respectively).  Ewe body condition score on day 130 and the percentage change from day 40 top 
Figure 2.3. An image of a day 90 fetus where fetal biparietal diameter was 
obtained by measuring the width of the frontal bone immediately dorsal to the 
orbital sinus.  
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130 of gestation in ewe body condition score were different among all three groups (body 
condition score: 2.4, 3.7, 4.3 ± 0.23 for RES, CON, and OVR, respectively and the percentage 
change in body condition score: -30.3, 4.66, 26.5 ± 5.33% for RES, CON, and OVR, respectively).  
There was little evidence of a nutritional plane by day of gestation interaction for either the 
percentage change in umbilical artery PI (P = 0.60; Figure 2.5A) or RI (P = 0.72; Figure 2.5D).  
Both the percentage change in PI and RI were affected by day of gestation (P ≤ 0.03; Figures 2.5B 
and 2.5E).  Similar patterns were observed for percentage change in PI and RI with values 
remaining steady through day 80 of gestation where values numerically peaked, and decreasing 
thereafter (Figures 2.5B and 2.5E).  Plane of nutrition also affected the percentage change in 
umbilical artery PI (P = 0.03; Figure 2.5C) where CON ewes decreased, and RES ewes increased 
(16.66 vs. -15.57 ± 7.54%) PI with OVR being intermediate (3.19 ± 7.54%).  The effect of plane of 
nutrition on the percentage change in RI followed a similar pattern to that of percentage change in 
PI, but was not statistically different (P = 0.23; Figure 2.5F).   
There was no plane of nutrition by day of gestation interaction (P ≥ 0.17) or main effects 
(P ≥ 0.23) for fetal biparietal diameter, abdominal diameter, heart rate measurements, or 
placentome diameter.  As gestation advanced, fetal biparietal and abdominal diameters increased 
(P = 0.01) and fetal heart rate decreased (P = 0.01) from day 52 to 108 (Table 2.1). Placentome 
diameter increased (P = 0.01) through day 80 of gestation, was similar (P = 0.64) at day 80 and 94 
of gestation, and then decreased (P = 0.01) by day 108 of gestation (Table 2.1).   
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Figure 2.4. The interaction of maternal nutritional plane by day of gestation [Control (CON) = 100% of energy requirements; 
restricted (RES) = 60% of CON; overfed (OVR) = 140% of CON] on ewe body weight (A, BW), the percentage change from day 40 in 
ewe body weight (B), ewe body condition score (C, BCS), and the percentage change from day 140 in ewe body condition score (D).  
Percentage change in ewe body weight and ewe body condition score were calculated as [(value on any day - day 40 value) / day 40 
value] × 100.  * Means between RES and CON and between RES and OVR are statistically different (P ≤ 0.05) on that particular day, 
with CON and OVR being similar (P ≥ 0.05).  **Means between RES and CON, RES and OVR, and CON and OVR are statistically 
different (P ≤ 0.05) on that particular day.  
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Table 2.1. The interaction of nutrition and day of gestation and the main effect of day of gestation on fetal 
biparietal diameter, abdominal diameter, heart rate, and average placentome diameter1 on days 40, 45, 52, 
80, 94, and 108 of gestation. 
 Measurement 
Day of 
gestation 
Biparietal 
diameter, 
cm SE 
Abdominal 
diameter, cm SE 
Heart rate, 
beats per 
minute SE 
Average 
placentome 
diameter1, cm SE 
P-value 0.01  0.01  0.01  0.01  
40 1.22a 0.03 1.27a 0.03 219a 1.06 1.12a 0.06 
45 1.74b 0.04 1.74b 0.02 222a 2.62 1.73b 0.06 
52 2.02c 0.03 2.37c 0.04 221a 1.89 2.17c 0.06 
80 3.73d 0.09 4.58d 0.08 199b 3.14 2.70d 0.06 
94 4.31e 0.11 6.71e 0.12 183c 3.00 2.68d 0.06 
108 5.20f 0.11 7.33f 0.17 178c 2.63 2.42e 0.06 
1Average placentome diameter was obtained by measuring the widest diameter of ten different placentomes 
and calculating the average.  
2Biparietal diameter P-values: Nutrition by day interaction P = 0.38; Nutrition P = 0.32; Day P = 0.01 
3Abdominal diameter P-values: Nutrition by day interaction P = 0.17; Nutrition P = 0.23; Day P = 0.01 
4Heart rate P-values: Nutrition by day interaction P = 0.17; Nutrition P = 0.63; Day P = 0.01 
5Average placentome diameter P-values: Nutrition by day interaction P = 0.56; Nutrition P = 0.52; Day P = 
0.01 
abcdefLSMeans with different superscripts differ by P ≤ 0.05. 
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Figure 2.5.  The impacts of maternal nutritional plane [Control (CON) = 100% of energy requirements; 
restricted (RES) = 60% of CON; overfed (OVR) = 140% of CON; C and F] and day (40, 45, 52, 80, 94, 
and 108 of gestation; B and E) and their interaction (A and D) on percentage change from day 40 in 
pulsatility index (PI; A, B and C) and resistance index (RI; D, E and F). Percentage change in PI and 
RI were calculated as [(value on any day – day 40 value) / day 40 value] × 100.  Plane of nutrition 
dietary treatments were initiated on day 40.  abcLSMeans with different subscripts differ by P ≤ 0.05.  
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Discussion 
Relatively few IUGR models in sheep have reported using Doppler ultrasonography to 
measure fetal and placental growth and umbilical artery indices throughout gestation.  The limited 
data available, including the present study, are in agreement that fetal growth measurements 
increase with advancing gestation, placentome size peaks around d 80 of gestation, and umbilical 
artery PI and RI decrease throughout gestation in normal pregnancies (Galan et al., 1998; Galan 
et al., 2005; Carr et al., 2012; Lemley et al., 2012). 
The ewes in this study were part of a larger study (Meyer et al., 2010a, 2010b) utilizing 
84 ewes.  The observed patterns for ewe body weight, the percentage change from day 40 in 
ewe body weight, ewe body condition score, and the percentage change from day 40 in ewe body 
condition score were expected due to the design of the study (Meyer et al., 2010b). 
In the present study, fetal biparietal and abdominal diameters, measured via Doppler 
ultrasonography, increased with advancing gestation.  This is in agreement with Carr et al. (2012) 
and Lemley et al. (2012) who also used Doppler ultrasonography to measure fetal growth 
throughout gestation.  Using an established model of overfeeding adolescent ewes to result in 
IUGR, Carr et al. (2012) observed IUGR fetuses had smaller abdominal circumferences by day 
98 of gestation and smaller biparietal diameters by day 110 of gestation compared to fetuses 
from control ewes, and these reductions in fetal growth remained through the end of ultrasound 
measurements at day 126 of gestation.  When ewes were nutrient restricted beginning on day 50 
of gestation, reductions in fetal abdominal girth were not observed until day 110 of gestation 
(Lemley et al., 2012).  In the present study, maternal plane of nutrition did not alter fetal biparietal 
and abdominal diameters, however, ultrasound measurements ended at day 108 of gestation.  
Because maternal nutrition did not influence fetal growth measurements until later in gestation 
(Carr et al., 2012; Lemley et al., 2012), it is likely that differences in fetal growth measurements 
would have been observed in the present study if ultrasound measurements continued past day 
108 of gestation.   
 Placentome diameter increased from day 40 to 80, and then decreased by day 108 of 
gestation.  Similar patterns of placental growth have been reported in studies measuring 
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placentome diameter with ultrasound technology (Doizé et al., 1997; Carr et al., 2012; Lemley et 
al., 2012). The percentage change in PI and RI also peaked at day 80 gestation before 
decreasing through day 108 of gestation. This is similar to Lemley et al. (2012), where RI peaked 
at the time when placentome size peaked. After attainment of maximal size, ovine placentome 
enhance their vascular development (Borowicz et al., 2007).  Perhaps this increase in vascularity 
allows for the decrease in resistance indices as gestation advances (Newnham, et al., 1987; 
Wallace, et al., 2001; Acharya et al., 2004).    
 Resistance indices (i.e. PI and RI) decreased ~10-15% in CON ewes, whereas a similar 
increase was observed in RES ewes. Because Doppler-derived measurements of PI and RI 
correlate negatively to blood flow (Acharya et al., 2004) these results could indicate reduced 
umbilical blood flow (Lemley et al., 2012) or reduced placentome vascularity (Luther et al., 2007) 
in the RES ewes compared with CON.  Because differences in PI and RI are observed before 
differences in fetal size (Carr et al., 2012; Lemley et al., 2012) using these Doppler-derived 
indices may serve as an easy and noninvasive method to recognize compromised pregnancies 
earlier in gestation.   
 In conclusion, maternal nutritional plane appears to impact resistance indices of the 
umbilical artery in sheep. More studies are needed to determine how monitoring umbilical 
resistance could help improve fetal outcomes. 
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CHAPTER 3. MATERNAL METABOLIZABLE PROTEIN RESTRICTION DURING LATE 
GESTATION ON UTERINE AND UMBILICAL BLOOD FLOW, FETAL ORGAN WEIGHTS, AND 
MATERNAL AND FETAL AMINO ACID CONCENTRATIONS NEAR TERM IN SHEEP 
 
Abstract 
To examine the effects of maternal metabolizable protein (MP) restriction during late 
gestation on uterine and umbilical blood flow, fetal weight, fetal organ weight, and amino acid 
concentrations in the uterine and umbilical vessels, a subset of 11 ewes with singleton 
pregnancies were assigned to one of three isocaloric diets that were formulated to provide 60% of 
MP (MP60), 80% of MP (MP80), or 100% of MP (MP100) requirements from day 90 to 130 of 
gestation.  On day 130 of gestation, intraoperative uterine and umbilical blood flows were 
obtained as well as serum samples from the uterine artery, uterine vein, umbilical artery, and 
umbilical vein.  Fetuses and placentas were collected and weighed, and fetal organs were 
harvested and weighed.  Serum samples were analyzed for amino acid concentrations.  Ewes on 
the MP60 diet had lighter (P = 0.04) fetuses, shorter fetal CCR (P = 0.05) and smaller fetal girth 
(P = 0.03) but increased (P = 0.02) uterine blood flow relative to fetal weight compared to the 
MP100 ewes, with MP80 being intermediate.  Placental weight did not differ (P = 0.41) among 
treatments.  Fetal adrenal, kidney, and liver weight was lighter (P ≤ 0.05) in the MP60 ewes 
compared with the MP100 ewes, with MP80 ewes being intermediate and fetal lung and pancreas 
weight was lighter (P ≤ 0.02) in the MP60 ewes compared to both the MP80 and MP100 ewes.  
However, when expressed relative to fetal weight, there were no organ weight differences (P ≥ 
0.08).  Glutamine, glycine, leucine, ornithine, serine, and valine concentrations were all impacted 
(P ≤ 0.02) by maternal metabolizable protein level.  In summary, the MP60 diet resulted in lighter 
and smaller fetuses compared to the MP100 ewes despite the increase in uterine blood flow 
relative to fetal weight and similar placental sizes.  Further, the MP60 diet resulted in lighter fetal 
organ weights.  When the ratio of fetal organ weights and fetal weight was calculated, there were 
no treatment differences, indicating synchronous intrauterine growth restriction.  This study 
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provides novel information regarding the effect of maternal metabolizable protein restriction on 
fetal growth, but further, and larger, studies are needed.  
Key words: ewes, blood flow, late gestation, metabolizable protein 
 
Introduction 
 Many models of intrauterine growth restriction caused by alterations to maternal diet in 
sheep exist (Chandler et al., 1985; Wallace et al., 2001; Carr et al., 2012; Lemley et al., 2012).  
Maternal nutrient restriction in sheep alters umbilical blood flow throughout gestation and uterine 
blood flow at day 130 of gestation (Lemley et al., 2012) and also decreases the concentrations of 
amino acids in the uterine artery and umbilical vein (Kwon et al., 2004; Satterfield et al., 2010).  
The question remains if these alterations to blood flow and amino acid concentrations are due to 
an overall global restriction of nutrients or if there is a specific nutrient or nutrients that is driving 
these changes.  Evidence from rodent models of maternal protein restriction demonstrates 
reduced offspring birth weight, elevated blood pressure in the offspring, and decreased vascular 
responses of the uterine artery (Langley et al, 1994; Langley-Evans and Jackson, 1996; Itoh et 
al., 2002).  While much has been learned about the effects of maternal protein restriction in 
rodents, these findings cannot directly be applied to a ruminant, and data regarding the effects of 
protein restriction on uteroplacental function during gestation in ruminants is largely lacking.  
 Therefore, for the purposes of this study, isocaloric diets with varied amounts of 
metabolizable protein were evaluated.  Metabolizable protein (MP) is defined by the NRC (2007) 
as the true protein, which is derived from dietary and microbial protein that is digested post-
ruminally and from which the constituent AA are absorbed from the intestine.  Therefore, 
providing adequate MP during gestation may serve as a more appropriate indicator of how 
protein intake affects ruminant dams and their offspring.  
 We hypothesized that isocaloric diets provided to dams with lower amounts of MP would 
decrease fetal growth by reducing uteroplacental blood flow and nutrient delivery to the 
conceptus. Further, we hypothesized that MP restriction would reduce amino acid concentrations 
in uterine and umbilical vessels.  Therefore, the objectives of this study were to evaluate the 
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effects of isocaloric diets with varied levels of MP during late gestation (day 100 to 130) on 
uterine and umbilical blood flow, fetal weight, fetal organ weight, and amino acid concentrations in 
the uterine and umbilical vessels at day 130 of gestation.  
 
Materials and methods 
Animal care and use were according to protocols approved by the North Dakota State 
University (NDSU) Animal Care and Use Committee (#A0921).  
 
Animals and experimental design 
The breeding protocol used for this study was previously published (Van Emon, 2013). 
On ~ day 90 of gestation, 45 pregnant multiparous ewes were transported from the Hettinger 
Research Extension Center (Hettinger, ND) to the Animal Nutrition and Physiology Center at 
NDSU (Fargo, ND) where they were housed in individual pens (0.91 × 1.2 m) in an indoor facility 
until necropsy (130 ± 2 days of gestation).  Within the facility, the temperature was held constant 
at 12ºC, and lighting was controlled automatically (12:12-h light-dark cycle with lights on at 07:00 
and of at 19:00).    
Ewes were acclimated to low-quality hay (Table 3.1) and the MP100 supplement (100% 
of the MP requirements, as determined by NRC, 2007; Table 2) for 10 days prior to starting 
dietary treatments.  Ewes were weighed on two consecutive days (days 99 and 100 of gestation) 
prior to the initiation of treatments.  On day 100 ± 2 (SD) of gestation ewes were randomly 
assigned to one of three isocaloric dietary treatments (Table 3.2): MP60: 60% of MP 
requirements, MP80: 80% of MP requirements, and MP100: 100% of the MP requirements on a 
DM basis during the last 4 weeks of gestation (NRC, 2007; Van Emon et al., 2013).  Dietary 
treatments were fed from 100 to 130 ± 2 days of gestation.   Metabolizable protein intake was 
determined by the average of the days 99 and 100 body weight and offered once daily at 0700 h.  
Ewes were given one hour to consume the supplement, which was always completely consumed, 
then low-quality forage (Table 3.1) was offered. There were no orts throughout the study.  Body 
weights were determined every 7 days throughout the dietary treatment period, and the amount 
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of supplement and low-quality forage offered was adjusted for changes in body weight.  All ewes 
had access to fresh water and trace mineralized salt (4,000 ppm Zn, 1,600 ppm Fe, 1.200 ppm 
Mn, 325 ppm Cu, 100 ppm I, 40 ppm Co; American Stockman, Overland Park, KS).    
 
 
 
 
 
 
 
 
Table 3.2. Ingredient and nutrient composition of dietary supplements fed 
to ewes. 
  Treatment1 
Item  MP60  MP80  MP100 
Ingredient, % DM       
Corn  18.50  15.00  5.00 
DDGS2  7.00  20.00  30.00 
Soyhulls  9.50  —  — 
       
Nutrient composition       
DM, %  95.51  95.89  95.90 
NEm, Mcal/kg  2.00  2.22  2.14 
CP, % of DM  13.45  20.53  25.03 
MP, % of DM  8.41  13.01  16.31 
NDF, % of DM  33.61  32.11  40.79 
ADF, % of DM  15.71  8.33  11.61 
Ash, % of DM  3.17  3.50  4.38 
1Maternal diets (DM basis) were balanced for mature ewes during the last 
4 weeks of gestation according to NRC (2007).  Treatments: MP60: 60% 
of MP requirements; MP80: 80% of MP requirements; and MP100: 100% 
of MP requirements. 
 
2Dried distillers grains with solubles 
 
 
 
 
 
Table 3.1.  Nutrient composition of fescue 
straw1. 
Item   
Diet, % DM   
DM, %  96.24 
NEm, Mcal/kg  2.22 
CP, % of DM  2.76 
MP, % of DM  1.95 
NDF, % of DM  80.17 
ADF, % of DM  48.66 
Ash, % of DM  6.00 
1Ewes were fed fescue straw to limit MP 
intake 
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Gestational day 130 intraoperative ultrasonography measurements and blood samples 
 On day 130 ± 2 days of gestation, a subset (n = 12) of the 45 ewes carrying singletons 
[MP60: n = 4; MP80: n = 4; MP100: n = 3 (of this subset, one MP100 ewe was carrying twins and 
eliminated from the analysis)] underwent surgery to obtain intraoperative ultrasonography 
measurements as previously described by Lemley et al. (2012).  Dams were weighed and 
anesthetized with 1.2 ml of 50 mg/ml pentobarbital sodium per 20 kg of body weight.  Anesthesia 
was maintained via a jugular catheter.   A catheter was placed into the maternal saphenous artery 
and advanced to the iliac artery via the femoral artery for monitoring and recording blood 
pressure throughout the procedure.  The uterus was exposed via midventral laparotomy, covered 
with warm surgical towels, and a liberal amount of physiological saline (37ºC) was applied to the 
uterus every 5 min.  The gravid uterine artery was located and a transonic flow probe (6 mm; 
Transonic Systems Inc., Ithaca, NY, USA) was placed around the gravid uterine artery prior to the 
first bifurcation of the uterine artery.  Blood flow, as measured by the flow probe (Transonic 
Systems), was recorded.  Intraoperative measurements of umbilical artery hemodynamics were 
assessed using a duplex B-mode (brightness mode) and D-mode (Doppler spectrum) program of 
the color Doppler ultrasound instrument (model SSD-3500; Aloka UST-672).  Umbilical artery 
hemodynamics were recorded by scanning the gravid uterine horn in B-mode until a clear image 
of the umbilical artery was located. Measurements were obtained by placing the cursor over the 
vessel in B-mode while simultaneously recording pulsatile waves in D-mode.   The average angle 
of insonation for intraoperative umbilical artery blood flow was 62.5 ± 9.49 degrees (mean ± 
SEM).  Three similar cardiac cycle waveforms were recorded and averaged per ewe.  Cardiac 
cycle waveforms were plotted in D-mode by velocity (cm/s; y-axis) and time (s; x-axis).  Blood 
flow (BF) was calculated using present functions on the ultrasound instrument.  Abbreviations for 
the blood flow equation are as follows: mean velocity (MnV) and cross-sectional area of vessel 
(CSA).  The blood flow equation is BF (ml/min) = MnV (cm/s) × CSA (cm2) × 60 s.   
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Gestational day 130 necropsy procedures 
Following intraoperative ultrasound measurements, the gravid uterine horn was cut and 
the umbilical cord was excised.  Blood samples were taken simultaneously from the uterine vein 
(of the gravid horn; UtV) and the iliac artery (via a catheter through the saphenous artery; 
maternal artery, MA) and then simultaneously from the umbilical artery (UmbA) and the umbilical 
vein (UmbV).  Blood (~ 60mL) was collected into three 10-mL nonheparinized tubes (Becton 
Dickinson Vacutainer Systems).  Serum was obtained by centrifugation (1,500 × g for 30 min) 
and stored at −20ºC until further analysis. 
 The fetus was removed, weighed, and exsanguinated.  Fetal curved crown rump length 
and abdominal girth were recorded.  Fetal organs were harvested and weighed.  The placenta 
was collected, and placentomes were counted, dissected, and total placentome weight recorded.  
The caruncular and cotyledonary tissues were separated and weighed.   
 
Amino acid analysis 
Serum amino acid (AA) profiles were determined using an Ultra Performance Liquid 
Chromatograph (UPLC). Two-hundred fifty microliters of serum was deproteinized with 250 µL of 
10% sulfosalicylic acid to which 250 µM norvaline was added as an internal standard. This 
mixture was vortexed and centrifuged for 5 min at 16,000 x g. Twenty microliters of supernatant 
was added to 60 µL of borate buffer and sodium hydroxide solution as well as 20 µL of 
MassTrac Amino Acid Analysis derivating reagent. The samples were then capped, mixed and 
heated in a digestion block at 55 ˚C for 10 min. Samples were then injected into the UPLC. This 
method utilizes the MassTrac Amino Acid Analysis system for the full profile of AA in 
physiological fluids.  Derivatization chemistry for physiological samples is a precolumn method 
and is based on a derivatizing reagent, 6-aminoquinolyl-N-hydroxysuccinimidyl carbamate, which 
converts both primary and secondary AA to stable chromophores for UPLC detection. 
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Calculations 
 Average placentome weight was calculated by dividing total placentome weight by 
placentome number.  Uterine and umbilical blood flow per fetal weight was calculated by dividing 
uterine and umbilical blood flow by fetal weight, respectively.   Gravid uterine, fetal, and 
uteroplacental uptake of amino acids were calculated.  The following abbreviations were used for 
amino acid uptake calculations: [aa MA] = amino acid concentration in the maternal artery (iliac 
artery via the saphenous cathether), [aa UtV] = amino acid concentration in the uterine vein 
(gravid horn), [aa UmbV] = amino acid concentration in umbilical vein, [aa UmbA] = amino acid 
concentration in umbilical artery, Uterine BF = uterine artery blood flow, and Umbilical BF = 
umbilical blood flow.  Equations for amino acid uptakes are as follows: gravid uterine uptake = 
([aa MA nmol/ml] – [aa UtV nmol/nl]) × UtBF ml/min; fetal uptake = ([aa UmbV nmol/ml] – [aa 
UmbA nmol/ml]) × UmbBF ml/min; uteroplacental uptake = gravid uterine uptake – fetal uptake.   
 
Statistical analysis  
 Initial ewe body weight, final ewe body weight, placental measurements, blood flow 
measurements, amino acid concentrations, amino acid uptakes, fetal measurements, and fetal 
organ weights were analyzed using the ordinary least squares [GLM procedure of SAS (SAS 
Institute, Cary, NC] with treatment in the model statement.  Ewe body weight throughout the study 
was analyzed with the generalized least squares [MIXED procedure of SAS (SAS Institute)] with 
treatment, day of gestation, and the interaction of treatment by day of gestation in the model.  
Means were separated using the PDIFF option of the LSMEANS statement.  Least square means 
and SE are reported.   
 
Results  
Ewe body weight 
 Initial (average of day 99 and 100; 67.0 ± 4.33 kg) or final (day 130; 66.6 ± 5.42 kg) ewe 
body did not differ (P = 0.85) among treatments.  There was no treatment × day of gestation 
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interaction (P ≥ 0.77) for either ewe body weight or the percentage change in ewe body weight 
(Figure 3.1A and 3.1C); however, there was an overall day effect (P = 0.01) on ewe body weight 
and the percentage change in ewe body weight (Figure 1B and 1D). 
 
Uterine and umbilical blood flows 
 Uterine and umbilical blood flows are presented in Table 3.  Maternal MP level tended (P 
= 0.08) to influence uterine blood flow, with the MP60 ewes having greater uterine blood flow 
compared with MP100 ewes, with the MP80 ewes being intermediate (Table 3.3).  When 
expressed as blood flow per fetal weight, MP60 ewes had greater (P = 0.02) uterine blood flow 
per fetal weight compared with the MP80 and MP100 ewes, which were similar (Table 3.3). There 
was no effect (P ≥ 0.14; Table 3.3) of maternal treatment on umbilical blood flow or umbilical 
blood flow per fetal weight. 
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Figure 3.1. The effect of maternal metabolizable protein (MP) restriction on 
(A) ewe body weight throughout gestation and (C) the percentage change in 
ewe body weight throughout gestation and the effect of day of gestation on 
(B) ewe body weight and (D) the percentage change in ewe body weight 
throughout gestation.  Maternal diets were formulated to provide 60% of MP 
requirements (MP60), 80% of MP requirements (MP80), or 100% of MP 
requirements (MP100).  Diets were fed from day 100 to 130 of gestation.  
abcMeans with different superscripts differ (P ≤ 0.05).  
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Table 3.3. The effect of maternal metabolizable protein restriction from day 100 to 130 of gestation on 
uterine and umbilical blood flow measurements, conceptus weight, placentome weight and number, 
caruncular and cotyledonary weight, fetal membrane weight, and fetal weight, curved crown length, and 
girth measurements.  
  Treatments1     
Measurement  60  80  100  SE  P-value 
Uterine BF2 (mL/min)  818  661  447  105  0.08 
Uterine BF (mL/min) / fetal weight (g)  0.42a  0.22b  0.12b  0.07  0.02 
Umbilical BF 
(mL/min) 
 387  425  328  90.9  0.70 
Umbilical BF (mL/min) / fetal weight 
(g) 
 0.20  0.14  0.08  0.04  0.14 
Conceptus weight3 (g)  2643a  3616ab  4330b  398  0.03 
Total placentome weight (g)  491  560  482  47.9  0.41 
Total placentome number  63.0  75.2  54.7  15.4  0.61 
Average placentome weight (g)  8.45  7.55  12.15  2.38  0.36 
Total CAR4 weight (g)  103  118  70.9  27.0  0.45 
Total COT5 weight (g)  331  386  352  43.3  0.60 
Fetal membrane weight (g)  202  218  402  69.6  0.12 
Fetal weight (g)  2151a  3056ab  3848b  423  0.04 
Fetal CCL6 (cm)  50.8a  55.1ab  62.5b  3.02  0.05 
Fetal girth (g)  28.2a  31.8ab  35.6b  1.61  0.03 
1Maternal diets (DM basis) were balanced for mature ewes baring twins during the last 4 weeks of 
gestation according to NRC (2007).  Treatments: MP60: 60% of metabolizable protein (MP) 
requirements; MP80: 80% of MP requirements; and MP100: 100% of MP requirements. Diets were fed 
from day 100 to 130 of gestation. 
2BF = blood flow 
3Conceptus = placental weight plus fetal weight 
4CAR = caruncular 
5COT = cotyledonary 
6CCL = curved crown length 
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Placental and fetal measurements 
 Placental and fetal measurement data are presented in Table 3.  The MP60 ewes had a lighter (P 
= 0.03) conceptus weight compared with the MP100 ewes with the MP80 ewes being intermediate (Table 
3.3).  Total placentome weight, placentome number, average placentome weight, total caruncular weight, 
total cotyledonary weight, and fetal membrane weight did not differ (P ≥ 0.12) among the treatment 
groups (Table 3.3).   Fetuses from MP60 ewes were lighter (P = 0.04) compared with fetuses from MP100 
ewes, with fetuses from MP80 ewes being intermediate (Table 3.3).  Fetal CCR was shorter (P = 0.05) 
and fetal girth was less (P = 0.03) in MP60 ewes compared with fetal CCR in MP100 ewes, with MP80 
ewes being intermediate (Table 3.3).  
 Fetal organ data is presented in Table 3.4. Fetal brain, large intestine, perirenal fat, small 
intestine, and thyroid weights did not differ (P ≥ 0.11) among treatment groups (Table 3.4).  Fetal heart, 
spleen, and stomach weights tended (P ≥ 0.06 to P ≤ 0.09) to be lighter in MP60 ewes compared with 
MP100 ewes (Table 3.4).  Fetal adrenal glands, kidneys, and liver were lighter (P ≤ 0.05) in fetuses from 
MP60 ewes compared with fetuses from MP100 ewes, with MP80 ewes being intermediate (Table 3.4). 
Fetal lung and pancreas weights were lighter (P ≤ 0.02) in fetuses from MP60 ewes compared with 
fetuses from both MP80 and MP100 ewes, which were similar (Table 3.4).  When evaluated on a organ 
weight per fetal weight (g/kg) basis, only fetal brain weight per fetal weight tended (P = 0.08) to differ 
among treatments with MP60 ewes having a heavier brain weight per fetal weight compared with the 
MP100 ewes, with MP80 ewes being intermediate (Table 3.4).  All other organ weights per fetal weight 
did not differ (P ≥ 0.14, Table 3.4).  
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Amino acids and uterine, fetal, and uteroplacental uptake 
 All amino acid concentrations in the maternal artery, uterine vein, umbilical vein, and umbilical 
artery can be found in Supplement Table 3.1.  Amino acids that differed (P ≤ 0.05) among treatment 
groups are depicted in Table 3.5.  Glutamine concentrations in the maternal artery, umbilical vein, and 
umbilical artery were not impacted (P ≥ 0.14) by maternal protein level; however, glutamine 
concentrations in the uterine vein were greater (P = 0.02) in the MP60 and MP80 ewes compared with the 
MP100 ewes (Table 3.5).  Glycine concentrations were also greater (P ≤ 0.04) in the maternal artery, 
uterine vein, umbilical vein, and umbilical artery in the MP60 and MP80 ewes compared with the MP100 
ewes (Table 3.5).  Leucine concentrations in the maternal artery, uterine vein, and umbilical vein were not 
Table 3.4. The effect of maternal metabolizable protein restriction from day 100 to 130 of 
gestation on fetal organ weights and fetal organ weight expressed relative to fetal weight.  
  Treatments1     
Measurement   MP60  MP80  MP100  SE  P-value 
Adrenal weight (g)  0.22a  0.30ab  0.34b  0.03  0.05 
   g / kg2fetal weight  0.10  0.10  0.09  0.01  0.51 
Brain weight (g)  36.8  44.2  45.6  4.47  0.30 
   g / kg fetal weight  17.9  14.9  11.9  1.69  0.08 
Heart weight (g)  15.4  21.1  26.0  2.98  0.07 
   g / kg fetal weight  7.12  7.02  6.76  0.30  0.66 
Kidney weight (g)  16.7a  20.3ab  25.6b  1.97  0.03 
   g / kg fetal weight  8.00  6.87  6.63  0.52  0.15 
Large intestine weight (g)  6.03  8.24  9.22  1.05  0.11 
   g / kg fetal weight  2.79  2.78  2.40  0.18  0.25 
Liver weight (g)  71.0a  78.7ab  102.0b  4.71  0.01 
   g / kg fetal weight  34.5  28.1  26.5  4.42  0.37 
Lung weight (g)  79.8a  116b  139b  13.0  0.02 
   g / kg fetal weight  38.5  38.5  36.2  2.47  0.73 
Pancreas weight (g)  2.08a  3.24b  3.88b  0.30  0.01 
   g / kg fetal weight  1.03  1.09  1.01  0.11  0.86 
Perirenal fat weight (g)  14.4  18.5  16.9  2.71  0.49 
   g / kg fetal weight  6.55  6.47  4.43  0.79  0.14 
Small intestine weight (g)  20.3  32.5  30.4  8.66  0.51 
   g / kg fetal weight  9.10  10.63  8.07  1.99  0.63 
Spleen weight (g)  4.32  5.77  5.34  0.47  0.09 
   g / kg fetal weight  2.10  2.17  1.39  0.47  0.44 
Stomach weight (g)  15.7  21.7  27.3  3.01  0.06 
   g / kg fetal weight  7.29  7.25  7.08  0.45  0.94 
Thyroid weight (g)  0.51  0.68  0.83  0.13  0.24 
   g / kg fetal weight  0.24  0.22  0.22  0.03  0.72 
1Maternal diets (DM basis) were balanced for mature ewes during the last 4 weeks of 
gestation according to NRC (2007).  Treatments: MP60: 60% of metabolizable protein 
(MP) requirements; MP80: 80% of MP requirements; and MP100: 100% of MP 
requirements.  Diets were fed from day 100 to 130 of gestation.  
2Each organ weight is also expressed as ratio of organ weight (g) per fetal weight (kg) 
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different (P ≥ 0.06) among the treatment groups, but leucine concentration in the umbilical artery were 
lower (P = 0.04) in the MP60 and MP80 ewes compared with the MP100 ewes (Table 3.5).  Ornithine 
concentration in the maternal artery and uterine vein were greater (P ≤ 0.02) in the MP80 ewes compared 
with both the MP60 and MP100 ewes (Table 3.5); however concentration in the umbilical artery and vein 
were not different (P ≥ 0.66) due to treatment (Table 3.5).  Serine concentration in the maternal artery, 
umbilical vein, and umbilical artery were not altered (P ≥ 0.08) by maternal protein level (Table 3.5), but 
was greater (P = 0.03) in the uterine vein in MP60 and MP80 ewes compared with the MP100 ewes 
(Table 3.5).  Valine concentration in the maternal artery and uterine vein were not different (P ≥ 0.39) 
among the treatment groups (Table 3.5); however, in the umbilical vein, valine concentration was lower (P 
= 0.04) in the MP60 and MP80 ewes compared with the MP100 ewes, and in the umbilical vein, valine 
was lower (P = 0.03) in the MP60 ewes compared with the MP100 ewes, with MP80 ewes being 
intermediate (Table 3.5).  
Discussion 
There are many well-established models of intrauterine growth restriction in sheep, but until now, 
no studies exist examining the effects of maternal metabolizable protein during late gestation on uterine 
and umbilical blood flow, fetal organ weight, and amino acid concentrations in uterine and umbilical 
vessels.   This novel study indicates that maternal metabolizable protein restriction from day 90 to 130 of 
gestation does not negatively impact ewe weight, or circulating amino acid concentrations. In fact, while 
maternal metabolizable protein restriction resulted in lighter fetuses, the restriction may also result in 
compensatory mechanisms, as indicated by the increase uterine blood flow per fetal weight and increase 
in certain amino acids.  It should be stressed that this study, while the first of its kind, does have a small 
sample size (n = 11), and caution should be taken when interpreting the results.  The study does provide 
preliminary data that may be useful when designing studies to further investigate the effects of maternal 
metabolizable protein restriction in sheep.  
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Table 3.5.  The effect of maternal metabolizable protein restriction on select 
amino acid concentrations in the maternal artery, uterine vein, umbilical 
vein, and umbilical artery.  
  Treatments1     
Amino 
acid 
(nmol/mL) 
 
MP60  MP80  MP100  SEM  P-value 
Glutamine 
          
MA2  265  255  226  13.2  0.14 
UtV3  246a  229a  129b  11.4  0.02 
UmbV4  704  739  647  76.6  0.68 
UmbA5  615  589  548  57.1  0.68 
Glycine 
          
MA  408a  369a  226b  46.1  0.04 
UtV  417a  367a  178b  60.8  0.04 
UmbV  648a  765a  429b  47.9  0.04 
UmbA  595a  642a  388b  56.7  0.02 
Leucine 
          
MA  58.3  89.0  97.9  11.3  0.06 
UtV  52.5  81.3  78.6  10.7  0.12 
UmbV  126  160  244  31.0  0.06 
UmbA  101a  132a  219b  27.9  0.04 
Ornithine 
          
MA  19.3a  35.0b  20.0a  2.60  0.01 
UtV  16.9a  28.8b  13.3a  2.54  0.02 
UmbV  52.4  50.4  56.6  5.17  0.66 
UmbA  59.7  49.5  54.6  4.98  0.70 
Serine 
          
MA  45.2  42.9  33.0  3.58  0.08 
UtV  40.9a  38.0a  27.3b  2.97  0.03 
UmbV  640  742  503  98.0  0.24 
UmbA  663  734  520  94.8  0.29 
Valine  
          
MA  69.9  90.5  87.9  12.4  0.39 
UtV  63.2  82.8  71.2  11.2  0.40 
UmbV  175a  235a  323b  36.4  0.04 
UmbA  153a  214ab  302b  33.3  0.03 
1Maternal diets (DM basis) were balanced for mature ewes baring twins 
during the last 4 weeks of gestation according to NRC (2007).  Treatments: 
MP60: 60% of MP requirements; MP80: 80% of MP requirements; and 
MP100: 100% of MP requirements. 
2MA = maternal artery (saphenous artery) 
3UtV = uterine vein 
4UmbV = umbilical vein 
5UmbA = umbilical artery 
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In the present study, maternal dietary treatment did not alter ewe body from day 100 to day 130 
of gestation.   Van Emon et al. (2012) fed similar metabolizable protein supplements to a larger group of 
ewes (n = 295) from day 90 until lambing and found that ewes receiving less than the NRC 
recommendations for metabolizable protein (60% MP) weighed less than ewes meeting MP 
recommendations (100% MP) on days 114 and 142 of gestation.   In the present study, a much smaller 
number of ewes were utilized (n = 11); perhaps statistical differences among treatments would have been 
observed with a larger sample size.  Further, Van Emon et al. (2012) fed the dietary treatments from day 
100 of gestation until lambing, whereas ewes were sacrificed on day 130 of gestation in the present 
study.  It is possible that had the diets in the present study been fed until lambing, statistical differences in 
ewe body weight would have been observed.  The sharp drop in ewe body weight and the percent 
change in ewe body weight between days 128 and 130 of gestation is likely due to the fact that all ewes 
in this study underwent surgery on day 130 of gestation, and were removed from food for 24 hours prior 
to surgery.   
 In the present study, ewes receiving 60% of MP requirements had increased uterine blood flow 
per fetal weight (ml/min/fetal body weight) but similar placental weights compared with the ewes meeting 
MP requirements.  Despite the greater uterine blood flow per fetal weight, fetal weight was lighter, fetal 
CCR was shorter, and fetal girth was less in the MP60 ewes compared with the MP100 ewes.  The diets 
in the current study were formulated to be isolcaloric, so even though ewes had similar caloric intake, 
fetal weight, CCR, and girth were all negatively altered by day 130 of gestation, which indicates that 
maternal metabolizable protein may play a key role in the growth of the developing fetus.  The increase in 
uterine blood flow per fetal weight without an increase in placental weight could indicate a compensatory 
mechanism in the MP60 ewes.   
Currently, no data exist on the effects of maternal metabolizable protein during late gestation on 
uterine and umbilical blood flow in sheep.   Lemley et al. (2012) recorded intraoperative uterine and 
umbilical blood flow measurements following a similar procedure to the current study using a color-
Doppler ultrasound.  In this study, ewes received a control diet (100% of NRC requirements) or a globally-
restricted diet (60% of NRC recommendations) from day 50 to day 130 of gestation.  At day 130 of 
gestation, intraoperative ultrasound measurements showed a decrease in uterine blood flow in the 
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restricted group; however, when expressed as uterine blood flow per fetal weight, there were no 
differences between the two treatment groups (Lemley et al., 2012).  Umbilical blood flow and umbilical 
blood flow per fetal weight were not different at day 130 of gestation (Lemley et al., 2012), which is similar 
to the current study.  Also similar to the current study, Lemley et al. (2012) observed lighter fetal weight in 
the restricted ewes compared with the control ewes, but similar placental weight between the two groups.  
It is important to remember that Lemley et al. (2012) were studying the effects of a control diet versus a 
globally restricted diet, whereas in the current study, diets were formulated to be isocaloric and only differ 
in the level of metabolizable protein.  Taking this into account, it appears that while an overall nutrient 
restriction may lead to decreases in uterine blood flow (Lemley et al., 2012), specifically restricting 
metabolizable protein may result in greater uterine blood flow per fetal weight.   The current study 
suggests the decrease in fetal weight observed by Lemley et al. (2012) may be specifically due to a 
decrease in maternal protein in the diet.  
In a well-established model of intrauterine growth restriction where adolescent ewes are 
overnourished, Wallace et al. (2008) demonstrated that both fetal weight and uterine blood flow were 
decreased in the overfed adolescent ewes compared with controls on day 135 of gestation.   This study 
was examining the effects of overnourishing adolescent dams (Wallace et al., 2008), where the current 
study was specifically looking at metabolizable protein levels in multiparous ewes These variables make it 
difficult to compare and contrast the results from Wallace et al. (2008) and the present study.  
While there is a wealth of literature examining the effects of maternal undernutrition on fetal 
and/or offspring organ weight, few studies exist that look specifically at the effects of maternal 
metabolizable protein in ruminants on fetal and/or offspring organ weight.  In the current study, maternal 
protein restriction (MP60) tended to decrease fetal heart, spleen, and stomach weights compared with the 
control group (MP100), deceased the fetal kidney and liver weight compared with the controls, and 
decreased fetal lung and pancreas weight compared with both a moderately restricted metabolizable 
protein group (MP80) and the control group.  This indicates that maternal metabolizable protein restriction 
does result in intrauterine growth restriction.  When expressed as fetal organ weight per fetal weight, only 
the fetal brain tended to be different, with the MP60 ewes tending to have a heavier brain weight per fetal 
weight ratio compared with the MP100 ewes.  This indicates a synchronous growth restriction in the 
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MP60 ewes with the brain weight being spared.  He et al. (2013) restricted maternal protein intake during 
late gestation in goats and found that at birth, protein restriction decreased birth weight and offspring 
weights of the thymus, heart, and small intestine.  When kid weights were expressed relative to birth 
weight, the thymus and small intestine were lighter in the protein-restricted goats compared to the 
controls (He et al., 2013).  The goats in the He et al. (2013) study received similar protein requirements 
as the ewes in the current study (a 40% reduction in protein requirements, or fed 60% of requirements).   
In the uterine artery, the only amino acids that were influenced by maternal protein restriction 
were glycine and ornithine.  Glycine concentration in the maternal artery was greater in the protein-
restricted groups compared with the control ewes.  Ornithine concentration in the maternal artery was 
greatest in the MP80 ewes compared with the MP60 and MP100 ewes.  In the umbilical vein, the only 
amino acid influenced by maternal diet was glycine, with both the protein-restricted groups having greater 
glycine concentrations in the umbilical vein compared with the control ewes.   The lack of treatment 
differences in amino acid concentrations in the uterine artery and umbilical artery indicate that maternal 
protein restriction does not greatly affect amino acid concentrations in the uterine artery and umbilical 
vein.  This is in contrast to ewes that are globally restricted.  For example, when ewes were globally 
restricted to 50% of NRC requirements from day 28 to 115 of gestation and blood samples obtained from 
the uterine artery and umbilical vein, the concentrations of most amino acids in the uterine artery and 
umbilical vein were less compared with ewes that were fed to meet requirements (Satterfield et al., 2010).   
Also, when ewes were fed 50% of NRC requirements from either day 28 to 78 of gestation or from day 28 
to 135 of gestation, amino acid concentrations in the uterine artery and umbilical vein were decreased at 
days 78 and 135 of gestation (Kwon et al., 2004).  It is difficult to compare the current study to those of 
Satterfield et al. (2010) and Kwon et al. (2004) for a few reasons.  First, the dietary treatments are very 
different between the current study and these two studies.  Satterfield et al. (2010) and Kwon et al. (2004) 
examined a 50% global nutrient restriction whereas the current study is investigating isocaloric diets that 
differ in metabolizable protein.  Further, Satterfield et al. (2010) fed the dietary treatments much earlier in 
gestation and collected blood samples at slaughter on day 115 of gestation.  Kwon et al. (2004) also 
began dietary restriction early in gestation (d 28) and collected samples at days 78 and 135 of gestation.  
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In the present study, dietary treatments were fed during late gestation (day 90 to 130 of gestation), and 
blood samples obtained under anesthesia at day 130 of gestation.   
In the current study, the uterine, uteroplacental, and fetal uptakes of each amino acid were 
calculated (Table 3.6) using amino acid concentrations in the uterine artery and vein, umbilical artery and 
vein, and the uterine and umbilical blood flows.  Amino acid uptakes did not differ with treatment (Table 
3.6), which indicates that maternal protein restriction is not affecting amino acid availability to the fetus.   
In conclusion, maternal metabolizable protein restriction from day 90 to 130 of gestation does not 
appear to negatively affect ewe body weight, uterine or umbilical blood flow, or amino acid concentrations 
in the uterine artery and umbilical vein.   Fetal weight was decreased in the most severely protein-
restricted ewes, which indicates that maternal metabolizable protein significantly impacts fetal growth.  
Interestingly, this decrease in fetal weight occurred despite an increase in uterine blood flow (expressed 
relative to fetal weight) and without changes in placental weight.  Future studies are needed to investigate 
possible compensatory mechanisms, such as increased blood flow and altered amino acid pathways, that 
may occur in dams experiencing reduced metabolizable protein during late gestation.   
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Table 3.6.  The effect of maternal metabolizable protein restriction on amino acid 
concentrations in the maternal artery, uterine vein, umbilical vein, and umbilical 
artery and the uterine, fetal, and uteroplacental uptakes of amino acids.  
  Treatments1     
Amino acid 
(nmol/mL) 
Amino acid 
uptake 
(nmol/min) 
 
MP60  MP80  MP100  SEM  P-Value 
Alanine 
          
MA2  179  178  151  23.1  0.63 
UtV3  162  171  124  24.3  0.36 
Uterine uptake4  13672  5560  12646  4835  0.38 
UmbV5  499  562  449  39.8  0.15 
UmbA6  447  519  415  36.9  0.14 
Fetal uptake7  19771  17664  13474  10032  0.88 
Uteroplacental 
uptake8 
 -6099  -12105  2215  7491  0.35 
Arginine 
          
MA  73.7  89.6  77.6  9.62  0.42 
UtV  87.9  82.9  92.9  8.99  0.58 
Uterine uptake  1609  4430  2440  1586  0.38 
UmbV  109  100  120  11.3  0.45 
UmbA  90.3  71.0  102  15.2  0.34 
Fetal uptake  7462  12469  8978  5804  0.69 
Uteroplacental 
uptake 
 -5853  -8040  -5893  5792  0.92 
Asparagine 
          
MA  23.2  27.2  25.6  2.22  0.37 
UtV  22.5  24.4  22.5  1.69  0.62 
Uterine uptake  429  1827  1382  619  0.23 
UmbV  93.6  92.0  78.5  11.6  0.60 
UmbA  73.7  72.7  67.8  7.09  0.80 
Fetal uptake  7541  7524  4922  4660  0.88 
Uteroplacental 
uptake 
 -7111  -5697  -3087  4882  0.80 
Aspartic acid 
          
MA  8.23  8.04  8.66  0.87  0.86 
UtV  9.10  10.6  9.53  1.46  0.69 
Uterine uptake  -609  -1602  -390  497  0.17 
UmbV  9.71  8.22  7.40  1.11  0.32 
UmbA  10.2  9.17  8.27  0.84  0.29 
Fetal uptake  -142  -516  -175  317  0.49 
Uteroplacental 
uptake 
 -467  -1085  -99.5  578  0.38 
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Table 3.6. The effect of maternal metabolizable protein restriction on amino acid 
concentrations in the maternal artery, uterine vein, umbilical vein, and umbilical 
artery and the uterine, fetal, and uteroplacental uptakes of amino acids (continued). 
 
 Treatments1     
Amino acid 
(nmol/mL) 
Amino acid 
uptake 
(nmol/min) 
 
MP60  MP80  MP100  SEM  P-Value 
Citrulline 
          
MA  82.3  77.6  77.7  12.9  0.94 
UtV  79.7  71.1  72.3  11.9  0.82 
Uterine uptake  1640  4417  2692  1985  0.54 
UmbV  121  114  136  15.6  0.56 
UmbA  121  115  136  14.8  0.59 
Fetal uptake  -465  69.1  469  1509  0.87 
Uteroplacental 
uptake 
 2105  4348  2975  2443  0.67 
Glutamine 
          
MA  265  255  226  13.2  0.14 
UtV  246a  229a  129b  11.4  0.02 
Uterine uptake  14580  17089  15948  4994  0.92 
UmbV  704  739  647  76.6  0.68 
UmbA  615  589  548  57.1  0.68 
Fetal uptake  36045  60885  43225  27843  0.68 
Uteroplacental 
uptake 
 -
21465 
 -43796  -23811  28791  0.72 
Glutamic acid 
          
MA  75.3  70.0  70.0  3.88  0.49 
UtV  78.3  86.0  73.6  11.9  0.73 
Uterine uptake  -2346  -8561  -1582  4425  0.43 
UmbV  27.0  33.4  28.8  6.13  0.69 
UmbA  54.6  53.0  44.6  8.91  0.68 
Fetal uptake  -
10535 
 -8400  -7377  4800  0.84 
Uteroplacental 
uptake 
 8189  -161  7010  8634  0.62 
Glycine 
          
MA  408a  369a  226b  46.1  0.04 
UtV  417a  367a  178b  60.8  0.04 
Uterine uptake  -7428  1578  16771  8023  0.13 
UmbV  648a  765a  429b  47.9  0.04 
UmbA  595a  642a  388b  56.7  0.02 
Fetal uptake  21627  39609  17950  17675  0.52 
Uteroplacental 
uptake 
 -
29056 
 -38031  6459  21468  0.29 
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Table 3.6. The effect of maternal metabolizable protein restriction on amino acid 
concentrations in the maternal artery, uterine vein, umbilical vein, and umbilical artery 
and the uterine, fetal, and uteroplacental uptakes of amino acids (continued). 
 
 Treatments1     
Amino acid 
(nmol/mL) 
Amino acid 
uptake 
(nmol/min) 
 
MP60  MP80  MP100  SEM  P-Value 
Isoleucine 
          
MA  41.3  59.8  56.8  7.70  0.18 
UtV  37.1  54.0  45.9  6.79  0.19 
Uterine uptake  3279  3742  4873  1487  0.72 
UmbV  59.9  81.1  126  17.7  0.06 
UmbA  50.0a  69.0ab  113b  16.0  0.05 
Fetal uptake  3828  5538  4690  3102  0.76 
Uteroplacental 
uptake 
 -549  -1796  -2.14  3663  0.90 
Leucine 
          
MA  58.3  89.0  97.9  11.3  0.06 
UtV  52.5  81.3  78.6  10.7  0.12 
Uterine uptake  4459  5101  8468  2247  0.41 
UmbV  126  160  244  31.0  0.06 
UmbA  101a  132a  219b  27.9  0.04 
Fetal uptake  9653  11512  11961  6165  0.94 
Uteroplacental 
uptake 
 -5194  -6410  -909  6896  0.81 
Histidine 
          
MA  34.6  36.2  31.2  3.03  0.48 
UtV  32.8  33.7  20.8  2.83  0.33 
Uterine uptake  1253  1773  1492  600  0.78 
UmbV  56.9  61.7  52.7  8.87  0.56 
UmbA  56.2  53.5  50.8  5.00  0.73 
Fetal uptake  3663  2935  1089  2994  0.78 
Uteroplacental 
uptake 
 -2411  -1162  424  3198  0.77 
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Table 3.6. The effect of maternal metabolizable protein restriction on amino acid 
concentrations in the maternal artery, uterine vein, umbilical vein, and umbilical 
artery and the uterine, fetal, and uteroplacental uptakes of amino acids (continued). 
 
 Treatments1     
Amino acid 
(nmol/mL) 
Amino acid 
uptake 
(nmol/min) 
 
MP60  MP80  MP100  SEM  P-Value 
Lysine 
          
MA  86.8  102  98.8  12.0  0.59 
UtV  83.4  99.8  94.2  11.0  0.50 
Uterine uptake  3278  1111  1737  2327  0.75 
UmbV  150  141  133  22.2  0.84 
UmbA  128  126  115  20.8  0.90 
Fetal uptake  8932  6620  7529  4947  0.90 
Uteroplacental 
uptake 
 -5654  -5509  -4890  4831  0.99 
Methionine  
          
MA  12.4  15.0  13.0  1.50  0.38 
UtV  11.2  13.2  13.2  1.34  0.29 
Uterine uptake  909  1215  1242  353  0.72 
UmbV  56.8  54.8  55.8  5.58  0.96 
UmbA  48.5  45.4  48.8  5.06  0.84 
Fetal uptake  3100  3897  3231  2118  0.93 
Uteroplacental 
uptake 
 -2191  -2681  -1666  2195  0.93 
Ornithine 
          
MA  19.3a  35.0b  20.0a  2.60  0.01 
UtV  16.9a  28.8b  13.3a  2.54  0.02 
Uterine uptake  1895  1113  2545  618  0.27 
UmbV  52.4  50.4  56.6  5.17  0.66 
UmbA  59.7  49.5  54.6  4.98  0.70 
Fetal uptake  971  399  952  712  0.70 
Uteroplacental 
uptake 
 -2191  -2682  -1666  2195  0.49 
Phenylalanine 
          
MA  28.0  32.5  34.4  3.22  0.33 
UtV  26.3  30.7  27.9  3.01  0.51 
Uterine uptake  1167  1211  2927  629  0.12 
UmbV  115  110  155  22.8  0.33 
UmbA  98.8  90.3  138  20.1  0.23 
Fetal uptake  5931  7888  8087  4591  0.89 
Uteroplacental 
uptake 
 -4794  -6676  -4344  4761  0.89 
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Table 3.6. The effect of maternal metabolizable protein restriction on amino acid 
concentrations in the maternal artery, uterine vein, umbilical vein, and umbilical 
artery and the uterine, fetal, and uteroplacental uptakes of amino acids (continued). 
 
 Treatments1     
Amino acid 
(nmol/mL) 
Amino acid 
uptake 
(nmol/min) 
 
MP60  MP80  MP100  SEM  P-Value 
Proline 
          
MA  54.1  52.9  47.0  6.20  0.78 
UtV  50.4  51.9  44.9  6.76  0.73 
Uterine uptake  733  822  968  955  0.98 
UmbV  171  187  159  13.1  0.31 
UmbA  155  171  147  11.1  0.30 
Fetal uptake  6485  7309  4669  3655  0.84 
Uteroplacental 
uptake 
 -5753  -6488  -3357  3239  0.74 
Serine 
          
MA  45.2  42.9  33.0  3.58  0.08 
UtV  40.9a  38.0a  27.3b  2.97  0.03 
Uterine uptake  3096  3139  2625  851  0.89 
UmbV  640  742  503  98.0  0.24 
UmbA  663  734  520  94.8  0.29 
Fetal uptake  -7675  4375  -6856  6326  0.19 
Uteroplacental 
uptake 
 10772  -1236  10058  6251  0.19 
Taurine 
          
MA  40.0  81.3  98.7  20.2  0.13 
UtV  39.3  82.3  97.6  21.4  0.15 
Uterine uptake  463  -314  973  1500  0.81 
UmbV  95.6  166  154  60.6  0.62 
UmbA  87.6  162  153  58.3  0.56 
Fetal uptake  2650  1056  157  2603  0.71 
Uteroplacental 
uptake 
 -2187  -1371  577  4035  0.86 
Threonine 
          
MA  42.7  49.3  44.2  6.52  0.70 
UtV  39.3  44.0  38.0  5.67  0.69 
Uterine uptake  2634  3623  2916  1410  0.84 
UmbV  251  235  221  21.6  0.59 
UmbA  229  209  203  23.7  0.68 
Fetal uptake  8049  10822  9307  5710  0.89 
Uteroplacental 
uptake 
 -5415  -7199  -5486  6176  0.95 
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Table 3.6. The effect of maternal metabolizable protein restriction on amino acid 
concentrations in the maternal artery, uterine vein, umbilical vein, and umbilical 
artery and the uterine, fetal, and uteroplacental uptakes of amino acids (continued). 
 
 Treatments1     
Amino acid 
(nmol/mL) 
Amino acid 
uptake 
(nmol/min) 
 
MP60  MP80  MP100  SEM  P-Value 
Tryptophan 
          
MA  18.6  15.0  15.4  1.78  0.27 
UtV  18.1  15.0  13.7  1.85  0.22 
Uterine uptake  312  144  778  283  0.28 
UmbV  59.5  45.5  59.4  7.14  0.26 
UmbA  55.3  40.3  54.3  6.88  0.21 
Fetal uptake  1339  2129  2598  1921  0.85 
Uteroplacental 
uptake 
 -1027  -1984  -1708  1744  0.86 
Tyrosine 
          
MA  26.8  19.6  30.6  3.24  0.08 
UtV  24.7  16.6  25.5  3.46  0.14 
Uterine uptake  1694  1744  2272  789  0.84 
UmbV  106  66.4  132  22.1  0.13 
UmbA  94.9  57.5  119  20.2  0.12 
Fetal uptake  3760  3138  6132  4284  0.85 
Uteroplacental 
uptake 
 -2066  -1394  -3379  4174  0.93 
Valine  
          
MA  69.9  90.5  87.9  12.4  0.39 
UtV  63.2  82.8  71.2  11.2  0.40 
Uterine uptake  5071  5153  7380  2286  0.71 
UmbV  175a  235a  323b  36.4  0.04 
UmbA  153a  214ab   302b  33.3  0.03 
Fetal uptake  7167  9487  10231  4646  0.83 
Uteroplacental 
uptake 
 -2096  -4334  -608  5097  0.82 
1Maternal diets (DM basis) were balanced for mature ewes baring twins during the 
last 4 weeks of gestation according to NRC (2007).  Treatments: MP60: 60% of MP 
requirements; MP80: 80% of MP requirements; and MP100: 100% of MP 
requirements. 
2MA = maternal artery (saphenous artery) 
3UtV = uterine vein 
4Uterine uptake = ([MA amino acids, nmol/ml] – [UtV amino acids, nmol/nl]) × uterine 
blood flow, ml/min 
5UmbV = umbilical vein 
6UmbA = umbilical artery 
7Fetal uptake = ([UmbV amino acids, nmol/ml] – [UmbA amino acids, nmol/ml]) × 
Umbilical blood flow, mn/min 
8Uteroplacental uptake= gravid uterine uptake – fetal uptake 
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CHAPTER 4.  THE EFFECTS OF MATERNAL METABOLIZABLE PROTEIN RESTRICTION DURING 
GESTATION ON THE VASCULAR FUNCTION OF MATERNAL AND FETAL PLACENTAL ARTERIES 
IN SHEEP 
 
Abstract 
We hypothesized that a maternal diet formulated to provide low levels of protein would result in 
decreased sensitivity of the caruncular (CAR) and cotyledonary (COT) arteries compared to placenta 
arteries from ewes receiving an isocaloric diet that was formulated to meet metabolizable protein (MP) 
requirements; therefore, our objective was to determine how maternal MP level impacted the vascular 
responses to bradykinin (BK) of CAR and COT arteries of sheep.  Pregnant ewes were fed one of three 
isocaloric dietary treatments that provided 60%, 80%, or 100% of the MP requirements (MP60, MP80, 
and MP100, respectively).  Diets were fed from day 100 to 130 of gestation.  On day 130, ewes were 
necropsied, fetal and placental measurements were obtained, and CAR and COT arteries were analyzed 
for vascular reactivity and mRNA expression of selected genes. Dose response curves to BK, sodium 
nitroprusside (SNP), potassium chloride (KCl), and phenylephrine (PE) in CAR and COT arteries were 
performed.  Maternal MP did not alter (P ≥ 0.24) any fetal or placental measurements.  As MP decreased, 
the sensitivity to a low dose of KCl increased (P = 0.05) in the COT arteries. There was an overall 
treatment effect in the CAR and COT arteries for the BK dose response curve, where CAR arteries of 
MP80 ewes were more sensitive (P = 0.05) to BK compared with MP60 and MP100 ewes, and COT 
arteries of MP60 and MP80 ewes were more sensitive (P = 0.01) to BK compared with MP100 ewes.  
There were no treatment effects (P ≥ 0.09) on the SNP or PE dose response curves in CAR or COT 
arteries.  The mRNA expression of BK receptors 1 and 2, endothelial nitric oxide synthase, and soluble 
guanylate cyclase were not altered (P ≥ 0.38) by MP level during gestation.  Results from this study 
indicate that while maternal MP restriction may not negatively impact fetal or placental growth, MP 
restriction appears to alter placental vascular function, which could alter nutrient availability to the 
conceptus.  
 
Key words: bradykinin, ewes, metabolizable protein, pregnancy, vascular function 
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Introduction 
Several animal models have linked maternal undernutrition during gestation to fetal growth 
restriction (Holst et al., 1986; 1992; Bloomfield et al., 2000; Vonnahme et al., 2003; Scheaffer et al., 2004; 
Lekatz et al., 2010a; 2010b; Lemley et al., 2012), placental growth restriction (McCrabb et al., 1991; 
1992a; 1992b; Heasman et al, 1998; McMullen et al., 2005), or both (Charlton and Johengen, 1985; 
Faichney and White, 1987). Increasing uterine blood flow during the last half of gestation is critical for 
oxygen and nutrient delivery to the exponentially growing fetus, and alterations to placental blood flow 
vasculature may compromise the growth of the developing fetus (Ford, 1995; Meschia, 1983; Redmer et 
al., 2004; Reynolds et al., 2005; Reynolds et al., 2006).  In sheep, maternal nutrient restriction reduces 
uterine (Lemley et al., 2012) and umbilical blood flow (Lemley et al., 2012) and increases resistance of 
the umbilical artery (Lekatz, Chapter 2). However, it is not clear if these alterations in placental function 
are due to an overall caloric restriction or to restriction of a specific component in the diet.   
 Evidence in rodent models suggests that maternal dietary protein level plays an important role in 
the health of the offspring.  For example, maternal restriction of dietary protein results in offspring with 
glucose intolerance (Dahri et al., 1991; Langley et al., 1994), insulin resistance (Dahri et al., 1991), 
elevated blood pressure (Langley and Jackson, 1994; Ozaki et al., 2001), and vascular dysfunction 
(Torrens et al., 2002; Brawley et al., 2003).  While much has been learned about the role of maternal 
protein level and offspring health in rodents, this data cannot be directly applied to ruminants.  
Furthermore, these rodent studies utilized diets that were not isocaloric, so the question if placental 
adaptations are due to a decrease in total energy intake or to a decrease in protein still remains.  We 
hypothesized that lower levels of maternal MP would have negative effects on the vascular function of 
placental arteries. Therefore, the objective of the current study is to investigate the effect of isocaloric 
diets with varied levels of metabolizable protein (MP) on the vascular function of placental arteries. 
 
Materials and methods 
Animal care and use were according to protocols approved by the North Dakota State University 
Animal Care and Use Committee (#A0921).  
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Animals and experimental design 
On day ~ 90 of gestation, 18 pregnant multiparous ewes carrying singletons were transported 
from the Hettinger Research Extension Center (Hettinger, ND) to the Animal Nutrition and Physiology 
Center at North Dakota State University (Fargo, ND) where they were housed in individual pens (0.91 × 
1.2 m) in an indoor facility until necropsy (130 ± 2 days of gestation).  Within the facility, the temperature 
was held constant at 12ºC, and lighting was controlled automatically (12:12-h light-dark cycle with lights 
on at 07:00 and of at 19:00).   
Ewes were acclimated to low-quality hay (Table 4.1) and the MP100 supplement (100% of the 
MP requirements, as determined by NRC, 2007; Table 4.2) for 10 days prior to starting dietary 
treatments.  Ewes were weighed on two consecutive days (days 99 and 100 of gestation) prior to the 
initiation of treatments. On day 100 ± 2 (SD) of gestation ewes were randomly assigned to one of three 
isocaloric dietary treatments (Table 4.2): MP60: 60% of MP requirements, MP80: 80% of MP 
requirements, and MP100: 100% of the MP requirements on a DM basis during the last 4 weeks of 
gestation of pregnant ewes (NRC, 2007).  Dietary treatments were fed from 100 to 130 ± 2 days of 
gestation.   Metabolizable protein intake was determined by the average of the days 99 and 100 body 
weight and offered once daily at 0700 h.  Ewes were given one hour to consume the supplement then 
low-quality forage (Table 4.1) was offered.  Body weights were collected every 7 days throughout the 
dietary treatment period, and the amount of supplement and low-quality forage offered was adjusted for 
changes in body weight.  All ewes had access to fresh water and trace mineralized salt (4,000 ppm Zn, 
1,600 ppm Fe, 1.200 ppm Mn, 325 ppm Cu, 100 ppm I, 40 ppm Co; American Stockman, Overland Park, 
KS).    
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Tissue collection and fetal and placental measurements 
On day 130 ± 2 days of gestation, were weighed and euthanized by captive bolt (Supercash Mark 
2, Accles and Shelvoke Ltd., Sutton Coldfield, West Midlands, UK)  
followed by exsanguination.  The gravid uterus was immediately dissected cranial to the cervix and 
weighed.  The uterus was opened along the antimesometrial side, the umbilical cord was ligated, and the 
 
 
 
 
Table 4.1.  Nutrient composition of fescue 
straw1. 
Item   
Diet, % DM   
DM, %  96.24 
NEm, Mcal/kg  2.22 
CP, % of DM  2.76 
MP, % of DM  1.95 
NDF, % of DM  80.17 
ADF, % of DM  48.66 
Ash, % of DM  6.00 
1Ewes were fed fescue straw to limit MP 
intake 
Table 4.2. Ingredient and nutrient composition of dietary supplements fed 
to ewes. 
  Treatment1 
Item  MP60  MP80  MP100 
Ingredient, % DM       
Corn  18.50  15.00  5.00 
DDGS2  7.00  20.00  30.00 
Soyhulls  9.50  —  — 
       
Nutrient composition       
DM, %  95.51  95.89  95.90 
NEm, Mcal/kg  2.00  2.22  2.14 
CP, % of DM  13.45  20.53  25.03 
MP, % of DM  8.41  13.01  16.31 
NDF, % of DM  33.61  32.11  40.79 
ADF, % of DM  15.71  8.33  11.61 
Ash, % of DM  3.17  3.50  4.38 
1Maternal diets (DM basis) were balanced for mature ewes during the last 
4 weeks of gestation according to NRC (2007).  Treatments: MP60: 60% 
of MP requirements; MP80: 80% of MP requirements; and MP100: 100% 
of MP requirements. 
 
2Dried distillers grains with solubles 
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fetus was removed, weighed, and fetal curved crown rump and abdominal girth were recorded.  
Immediately after the fetus was removed, the terminal branches of fetal placental arteries (cotyledonary 
arteries; COT arteries) were dissected and either immersed in cold physiological salt solution for the 
organ bath chamber study (described below) or snap frozen in liquid nitrogen and stored at -80ºC for 
qPCR (described below).  These COT arteries, terminating directly into the cotyledon, were typically 
secondary branches of the umbilical artery.   Following removal of the fetal placental arteries, the gravid 
uterine artery was located and maternal placental arteries (caruncular arteries; CAR arteries) terminating 
at the caruncle were dissected and dissected and either immersed in cold physiological salt solution for 
the organ bath chamber study (described below) or snap frozen in liquid nitrogen and stored at -80ºC for 
qPCR (described below).  These CAR arteries, terminating directly into the caruncle, were typically 4th or 
5th branches of the gravid uterine artery.  Because placentome size has been shown to influence vascular 
reactivity (Vonnahme et al., 2008) similarly sized placentomes were selected for each animal.    
Next, the fetal fluid was collected and the volume recorded.  Placentomes were counted, 
dissected, weighed, and the CAR and COT tissues were separated and weighed.  The fetal membranes 
and empty uterine weight were also weighed. 
 
Organ chamber studies 
After transfer to the laboratory, the CAR and COT arteries were dissected free from surrounding 
placental tissue, cleaned of adherent fat and connective tissue, and cut into rings 4-5 mm in length.  Four 
rings were prepared from both CAR and COT arteries for each ewe.  The endothelium remained intact 
(E+) in half of the CAR arterial rings and half of the COT arterial rings, while the other half of the arterial 
rings were denuded of endothelium (E-) by gently rubbing the intimal surface with a fine forceps.  
The following drugs were used: KCl, phenylephrine (PE), norepinephrine (NE), bradykinin (BK), 
and sodium nitroprusside (SNP; Sigma Chemical, St. Louis, MO), and 9, 11-dideoxy-11α,9α-
epoxymethano-PGF2α (U46619; Cayman Chemical, Ann Arbor, MI).  Drug solutions were prepared daily, 
kept on ice, and protected from light until used.  All drugs were dissolved initially in double-distilled water.  
Drug concentrations are reported as final molar concentrations in the organ chamber.  The composition of 
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the physiological salt solution was (in mM): 118.3 NaCl, 4.7 KCl, 2.5 CaCl2, 1.2 MgSO4, 1.2 KH2PO4, 25.0 
NaHCO3, and 11.1 glucose.  
 Caruncular (n = 4 for each ewe; E+: n = 2; E-: n =2) and COT arterial rings (n = 4 for each ewe; 
E+: n = 2; E-: n =2) were suspended in water-jacketed organ chambers filled with 25 ml of physiological 
salt solution, as previously described (Tunstall et al., 2011; Shukla et al., 2012).  Oxygen levels (95% 
O2/5% CO2) and temperature (37˚C) were maintained throughout the experiment.  Each ring was 
suspended by means of two fine stainless-steel wire clips passed through the lumen; one clip was 
anchored inside the organ chamber, the other connected to a force transducer (Model FT03, Grass 
Instrument Company, Quincy, MA, USA).  Isometric tension was measured and recorded on a Grass 
polygraph.  The tissues were stretched progressively to the optimal point of their length-tension 
relationship, using KCl (20mM) to generate a standard contractile response.  After this procedure, the 
rings were allowed to equilibrate at their optimal length-tension for one hour prior to further exposure to 
any vasoactive substances.  The presence or absence of intact endothelium was confirmed in each 
preparation by contracting the rings with NE (10-6 M) and observing the presence or absence of relaxation 
to the endothelium-dependent vasodilator, BK (10-7 M).  
 Concentration-response curves to KCl (10 to100 mM) and phenylephrine (10-8 M - 10-5 M) were 
obtained in both endothelium intact (E+) and endothelium-removed (E-) rings for both the CAR and COT 
arterial rings.  The remaining CAR and COT arterial rings were contracted with U46619 (1 to 3 x 10-9 M), a 
thromboxane A2-mimetic. After the U46619-induced contraction had reached a stable plateau, relaxation 
responses to increasing concentrations of the endothelium-dependent vasodilator BK1(10-9 to10-6 M) or 
the endothelium-independent vasodilator, SNP (10-9 to 10-6 M) were obtained.  At the end of the 
concentration-response curves to the contractile agonists, arterial rings were stimulated with 60 mM KCl 
to determine the maximum tissue contraction.  
 
Quantification of mRNA 
 The relative mRNA expression of endothelial nitric oxide synthase (eNOS), soluble guanylate 
cyclase (GUCY1B3), bradykinin receptor 1 (BKR1), and bradykinin receptor 2 (BKR2) was determined in 
the CAR and COT arteries.  Caruncular and COT arteries (30 mg) were homogenized using a Polytron 
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homogenizer fitted with a 7 mm generator.  Messenger RNA was isolated using a QIAshredder spin 
column and the RNeasy Mini Kit as described by the manufacturer (Qiagen, Valencia, CA).  RNA was 
quantified by measuring the absorbance on a Nanodrop 2000c spectrophotometer.  Synthesis of cDNA 
synthesis was performed using the QuantiTect Reverse Transcription Kit as described by the 
manufacturer (Qiagen).  This protocol includes a genomic DNA removal step, which was performed for all 
samples.  Quantitative PCR (qPCR) reactions for eNOS and sGC contained the following: 1x TaqMan 
Universal PCR Master Mix (Life Technologies), forward and reverse primers (each 1 µM), water and 
cDNA for a final volume of 12.5 µl. Reactions to detect BKR1 and BKR2 contained the following:  1X 
SYBR Green PCR Master Mix (Life Technologies), forward and reverse primers (each 500 nM), water 
and cDNA for a final volume of 12.5 µl. Dissociation curves confirmed a single amplification species for 
both BKR1 and BKR2.  Amplification of 18s rRNA using a 20X predesigned assay reagent, which 
contained both forward and reverse primers and a probe (Life Technologies), was performed for each 
sample and was used to normalize expression of each gene.  The ratio of the gene of interest to 18S 
rRNA was used for quantifying the gene expression and is the data presented. 
 
Data analysis 
 One MP100 ewe was removed from the study as she was carrying triplets. Contractile responses 
are expressed as a percentage of the maximal contraction to KCl (60 mM).  Relaxation responses are 
expressed as a percentage of the initial tension induced by U46619.  For each vasoactive agent, the 
concentration necessary to produce 50% of its own maximal response (EC50) was determined using 
Prism 6 software (GraphPad Software, Inc., La Jolla, CA).  Briefly, the log[M concentration] was plotted 
along the x-axis and percent of maximal contraction plotted along the y-axis.  Next, Prism 6 software was 
used to find the best fit curve using nonlinear regression with the dose response equation for log(dose) 
vs. response.  The EC50 values were converted to the negative logarithms and expressed as -log molar 
EC50 (pD2).  Initial and final ewe body weight, fetal measurements, placental measurements [including the 
average placentome weight, calculated as: (total placentome weight / placentome number)], placental 
efficiency [calculated as: (total fetal weight per ewe / total placentome weight per ewe)], and the qPCR 
data, were analyzed by ordinary least squares [GLM procedure of SAS (SAS software version 9.2; SAS 
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Institute, Cary, NC)], with treatment in the model statement.  The dose response curves for BK and SNP 
were also analyzed using ordinary least squares [GLM procedure of SAS (SAS Institute)], with treatment, 
dose, and the treatment by dose interaction in the model statement.  The dose response curves for KCl 
and PE were also analyzed using ordinary least squares [GLM procedure of SAS (SAS Institute)], with 
treatment, dose, endothelium, the treatment by dose interaction, the treatment by endothelium interaction, 
the endothelium by dose interaction, and the treatment by endothelium by dose interaction in the model 
statement. The pD2 values were analyzed using Prism 6 software (GraphPad Software, Inc.).  Ewe body 
weight throughout gestation and the percentage change from day 100 in ewe body weight {calculated as: 
[(weight on any day – day 100 weight) / day 100 weight] × 100} were analyzed using generalized least 
squares [MIXED procedure of SAS (SAS Institute)] using repeated-measures ANOVA (day 100 to day 
130 of gestation), with treatment, day of gestation, and the treatment by day of gestation interaction in the 
model.   For all data, if the F-test was significant, means were separated using the least significant 
difference.  Least squares means and SEM are reported.  
 
Results 
Ewe body weight and conceptus measurements 
 Initial ewe body weight did not differ (P = 0.11) among treatments (62.6, 73.1, and 68.7 ± 3.55 kg 
for MP60, MP80, and MP100, respectively).  The MP60 ewes were lighter (P = 0.02) at slaughter 
compared with the MP80 ewes, with MP100 ewes being intermediate (62.8 vs. 79.1 ± 3.78 kg, and 71.6 ± 
3.35 kg for MP60, MP80, and MP100 ewes, respectively).  There was a treatment by day interaction for 
ewe body weight throughout gestation (Figure 4.1), with MP60 ewes being lighter (P = 0.03) than MP80 
ewes on days 107, 114, 121, 128, and 130, with the MP100 ewes being intermediate (Figure 4.1A).  
There was also a treatment by day interaction for the percentage change from day 100 in ewe body 
weight (Figure 4.1), with MP60 ewes having a lower (P = 0.03) percentage change in body weight 
compared with MP100 ewes on day 107, with MP80 ewes being intermediate (Figure 4.1B).  
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Moreover MP60 ewes had a lower (P = 0.03) percentage change in body weight compared to both the 
MP80 and MP100 ewes on days 114, 121, 128, and 130 of gestation (Figure 4.1B). There was no 
statistical difference (P ≥ 0.24) on any fetal or placental measurement observed among the maternal 
metabolizable protein levels (Table 4.3).  
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Figure 4.1. The effect of maternal metabolizable protein (MP) restriction on (A) 
ewe body weight throughout gestation and (B) the percentage change in ewe 
body weight throughout gestation.  Maternal diets were formulated to provide 
60% of MP requirements (MP60), 80% of MP requirements (MP80), or 100% of 
MP requirements (MP100).  Diets were fed from day 100 to 130 of gestation.  
*MP60 differs from MP80 (P ≤ 0.05), **MP60 differs from MP100 (P ≤ 0.05), 
***MP60 differs from MP80 and MP100 (P ≤ 0.05) and MP80 and MP100 were 
similar (P > 0.05). 
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Table 4.3. The effect of maternal metabolizable protein level on gravid uterine weight, total fetal weight, 
average fetal weight, fetal curved crown length, fetal girth, total placentome weight, total placentome 
number, average placentome weight, total caruncular weight, total cotyledonary weight, fetal membrane 
weight, fetal fluid volume, empty uterine weight, and fetal weight to placental weight ratio. 
                     Treatments1  
Measurement  MP60  MP80  MP100  SE  P-value 
Gravid uterine weight (g)  9277  9756  9348  1097  0.95 
Total fetal weight2 (g)  2450  2908  2602  445  0.80 
Average fetal weight (g)  2110  2485  2187  443  0.79 
Fetal CCL3 (cm)  54.6  58.7  53.1  2.42  0.24 
Fetal girth (g)  32.6  33.8  31.3  1.60  0.51 
Total placentome weight4 (g)  754.1  780.8  774.3  60.9  0.93 
Total placentome number  80.0  89.5  79.7  7.10  0.50 
Average placentome weight (g)  9.24  9.16  9.76  1.19  0.91 
Total CAR5 weight (g)  123.3  126.5  122.5  12.7  0.97 
Total COT6 weight (g)  573.7  595.9  592.4  47.7  0.92 
Fetal membrane weight (g)  336.9  347.5  333.1  42.4  0.97 
Fetal fluid volume (mL)  2212  2304  2299  298  0.97 
Empty uterine weight (g)  66937  782.1  773.3  70.8  0.38 
Fetal weight/total placentome 
weight (g/g) 
 4.10  4.04  3.78  0.83  0.94 
1Maternal diets (DM basis) were balanced for mature ewes during the last 4 weeks of gestation according 
to NRC (2007).  Treatments: MP60: 60% of MP requirements; MP80: 80% of MP requirements; and 
MP100: 100% of MP requirements. 
2Total fetal weight = total fetal weight per ewe 
3Fetal CCL = fetal curved crown length 
4Total placentome weight = total placentome weight per ewe 
5CAR = caruncular 
6COT = cotyledonary  
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Organ bath studies  
 Bradykinin (BK) dose response curves.  The results of the BK dose response curve can 
visualized in Figures 4.1A and 4.1C for CAR and COT arteries, respectively.  There was little evidence of 
a treatment by dose interaction on the BK dose response curve (P ≥ 0.45) for either the CAR or the COT 
arteries (Figures 4.1A and 4.1C); however, there was an overall treatment effect (P ≤ 0.05) on the BK 
dose response curve for both the CAR and COT arteries.  In the CAR arteries, there is a slight leftward 
shift (P = 0.01; Figure 4.1A) in the MP80 ewes compared with the MP60 and MP100 ewes, which did not 
differ (pD2: 7.87 vs. 7.66, 7.65 ± 0.06 for MP80, MP60, and MP100, respectively).  In the COT arteries, 
there is a leftward shift of both (P = 0.01; Figure 4.1C) the MP60 and MP80 ewes compared with the 
MP100 ewes (pD2: 8.07 vs. 7.90 vs. 7.36 ± 0.07 for MP60, MP80, and MP100, respectively). 
Sodium nitroprusside (SNP) dose response curves.   The results of the SNP dose response curve 
are visualized in Figures 4.1B and 4.1D for CAR and COT arteries, respectively.  There was not a 
treatment by dose interaction (P ≥ 0.47) for either the CAR or COT SNP dose response curve (Figures 
4.1B and 4.1D).  Further, there were no overall treatment effects (P ≥ 0.16) for the CAR or COT SNP 
dose response curves (Figures 4.1B and 4.1D).  In the CAR arteries, dietary treatment did not affect the 
pD2 values (P = 0.99; pD2: 8.14, 8.41, 8.26 ± 0.14 for MP60, MP80, and MP100, respectively).  In the 
COT arteries, dietary treatment did not affect the pD2 values (P = 0.94; pD2: 8.07, 8.10, 8.13 ± 0.32 for 
MP60, MP80, and MP100, respectively).   
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Figure 4.2. The effect of maternal metabolizable protein (MP) restriction on (A) the 
bradykinin (BK) dose response curve in caruncular (CAR) arteries, (B) the sodium 
nitroprusside (SNP) dose response curve in CAR arteries, (C) the BK dose response 
curve in cotyledonary (COT) arteries, and (D) the SNP dose response curve in COT 
arteries. Maternal diets were formulated to provide 60% of MP requirements (MP60), 
80% of MP requirements (MP80), or 100% of MP requirements (MP100).  Diets were 
fed from day 100 to 130 of gestation.   
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Potassium chloride (KCl) dose response curves.   The results of the KCl dose response curves 
for CAR and COT arteries are visualized in Figures 4.3A and 4.3C, respectively).  There was no treatment 
by endothelium by dose interactions (P ≥ 0.59) on the KCl dose response curve for either the CAR or the 
COT arteries.  In the CAR arteries, there was no treatment by dose interaction (P = 0.98) for the KCl dose 
response curve (Figure 4.3A).  Further, there was no overall treatment effect (P = 0.59) on the KCl dose 
response curve in the CAR arteries (Figure 4.3A).  Further, there were no treatment by endothelium, 
endothelium by dose (Figure 4.3A), or overall endothelium effects (P ≥ 0.58) on the KCl dose response 
curve in the CAR arteries.  In the COT arteries, there was a treatment by dose interaction (P = 0.05) on 
the KCl dose response curve.  The MP60 ewes had a greater contraction (P = 0.05) to a lower dose of 
KCl compared with the MP80 and MP 100 ewes (Figure 4.3C), and the MP80 ewes had a greater 
contraction (P = 0.05) to a lower dose of KCl compared with the MP100 ewes (Figure 4.3C). However, 
after the 20mM dose of KCl, all COT arteries responded similarly to KCl regardless of maternal 
metabolizable protein level (Figure 4.3C).  The endothelium by treatment interaction for the KCl dose 
response curve in the COT arteries was not statistically significant (P = 0.75; Figure 4.4A); however, there 
was an endothelium by dose interaction (P = 0.01) on the KCl dose response curve in the COT arteries 
(Figure 4.4B).  The COT arterial rings that were denuded of the endothelium had a greater response (P = 
0.01) to a low dose of KCl compared with the endothelium-intact arterial rings (Figure 4.4B).   In the CAR 
arteries, dietary treatment did not affect the pD2 values (P = 0.99; pD2: 21.1, 21.5, 22.7 ± 1.41 for MP60, 
MP80, and MP100, respectively).  Maternal diet also did not impact pD2 values in the COT arteries (P = 
0.99; pD2: 19.9, 23.8, 29.9 ± 1.51 for MP60, MP80, and MP100, respectively).   
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Figure 4.3. The effect of maternal metabolizable protein (MP) restriction on (A) the 
potassium chloride (KCl) dose response curve in caruncular (CAR) arteries, (B) the 
phenylephrine (PE) dose response curve in CAR arteries, (C) the KCl dose response 
curve in cotyledonary (COT) arteries, and (D) the PE dose response curve in COT 
arteries. Maternal diets were formulated to provide 60% of MP requirements (MP60), 
80% of MP requirements (MP80), or 100% of MP requirements (MP100).  Diets were 
fed from day 100 to 130 of gestation.  *MP60 differs from MP80 and MP100 (P ≤ 0.05) 
and MP80 differs from MP100 (P ≤ 0.05). 
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Phenylephrine (PE) dose response curves.   The results of the PE dose response curves for CAR 
and COT arteries are visualized in Figures 4.3B and 4.3D, respectively.  A treatment by endothelium by 
dose interaction on the PE dose response curve was not observed (P ≥ 0.30) for either the CAR or the 
COT arteries. There were little evidence of treatment by dose interactions (P ≥ 0.32) or overall treatment 
effects (P ≥ 0.09) on the PE dose response curve for either the CAR or the COT arteries.  Further, the 
treatment by endothelium and endothelium by dose interactions and the overall endothelium effect on the 
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Figure 4.4. The effect of the presence (E+) or absence (E-) of endothelium on (A) the 
potassium chloride (KCl) dose response curve in caruncular arteries, (B) the KCl dose 
response curve in cotyledonary arteries.  *E+ differs from E- (P ≤ 0.05). 
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PE dose response curve were not statistically significant (P ≥ 0.17) for either the CAR or the COT 
arteries.  In the CAR arteries, dietary treatment did not affect the pD2 values (P = 0.13; pD2: 6.08, 6.45, 
6.30 ± 0.13 for MP60, MP80, and MP100, respectively).  Maternal protein level also did not alter (P = 
0.35) the pD2 values in the COT (pD2: 6.25, 6.51, 6.55 ± 0.18 for MP60, MP80, and MP100, respectively).   
 
Endothelial nitric oxide synthase, GUCY1B3, BKR1, and BKR2 mRNA expression 
 Maternal metabolizable protein level did not significantly influence the mRNA expression of eNOS 
(P = 0.79; 1.60, 1.67, 1.48 ± 0.20 arbitrary units for MP60, MP80, and MP100, respectively), GUCY1B3 
(P = 0.89; 1.47, 1.50, 1.41 ± 0.14 arbitrary units for MP60, MP80, and MP100, respectively), BKR1 (P = 
0.82; 1.48, 1.37, 1.54 ± 0.21 arbitrary units for MP60, MP80, and MP100, respectively), or BKR2 (P = 
0.74; 1.65, 1.76, 1.98 ± 0.31 arbitrary units for MP60, MP80, and MP100, respectively) in the CAR 
arteries.  Similarly, in the COT arteries, maternal metabolizable protein did not significantly influence the 
mRNA expression of eNOS (P = 0.95; 1.62, 1.57, 1.54 ± 0.18 arbitrary units for MP60, MP80, and 
MP100, respectively), GUCY1B3 (P = 0.89; 1.61, 1.52, 1.62 ± 0.16 arbitrary units for MP60, MP80, and 
MP100, respectively), BKR1 (P = 0.91; 1.37, 1.31, 1.45 ± 0.24 arbitrary units for MP60, MP80, and 
MP100, respectively), or BKR2 (P = 0.38; 1.62, 1.33, 2.06 ± 0.44 arbitrary units for MP60, MP80, and 
MP100, respectively). 
Discussion 
 This study aimed to investigate the effects of maternal metabolizable protein level on the vascular 
responses of the maternal and fetal placental arteries to two vasoconstrictors and two vasodilators.  We 
hypothesized that a maternal diet low in protein would negatively impair the sensitivity of the placental 
arteries, particularly to BK, an endothelium-dependent vasodilator.  We reject our hypothesis because 
placental arteries from ewes receiving the protein-restricted diet were more sensitive to BK compared to 
the placental arteries from control ewes.  To our knowledge, there are limited data in the literature with 
regards to protein supplementation on ovine placental arteriole function, and this study provides insight 
into how the placental arteriole function may be altered by maternal protein levels.  
While restricting MP during late gestation in sheep does not appear to negatively affect fetal 
weight or placental measurements at day 130 (current study), the present study suggests that decreasing 
 96 
 
maternal MP may impact endothelium-dependent vascular function of the placenta.  There was an overall 
treatment effect for the bradykinin dose response curves in both maternal and fetal placental arteries. The 
maternal placental arteries of the MP80 ewes were slightly more sensitive to BK compared with the MP60 
and MP100 ewes.  It is unclear why the placental arteries of MP80 ewes were more sensitive to BK-
induced relaxation but the maternal placental arteries from the MP60 ewes did not show this same 
increased sensitivity.  In the MP60 and MP80 fetal placental arteries were more sensitive to bradykinin-
induced vasorelaxation compared with the MP100 ewes.  Perhaps this increased sensitivity of the fetal 
placental arteries is a compensatory mechanism in the MP-restricted animals.   
There is a limited information in the literature concerning how maternal nutrition of any kind, let 
alone protein amounts, impacts placental vascular function. We demonstrated that isocaloric diets with 
differing levels of MP during late gestation have effects on placental arterial responses to 
vasoconstrictors, an endothelium-dependent relaxant (BK) and an endothelium-independent relaxant 
(SNP). Relatively few studies exist that investigate the role of maternal protein deprivation and vascular 
responses to BK and SNP.  One such study by Brawley et al. (2003) found that the mesenteric arteries 
from male offspring born to rats that were fed a 9% casein diet throughout gestation were less sensitive to 
BK-induced vasorelaxation at days 87 and 164 of life compared to males from rats fed an 18% casein 
diet.  It is difficult to compare the current study to that of Brawley et al. (2003) for four reasons.  First, 
different species were used in the two studies, and protein absorption in ruminants is different from that in 
rodents.  Second, in the Brawley et al. (2003) study, the diets did consist of different levels of dietary 
protein, but no measures were taken to provide isocaloric diets as in the current study.  Third, the current 
study investigated maternal and fetal placental arteries, whereas Brawley et al. (2003) studied the effects 
of protein restriction on the mesenteric artery.  Finally, the current study investigated maternal and fetal 
placental arteries in near term sheep (day 130 of gestation), and Brawley et al. (2003) studied arteries 
from only male offspring that were in young adult and adult stages of life. Therefore, it is not surprising 
that Brawley et al. (2003) and the current study found different results when looking at BK-induced 
vasorelaxation.  Ozaki et al. (2000) investigated the effects of global nutrient restriction (fed 50% of NRC 
requirements or 100% of NRC requirements) in pregnant ewes on the vascular response of small arteries 
from the fetal femoral bed to acetylcholine (an endothelium-dependent relaxant) on day 127 of gestation 
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and found that the restricted animals had a blunted response to ACh compared to the control animals 
(Ozaki et al., 2000).  This data indicates that perhaps it is the net caloric intake that is resulting in the 
decreased response of arteries to endothelium-dependent relaxants (as observed in Ozaki et al., 2000 
and Brawley et al., 2003) rather than protein restriction.    
In the current study, maternal metabolizable protein level did not impact the maternal or fetal 
placental arterial response to endothelium-independent vasorelaxation (induced by SNP).  Similar to their 
BK results, Brawley et al. (2003) found that the mesenteric arteries from male offspring born to rats that 
were fed a 9% casein diet throughout gestation were less sensitive to SNP-induced relaxation at days 87 
and 164 of life compared with arteries from males from rats fed an 18% casein diet.  Again, it is difficult to 
compare the current study with that of Brawley et al. (2003).  Ozaki et al. (2000) investigated the effects 
of global nutrient restriction (fed 50% of NRC requirements or 100% of NRC requirements) in pregnant 
ewes on the vascular response of small arteries from the fetal femoral bed to SNP on day 127 of 
gestation and found that the restricted animals had a blunted response to SNP compared to the control 
animals (Ozaki et al., 2000).  While Ozaki et al. (2000) utilized sheep, the design of the study was to 
investigate global nutrient restriction and not specifically protein deprivation.  The differing results 
between Ozaki et al. (2000) and the current study are likely due to differences in the nutritional design of 
the two studies.  Further, Ozaki et al. (2000) fed the restricted diets from day 0 to day 70 of gestation, 
whereas the current study fed MP-restricted diets from day 100 to 130 of gestation; therefore, 
comparisons between the two studies are difficult.   
Brawley et al. (2003) also measured blood pressure of the male offspring at day 130 of life and 
found that males from dams that were protein restricted had an increase in blood pressure compared with 
males from dams that were not protein restricted.  Based upon the blood pressure data and the BK and 
SNP results and, Brawley et al. (2003) concluded that maternal dietary protein restriction during gestation 
results in male offspring that were hypertensive due to vascular impairment of both endothelium-
dependent and endothelium-independent vasorelaxation.  The current study did not measure blood 
pressure, but the Brawley et al. (2003) results suggest that it is possible the maternal low protein diet 
could program the cardiovascular health of the offspring later in life, and if the current study were to have 
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collected day after day 130 of gestation, we may have observed hypertension in the offspring from 
protein-restricted dams.   
In the current study, maternal placental arteries responded similarly to KCl, regardless of 
maternal MP level; however, in the fetal placental arteries, the initial contraction to KCl (20 mM) increased 
as maternal MP decreased, suggesting that maternal MP-restriction may result in increased hypertension 
in the fetal placental arteries.  However, when taken together with the BK dose response curve data, it 
could be concluded that maternal MP-restriction may result in more sensitive fetal placental arteries, 
regardless if the stimulus is a relaxant or a constrictor. Maternal MP level did not influence the response 
to PE in either the maternal or the fetal placental arteries.  Itoh et al. (2002) fed pregnant rats either a 9% 
casein diet or an 18% casein diet from day 0 to day 18 or 19 of gestation, at which time the vascular 
response of the uterine artery to KCl and PE was investigated.  Itoh et al. (2002) did not find any 
differences between the two dietary groups for either vasoconstrictor.  Again, it is difficult to directly 
compare the current study to that of Itoh et al. (2002) because of the difference in species, diet design, 
and arteries investigated, particularly because Itoh et al. (2002) examined the uterine artery whereas the 
current study examined the CAR and COT arteries.   
In the present study, the fetal placental arteries were more sensitive to KCl when the endothelium 
was removed, but endothelium removal did not alter fetal placental responses to PE.  This is similar to 
Tsuji et al. (1994) who found that removing the endothelium potentiated the contractile response to KCl 
but had no effect on the contractile response to PE.  This indicates that while KCl acts upon vascular 
smooth muscle cells, the endothelium plays an important role in modulating the calcium influx into the 
smooth muscle cells.  
The mRNA expression of the BK receptors 1 and 2 (BKR1 and BKR2) was analyzed in the 
present study.  Because one of the mechanism of BK-induced relaxation involves nitric oxide, the mRNA 
of NO and it’s receptor soluble guanylate cyclase was also analyzed.  Since the current study observed 
an overall treatment effect on the maternal and fetal placental arterial response to BK, one might expect 
to see differences among the three MP diets in mRNA expression of BK receptors 1 and 2 in these 
arteries; however, this was not the case.   The mRNA expression of all genes investigated was similar 
among all treatments in both maternal and fetal placental arteries.  This is an important finding, as it 
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indicates that even though gene expression was not altered, vascular function was, and it supports the 
need for more vascular function studies.  
In the present study, feeding diets formulated to provide 60% of MP resulted in decreased ewe 
body weight throughout gestation compared with ewes fed 80% of MP as well as a lower percentage 
change in BW compared to ewes receiving either 80% or 100% of MP.  Van Emon et al. (2013) fed 
similar diets to a larger group of ewes (n = 295) and found that by lambing, ewe BW and percentage 
change in BW increased linearly as MP level increased from 60% to 100%.  It is possible that a linear 
effect on ewe BW and the percentage change in ewe BW would have been observed in the current study 
if a larger sample size was used or if the ewes were fed the diets through gestation.   
 Maternal undernutrition has been shown to cause fetal growth restriction in sheep (Charlton and 
Johengen, 1985; Holst et al., 1986; Faichney and White, 1987; Holst et al., 1992; Bloomfield et al., 2000; 
Vonnahme et al., 2003; Scheaffer et al., 2004; Lekatz et al., 2010a, 2010b; Lemley et al., 2012).  In the 
current study, maternal MP level did not alter fetal weight, length or girth, which indicates that fetal mass 
and size is more dependent on the overall amount of calories received rather than the level of MP in the 
maternal diet.  When isocaloric diets that differed in the level of MP were fed to ewes from day 100 to 
lambing, there was no difference in lamb birth weight (Van Emon et al., 2013), which indicates that even if 
the MP treatments are fed through lambing, there are no negative effects on fetal weight.  Also of 
importance, decreasing the MP level to 60% or 80% of NRC requirements did not alter the percentage of 
assisted births or the percentage of lambs requiring treatment for illness at birth, which also indicates that 
decreasing MP level during gestation does not have negative effects on birthing or neonatal health (Van 
Emon et al., 2013).  Therefore, neonatal health and performance does not appear to be influenced by 
maternal protein levels in the diet when fed at or above 60%. However, others have shown enhanced 
phenotypes in offspring born from dams that were supplemented with protein during the last third of 
gestation.  For example, Stalker et al. (2006) found that calves born to cows that were supplemented with 
crude protein during late gestation were heavier at weaning than calves born to cows that were not 
supplemented.  So while, we did not observe any differences due to diet on fetal weight and Van Emon et 
al. (2013) did not observe differences due to diet on lamb weight or health, the Stalker et al. (2006) data 
indicates that differences to the offspring may not be observed until later in life.   
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 Maternal nutrient restriction in sheep has also been linked to altered placental weight in some 
studies (Charlton and Johengen, 1985; Faichney and White, 1987; McCrabb et al., 1991, 1992a, 1992b; 
Heasman et al, 1998; McMullen et al., 2005) but not in others (Vonnahme et al., 2003; Scheaffer et al., 
2004; Holst et al., 1992; Bloomfield et al., 2000; Lemley et al., 2012; Lekatz et al., 2010a, 2010b). It is 
likely that the effects of maternal nutrition on placental characteristics vary among studies due to the 
timing and severity of nutrient restriction.  In the current study, diets were “adequate in calories”, however, 
maternal MP level from day 100 to 130 of gestation did not alter placental measurements.   However, 
weight is not always a good indicator of function.   
In conclusion, this study investigates the role of maternal MP restriction from day 100 to day 130 
of gestation on the vascular function of maternal and fetal placental arteries in near term sheep.  The lack 
of differences in fetal and placental measurements indicates that not meeting MP requirements does not 
negatively impact fetal or placental growth in fetal sheep.  However, MP level did influence vascular 
function of placental arteries.  Metabolizable protein restriction resulted in increased sensitivity to an 
endothelium-dependent relaxant in fetal placental arteries.  This may be a compensatory mechanism of 
the protein restricted animals, and this could be a beneficial result of low MP.  Further studies are needed 
to better understand how maternal MP alters placental vascular function, what mechanisms are 
responsible for the endothelium-dependent vasorelaxation of the placental arteries, and how maternal MP 
might influence the mechanisms of vasorelaxation.   
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CHAPTER 5. BRADYKININ-INDUCED VASORELAXATION IS ACHIEVED THROUGH DIFFERENT 
MECHANISMS IN MATERNAL AND FETAL PLACENTAL ARTERIES IN SHEEP 
 
Abstract 
We hypothesize that restricting or overfeeding maternal metabolizable protein (MP) during late 
gestation will increase the sensitivity to bradykinin (BK)-induced vasorelaxation in the fetal placental 
arteries.  Further, we hypothesize maternal MP level will influence the mechanism of BK-induced 
vasodilation in placental arteries.  Pregnant ewes (n = 18) were assigned to one of three isocaloric diets 
formulated to provide 60%, 100%, or 140% of the MP requirements (MP60, MP100, and MP140, 
respectively) from day 100 to 130 of gestation. Pharmacological studies investigated the dose response 
curves (DRCs) to BK in caruncular (CAR) or cotyledonary (COT) arteries in the absence or presence of 
one of three inhibitors: iberiotoxin (inhibits K+ channels), indomethacin (inhibits cyclooxygenase 1 and 2, 
COX-1 and -2) or N(omega)-L-arginine methyl ester (inhibits nitric oxide synthase, NOS).   There were no 
treatment by dose interactions for any of the DRCs (P ≥ 0.79) in CAR or COT arteries.  In CAR arteries, 
inhibiting K+ channels and NOS resulted in a rightward shift (P = 0.01) of the BK DRC, indicating that 
both of these mechanisms are important for BK-induced vasodilation in CAR arteries.  However, inhibition 
of COX-1 and -2 failed to attenuate (P = 0.89) the BK response, indicating that prostacyclin may not be 
involved in BK-responses in CAR arteries.  In the COT arteries, there was a leftward shift (P = 0.01) in the 
BK DRC for MP60 and MP140 ewes compared with MP100 ewes, indicating that both maternal MP 
restriction and excess results in increased sensitivity to BK in COT arteries.  Inhibition of K+ channels, 
COX-1 and -2, and NOS failed to prevent vasorelaxation in COT arteries as all Emax values were similar 
(P = 0.11) to the BK DRC with no inhibitor.  Because COT arteries relaxed in the presence of these 
inhibitors, BK-induced vasodilation in COT arteries in the current study must be achieved through an 
unclassified endothelium-dependent relaxing factor.   
 
Key words: bradykinin, ewes, metabolizable protein, pregnancy, vascular function 
 
 
 105 
 
Introduction 
Increasing uterine blood flow during the last half of gestation is critical for oxygen and nutrient 
delivery to the exponentially growing fetus, and alterations to placental blood flow vasculature may 
compromise the growth of the developing fetus (Ford, 1995; Meschia, 1983; Redmer et al., 2004; 
Reynolds et al., 2005; Reynolds et al., 2006).  In sheep, maternal nutrient restriction reduces uterine 
(Lemley et al., 2012) and umbilical (Lemley et al., 2012; Lekatz, Chapter 2) blood flow. 
 An important question to consider is if these alterations to the placenta and blood flow are due to 
an overall caloric restriction or to restriction of a specific component in the diet.  Evidence in rodent 
models suggests that maternal dietary protein level plays an important role in vascular tone of pregnant 
animals.  For example, protein restriction during pregnancy impairs vascular relaxation of peripheral 
arteries (Koumentaki et al., 2002) and the uterine artery (Itoh et al., 2002) in rats, which could negatively 
affect blood flow to the developing fetus.  Many of the rodent models investigating maternal protein 
restriction investigate vascular responses to acetycholine (Itoh et al., 2002; Koumentaki et al., 2002; 
Torrens et al., 2002; Musha et al., 2006), but bradykinin-induced vasoresponses may be of more 
importance, especially when considering hypertension in the offspring (Wirth et al., 1996) and 
bradykinin’s close association with the renin angiotensin system.  
Our laboratory found that restricting maternal metabolizable protein (MP) during late gestation 
resulted in increased sensitivity to bradykinin in the fetal placental cotyledonary arteries near term in 
sheep (Lekatz, Chapter 3).   This increased sensitivity of placental arteries to bradykinin may be a 
compensatory mechanism in sheep not meeting MP requirements. The exact mechanisms of bradykinin-
mediated vasodilation in placental arteries of sheep are not known.  Further how maternal metabolizable 
protein level might impact these mechanisms has not been investigated.  Therefore, the objective of this 
study was to examine the effect of three levels of maternal MP during late gestation on the mechanisms 
of bradykinin-induced vasorelaxation in the placental arteries of sheep.  
 
Materials and methods 
Animal studies were approved the by North Dakota State University Animal Care and Use 
Committee. On day 90 of gestation, 18 pregnant multiparous ewes carrying a single fetus, were housed in 
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individual pens (0.91 × 1.2 m) in an indoor facility until necropsy (130 ± 2 days of gestation).  
Temperature was held constant at 12ºC, and lighting was controlled automatically (12:12-h light-dark 
cycle with lights on at 07:00 and of at 19:00).    
Ewes were acclimated to low-quality hay (Table 5.1) and the MP100 supplement (100% of the 
MP requirements, as determined by NRC, 2007; Table 2) for 10 days prior to starting dietary treatments.  
Ewes were weighed on two consecutive days (days 99 and 100 of gestation) prior to the initiation of 
treatments. On day 100 of gestation ewes were randomly assigned to one of three isocaloric dietary 
treatments (Table 5.2): MP60: 60% of MP requirements, MP100: 100% of MP requirements, and MP140: 
140% of the MP requirements on a DM basis during the last 4 weeks of gestation (NRC, 2007).  Dietary 
treatments were fed from 100 to 130 days of gestation.   Metabolizable protein intake was determined by 
the average of the days 99 and 100 body weight and offered once daily at 0700 h.  Ewes were given one 
hour to consume the supplement then low-quality forage (Table 5.1) was offered.  Body weights were 
collected every 10 days throughout the dietary treatment period, and the amount of supplement and low-
quality forage offered was adjusted for changes in body weight.  All ewes had access to fresh water and 
trace mineralized salt (4,000 ppm Zn, 1,600 ppm Fe, 1.200 ppm Mn, 325 ppm Cu, 100 ppm I, 40 ppm Co; 
American Stockman, Overland Park, KS).    
 
Table 5.1.  Nutrient composition of fescue 
straw1. 
Item   
Diet, % DM  56.51 
DM, %  77.61 
NEm, Mcal/kg  2.12 
CP, % of DM  3.07 
MP, % of DM  1.97 
NDF, % of DM  81.13 
ADF, % of DM  51.10 
Ash, % of DM  7.78 
1Ewes were fed fescue straw to limit MP 
intake 
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Table 5.2. Ingredient and nutrient composition of dietary supplements fed 
to ewes. 
  Treatment1 
Item  MP60  MP100  MP140 
Ingredient, % DM       
Corn  30.00  19.00  5.00 
DDGS2  4.00  24.00  30.00 
Soyhulls  9.00  —  — 
       
Nutrient composition       
DM, %  88.64  90.19  92.16 
NEm, Mcal/kg  2.05  2.19  2.06 
CP, % of DM  10.21  18.67  28.68 
MP, % of DM  6.54  11.96  18.37 
NDF, % of DM  29.64  31.40  45.34 
ADF, % of DM  13.87  8.68  13.34 
Ash, % of DM  3.53  3.50  5.13 
1Maternal diets (DM basis) were balanced for mature ewes baring a 
singleton during the last 4 weeks of gestation according to NRC (2007).  
Treatments: MP60: 60% of MP requirements; MP100: 100% of MP 
requirements; and MP140: 140% of MP requirements. 
 
2Dried distillers grains with solubles 
 
 
 
Tissue collection and fetal and placental measurements 
On day 130 of gestation, ewes were weighed and euthanized by captive bolt (Supercash Mark 2, 
Accles and Shelvoke Ltd., Sutton Coldfield, West Midlands, UK) followed by exsanguination.  The gravid 
uterus was immediately dissected cranial to the cervix and weighed.  The uterus was opened along the 
antimesometrial side, the umbilical cord was ligated, and the fetus was removed, weighed, and fetal 
curved crown rump and abdominal girth were recorded.  Immediately after the fetus was removed, the 
terminal branches of fetal placental arteries (cotyledonary arteries; COT arteries) were dissected and 
either immersed in cold physiological salt solution for the organ bath chamber study (described below) or 
snap frozen in liquid nitrogen and stored at -80ºC for qPCR (described below).  These COT arteries, 
terminating directly into the cotyledon, were typically secondary branches of the umbilical artery.   
Following removal of the fetal placental arteries, the gravid uterine artery was located and maternal 
placental arteries (caruncular arteries; CAR arteries) terminating at the caruncle were dissected and 
dissected and either immersed in cold physiological salt solution for the organ bath chamber study 
(described below) or snap frozen in liquid nitrogen and stored at -80ºC for qPCR (described below).  
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These CAR arteries, terminating directly into the caruncle, were typically 4th or 5th branches of the gravid 
uterine artery.  Because placentome size has been shown to influence vascular reactivity (Vonnahme et 
al., 2008) similarly sized placentomes were selected for each animal.    
Next, the fetal fluid was collected and the volume recorded.  Placentomes were counted, 
dissected, weighed, and the CAR and COT tissues were separated and weighed.  The fetal membranes 
and empty uterine weight were also weighed. 
 
Quantification of mRNA 
 The relative mRNA expression of endothelial nitric oxide synthase (eNOS), soluble guanylate 
cyclase (GUCY1B3), bradykinin receptor 1 (BKR1), and bradykinin receptor 2 (BKR2) was determined in 
the CAR and COT arteries.  Caruncular and COT arteries (30mg) were homogenized using a Polytron 
homogenizer fitted with a 7mm generator.  Messenger RNA was isolated using a QIAshredder spin 
column and the RNeasy Mini Kit as described by the manufacturer (Qiagen, Valencia, CA).  RNA was 
quantified by measuring the absorbance on a Nanodrop 2000c spectrophotometer.  Synthesis of cDNA 
synthesis was performed using the QuantiTect Reverse Transcription Kit as described by the 
manufacturer (Qiagen).  This protocol includes a genomic DNA removal step, which was performed for all 
samples.  Quantitative PCR (qPCR) reactions for eNOS and sGC contained the following: 1x TaqMan 
Universal PCR Master Mix (Life Technologies), forward and reverse primers (each 1µM), water and cDNA 
for a final volume of 12.5 µl. Reactions to detect BKR1 and BKR2 contained the following:  1X SYBR 
Green PCR Master Mix (Life Technologies), forward and reverse primers (each 500 nM), water and cDNA 
for a final volume of 12.5 µl. Dissociation curves confirmed a single amplification species for both BKR1 
and BKR2.  Amplification of 18s rRNA using a 20X predesigned assay reagent, which contained both 
forward and reverse primers and a probe (Life Technologies), was performed for each sample and was 
used to normalize expression of each gene.  The ratio of the gene of interest to 18S rRNA was used for 
quantifying the gene expression and is the data presented. 
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Organ chamber studies 
After transfer to the laboratory, the CAR and COT arteries were dissected free from surrounding 
placental tissue, cleaned of adherent fat and connective tissue, and cut into rings either 2-3 mm in length 
(CAR arteries) or 4-5 mm in length (COT arteries).  Four rings were prepared from both CAR and COT 
arteries for each ewe.  The endothelium remained intact in all of the arterial rings.   
The following drugs were used: KCl, norepinephrine, bradykinin, indomethacin, N(omega)-L-
arginine methyl ester, iberiotoxin (Sigma Chemical, St. Louis, MO), and 9, 11-dideoxy-11α,9α-
epoxymethano-PGF2α (Cayman Chemical, Ann Arbor, MI).  Drug solutions were prepared daily, kept on 
ice, and protected from light until used.  All drugs were dissolved initially in double-distilled water.  Drug 
concentrations are reported as final molar concentrations in the organ chamber.  The composition of the 
physiological salt solution was (in mM): 118.3 NaCl, 4.7 KCl, 2.5 CaCl2, 1.2 MgSO4, 1.2 KH2PO4, 25.0 
NaHCO3, and 11.1 glucose.  
Caruncular (n = 4 for each ewe) rings were mounted onto a wire myograph chamber (DMT-USA, 
Inc., Ann Arbor, MI) by passing two 20 µm steel wires through the lumen and secured to either side via 
supporting jaws.  The chambers were aerated with 95% O2/5% CO2 and the temperature was maintained 
at 37˚C throughout the experiment. Isometric tension was measured and recorded using a PowerLab 
data acquisition system.  The tissues were stretched progressively to the optimal point of their length-
tension relationship, using KCl (100mM) to generate a standard contractile response.  After this 
procedure, the rings were allowed to equilibrate at their optimal length-tension for one hour prior to further 
exposure to any vasoactive substances.  The presence of intact endothelium was confirmed in each 
preparation by contracting the rings with norepinephrine (NE; 10-6 M) and observing the presence or 
absence of relaxation to the endothelium-dependent vasodilator, bradykinin (BK; 10-7 M).  
Cotyledonary arterial rings (n = 4 for each ewe) were suspended in water-jacketed organ 
chambers filled with 25 ml of physiological salt solution, as previously described (Tunstall et al., 2011; 
Shukla et al., 2012).  The chambers were aerated with 95% O2/5% CO2 and the temperature was 
maintained at 37˚C throughout the experiment.  Each ring was suspended by means of two fine stainless-
steel wire clips passed through the lumen; one clip was anchored inside the organ chamber, the other 
connected to a force transducer (Model FT03, Grass Instrument Company, Quincy, MA, USA).  Isometric 
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tension was measured and recorded on a Grass polygraph.  The tissues were stretched progressively to 
the optimal point of their length-tension relationship, using KCl (100mM) to generate a standard 
contractile response.  After this procedure, the rings were allowed to equilibrate at their optimal length-
tension for one hour prior to further exposure to any vasoactive substances.  The presence of intact 
endothelium was confirmed in each preparation by contracting the rings with 9, 11-dideoxy-11α,9α-
epoxymethano-PGF2α (U46619; 10-6 M) and observing the presence or absence of relaxation to the 
endothelium-dependent vasodilator, bradykinin (BK; 10-7 M).  
 The same dose response curves were obtained in CAR and COT arteries.  Briefly, one ring 
underwent a BK dose response curve in the absence of any inhibitor (no inhibitor, NI) and the remaining 
rings underwent a BK dose response curve in the presence of one of three inhibitors, iberiotoxin (IBTX), 
indomethacin (INDO), or N(omega)-L-arginine methyl ester (NLA).    
A BK dose response curve in the absence of an inhibitor was obtained in one CAR and one COT 
arterial ring.  The rings were contracted with U46619 (10-8 M); after the U46619-induced contraction had 
reached a stable plateau, relaxation responses to increasing concentrations of the endothelium-
dependent vasodilator BK (10-10 to 10-6 M) in the absence of an inhibitor (no inhibitor, NI) were obtained.  
The remaining rings were incubated with one of three inhibitors: IBTX (10-7 M), INDO (10-5 M), or NLA (10-
5 M) for 30 minutes before being contracted with U46619 (10-8 M).  After the U46619-induced contraction 
had reached a stable plateau, relaxation responses to increasing concentrations of the endothelium-
dependent vasodilator BK (10-10 to 10-6 M) were obtained.   
 
Data analysis 
 Relaxation responses are expressed as a percentage of the initial tension induced by U46619 or 
NE.  For each vasoactive agent, both the maximal percent response (Emax) and the concentration 
necessary to produce 50% of its own maximal response (EC50) were determined using Prism 6 software 
(GraphPad Software, Inc., La Jolla, CA).  Briefly, the log[M concentration] was plotted along the x-axis 
and percent of maximal contraction plotted along the y-axis.  Next, Prism 6 software was used to find the 
best fit curve using nonlinear regression with the dose response equation for log(dose) vs. response.  The 
EC50 values were converted to the negative logarithms and expressed as -log molar EC50 (pD2).  Initial 
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and final ewe body weight, fetal measurements, placental measurements [including the average 
placentome weight, calculated as: (total placentome weight / placentome number)], the fetal weight to 
placental weight [calculated as: (fetal weight / total placentome weight)], qPCR data, and Emax were 
analyzed by ordinary least squares [GLM procedure of SAS (SAS software version 9.2; SAS Institute, 
Cary, NC)], with treatment in the model statement.  The pD2 values were analyzed using Prism 6 software 
(GraphPad Software, Inc.). The dose response curves were also analyzed using ordinary least squares 
[GLM procedure of SAS (SAS Institute)], with treatment, dose, and inhibitor main effects, treatment by 
dose, dose by inhibitor, and treatment by inhibitor by dose interactions in the model statement.  Within 
each treatment, the dose response curves were analyzed using ordinary least squares [GLM procedure 
of SAS (SAS Institute)] with dose and inhibitor main effects and the dose by inhibitor interaction in the 
model statement.  For both maternal and fetal placental arteries, the overall inhibitor dose response 
curves were compared to the dose response curve with no inhibitor using ordinary least squares [GLM 
procedure of SAS (SAS Institute)] with dose and inhibitor main effects and the dose by inhibitor 
interaction in the model statement.  For all data, if the F-test was significant, means were separated using 
least significant difference.  Least squares means and SE are reported.  
 
Results  
Ewe body weight 
 Initial ewe body weight did not differ (P = 0.98) among treatments (61.9, 63.1, and 62.6 ± 4.23 kg 
for MP60, MP100, and MP140, respectively).  Maternal MP level also did not affect (P = 0.80) ewe weight 
at slaughter (63.4, 67.5, and 66.0 ± 4.33 kg for MP60, MP100, and MP140, respectively) or the 
percentage change in ewe BW at slaughter (P = 0.06; 0.01, 0.03, and 0.01 ± 0.001 % for MP10, MP100, 
and MP140, respectively).  There was a treatment by day interaction (P = 0.02) on ewe BW throughout 
gestation (Figure 5.1); however, when the means were separated (PDIFF option of LSMEANS statement; 
SAS, Inc.), no P-values were less than 0.05.  
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Fetal and placental measurements 
 Fetal weight, fetal curved crown rump, and fetal girth were not influenced (P ≥ 0.50) by maternal 
metabolizable protein level (Table 5.3).  Gravid uterine weight, empty uterine weight, total placentome 
weight, total placentome number, average placentome weight, total CAR weight, total COT weight, fetal 
membrane weight, fetal fluid volume, and fetal weight / placentome weight were also not influenced (P ≥ 
0.09) by maternal metabolizable protein level (Table 5.3).  
 
 
 
 
 
 
Organ bath studies  
 Caruncular artery bradykinin dose response curves in the absence or presence of an inhibitor. 
There were no interactions (P ≥ 0.79) on the BK dose response curves in COT arteries with no inhibitor 
(Figure 5.2A) or for COT arteries incubated with IBTX (Figure 5.2B), INDO (Figure 5.2C), or NLA (Figure 
5.2D). There was no treatment by dose by dose response curve interaction (P = 0.99), so the dose by 
dose response curve interaction, dose main effect, and dose response curve main effect were analyzed 
for each treatment (MP60, MP100, and MP140) individually (Figure 5.3).  In the MP60 ewes, there was a 
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Figure 5.1. The effect of maternal metabolizable protein (MP) level on ewe body 
weight throughout gestation.  Maternal diets were formulated to be isocaloric and 
provide 60% of MP requirements (MP60), 100% of MP requirements (MP100), or 
140% of MP requirements (MP140).  Diets were fed from day 100 to 130 of gestation.   
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dose by dose response curve interaction (P = 0.02), where the CAR placental arteries responded similarly 
to BK in the presence or absence of any inhibitor used (IBTX, INDO, or NLA) until the 3 × 10-8 M dose.  
After this dose, the MP60 CAR arteries without an inhibitor were more sensitive (P = 0.02) to BK 
compared with the CAR arteries incubated with IBTX or NLA for the remaining doses of BK (Figure 5.3A).  
The CAR arteries incubated with INDO responded similarly to CAR arteries with no inhibitor at the 3 × 10-
8
 M, 10-7 M, and 3 × 10-6 M doses (Figure 5.3A). In the MP100 ewes, the dose by treatment interaction 
was not significant (P = 0.13), but it appears CAR arteries incubated with INDO responded similarly to 
CAR arteries without an inhibitor (Figure 5.3B).  Further, it appears that incubation with either IBTX or 
NLA delayed the BK-induced relaxation compared with the CAR arteries with no inhibitor (Figure 5.3B). 
 
Table 5.3. The effect of maternal metabolizable protein level on gravid uterine weight, total fetal weight, 
average fetal weight, fetal curved crown length, fetal girth, total placentome weight, total placentome 
number, average placentome weight, total caruncular weight, total cotyledonary weight, fetal membrane 
weight, fetal fluid volume, empty uterine weight, and fetal weight to placental weight ratio. 
                     Treatments1  
Measurement  MP60  MP80  MP100  SE  P-value 
Gravid uterine weight (g)  9277  9756  9348  1097  0.95 
Total fetal weight2 (g)  2450  2908  2602  445  0.80 
Average fetal weight (g)  2110  2485  2187  443  0.79 
Fetal CCL3 (cm)  54.6  58.7  53.1  2.42  0.24 
Fetal girth (g)  32.6  33.8  31.3  1.60  0.51 
Total placentome weight4 (g)  754.1  780.8  774.3  60.9  0.93 
Total placentome number  80.0  89.5  79.7  7.10  0.50 
Average placentome weight (g)  9.24  9.16  9.76  1.19  0.91 
Total CAR5 weight (g)  123.3  126.5  122.5  12.7  0.97 
Total COT6 weight (g)  573.7  595.9  592.4  47.7  0.92 
Fetal membrane weight (g)  336.9  347.5  333.1  42.4  0.97 
Fetal fluid volume (mL)  2212  2304  2299  298  0.97 
Empty uterine weight (g)  66937  782.1  773.3  70.8  0.38 
Fetal weight/total placentome 
weight (g/g) 
 4.10  4.04  3.78  0.83  0.94 
1Maternal diets (DM basis) were balanced for mature ewes during the last 4 weeks of gestation according 
to NRC (2007).  Treatments: MP60: 60% of MP requirements; MP80: 80% of MP requirements; and 
MP100: 100% of MP requirements. 
2Total fetal weight = total fetal weight per ewe 
3Fetal CCL = fetal curved crown length 
4Total placentome weight = total placentome weight per ewe 
5CAR = caruncular 
6COT = cotyledonary  
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Figure 5.2. The interaction of maternal metabolizable protein (MP) level and bradykinin (BK) 
dose on the BK dose response curve in caruncular arteries (A) in the absence of an inhibitor (no 
inhibitor, NI), (B) after incubation with iberiotoxin (IBTX), (C) after incubation with indomethacin 
(INDO), and (D) after incubation with N(omega)-L-arginine methyl ester (NLA). Maternal diets 
were formulated to be isocaloric and provide 60% of MP requirements (MP60), 100% of MP 
requirements (MP100), or 140% of MP requirements (MP140).  Diets were fed from day 100 to 
130 of gestation.   
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Figure 5.3. The effect of dose response curve (DRC) in caruncular (CAR) arteries on the 
bradykinin (BK) DRC within each dietary treatment.  Ewes were fed diets formulated to provide 
(A) 60% of metabolizable protein (MP) requirements (MP60), (B) 100% of MP requirements 
(MP100), and (C) 140% of MP requirements (MP140). The CAR arteries were incubated with no 
inhibitor (NI) or incubated with iberiotoxin (IBTX), indomethacin (INDO), or N(omega)-L-arginine 
methyl ester (NLA).  Diets were fed from day 100 to 130 of gestation. †NI is statistically different 
from IBTX, NLA, and INDO (P ≤ 0.05).  *NI is statistically different from IBTX and NLA (P ≤ 
0.05).  #NI is statistically different from INDO (P ≤ 0.05).   
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 In the MP140 ewes, there was a dose by dose response curve interaction (Figure 5.3C).  The 
CAR arteries incubated with INDO were more sensitive (P = 0.04) to BK at the 3 × 10-9 M, 10-8 M, and 3 × 
10-8 M doses compared with arteries with no inhibitor (Figure 5.3A).  Beginning at the 10-8 M dose of BK, 
CAR arteries that were not incubated with an inhibitor were more sensitive (P = 0.04) to the remaining 
doses of BK compared with the CAR arteries incubated with either IBTX or NLA (Figure 5.3C).  
 When all treatments were combined, there was also a dose by dose response curve interaction 
on the BK dose response curves (Figure 5.4A).  Beginning at the 3 × 10-8 M dose, CAR arteries with no 
inhibitor were more sensitive (P = 0.01) to BK compared with CAR arteries in the presence of IBTX or 
NLA (Figure 5.4A).  The CAR arteries incubated with INDO were more sensitive (P = 0.01) to the 3 × 10-8 
M dose of BK compared with the arteries in the absence of an inhibitor, but after this dose, the CAR 
arteries incubated with INDO responded to BK similarly (P = 0.01) to CAR arteries with no inhibitor 
(Figure 5.4A).  
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Caruncular artery EC50, pD2, and Emax values. Maternal MP level did not impact (P = 0.46) the 
pD2 value for the BK dose response curve in CAR arteries with no inhibitor (7.20, 7.00, 7.28 ± 1.78 for 
MP60, MP100, and MP140, respectively).  In CAR arteries incubated with IBTX, the pD2 value was lower 
(P ≤ 0.04) in the MP100 ewes compared with the MP60 and MP140 ewes, which were similar (P = 0.38; 
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Figure 5.4. The effect of dose response curve (DRC) on the bradykinin (BK) DRC in (A) 
in caruncular and (B) cotyledonary arteries.  The CAR arteries were incubated with no 
inhibitor (NI) or incubated with iberiotoxin (IBTX), indomethacin (INDO), or N(omega)-L-
arginine methyl ester (NLA).  †NI is statistically different from IBTX, NLA, and INDO (P ≤ 
0.05).  *NI is statistically different from IBTX and NLA (P ≤ 0.05).  
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3.98 vs. 5.41 and 5.15 ± 0.74 for MP100, MP60, and MP140, respectively).  In CAR arteries incubated 
with INDO, the MP140 ewes had a greater (P = 0.01) pD2 value compared to both MP60 and MP100 
ewes, which were similar (P = 0.53; 8.21 vs. 6.72 and 6.60 ± 0.15 for MP140, MP60, and MP100, 
respectively).  In CAR arteries incubated with NLA, the MP100 ewes had a lower (P ≤ 0.03) pD2 value 
compared with MP60 and MP140 ewes, which were similar (P = 0.45; 4.95 vs. 5.80 and 5.64 ± 0.34 for 
MP100, MP60, and MP140, respectively).  The BK dose response pD2 values for CAR arteries with no 
inhibitor and CAR arteries incubated with INDO were similar (P = 0.89; 7.17 and 7.16 ± 0.08 for no 
inhibitor and INDO, respectively), and both of these pD2 values were greater (P = 0.01) than those for 
CAR arteries incubated with IBTX or NLA (7.17 and 7.16 vs. 4.97 and 5.50 ± 0.22 for no inhibitor, INDO, 
IBTX, and NLA, respectively).   
 Maternal MP did not impact the Emax of the BK dose response curve in CAR arteries with no 
inhibitor (P = 0.45; Figure 2A), with IBTX (P = 0.20; Figure 2B), with INDO (P = 0.09; Figure 2C), or with 
NLA (P = 0.42; Figure 2D).   In MP60 ewes, the BK dose response Emax was similar (P = 0.79) between 
the curves for CAR arteries with no inhibitor and with CAR arteries incubated with INDO (Figure 3A), but 
the Emax was lower (P = 0.02) for CAR arteries with no inhibitor compared with arteries incubated with 
IBTX or NLA (Figure 3A). There were similar results in the MP100 ewes (Figure 3B), where CAR arteries 
with no inhibitor had a similar (P = 0.70) Emax to CAR arteries incubated with INDO, but had a lower (P = 
0.01) Emax compared to CAR arteries incubated with IBTX or NLA (Figure 3B). The same held true in the 
MP140 ewes (Figure 3C).  The CAR arteries with no inhibitor had similar a similar (P = 0.65) Emax to CAR 
arteries incubated with INDO, but had a lower (P = 0.01) Emax compared to CAR arteries incubated with 
IBTX or NLA (Figure 3C).  Overall, the BK dose response Emax for CAR arteries with no incubator was 
similar (P = 0.79) to the Emax for CAR arteries incubated with INDO, but lower (P = 0.01) compared to 
CAR arteries incubated with IBTX or NLA (Figure 4A).  
Cotyledonary artery bradykinin dose response curves in the absence or presence of an inhibitor.  
There were no interactions (P ≥ 0.92) on the BK dose response curves in COT arteries with no inhibitor 
(Figure 5.5A), or for COT arteries incubated with IBTX (Figure 5.5B), INDO (Figure 5.5C), or INDO 
(Figure 5.5D).  There was no treatment by dose by dose response curve interaction (P = 0.99), so the 
dose by dose response curve interaction, dose main effect, and dose response curve main effect were 
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analyzed for each treatment (MP60, MP100, and MP140) individually (Figure 5.6).  There were no dose 
by dose response curve interactions (P ≥ 0.52) on the BK dose response curves in MP60 (Figure 5.6A), 
MP100 (Figure 5.6B), or MP140 (Figure 5.6C) ewes.  
  
 
 
 
 
 
 
 
 
Cotyledonary artery EC50, pD2, and Emax values.  In COT arteries, the pD2 value for the BK dose 
response curve was lower (P = 0.01) in MP100 ewes compared with MP60 and MP140 ewes, which were 
similar (P = 0.13; 7.36 vs. 7.81 and 8.05 ± 0.13 for MP100, MP60, and MP140, respectively).  In COT 
arteries incubated with IBTX, the pD2 value was higher P = 0.01) in MP100 ewes compared with MP140, 
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Figure 5.5. The interaction of maternal metabolizable protein (MP) level and 
bradykinin (BK) dose on the BK dose response curve in cotyledonary arteries (A) in 
the absence of an inhibitor (no inhibitor, NI), (B) after incubation with iberiotoxin 
(IBTX), (C) after incubation with indomethacin (INDO), and (D) after incubation with 
N(omega)-L-arginine methyl ester (NLA). Maternal diets were formulated to be 
isocaloric and provide 60% of MP requirements (MP60), 100% of MP requirements 
(MP100), or 140% of MP requirements (MP140).  Diets were fed from day 100 to 130 
of gestation.   
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with MP60 being intermediate (P ≥ 0.11; 8.67 vs. 7.83 ± 0.19 and 8.26 ± 0.19 for MP100, MP140, and 
MP60, respectively).  In COT arteries incubated with INDO, MP60 ewes had a greater (P = 0.01) pD2 
value compared with MP140 ewes, with MP100 ewes being intermediate (P ≥ 0.11; 8.15 vs. 7.60 ± 0.15 
and 7.95 ± 0.16 for MP60, MP140, and MP100, respectively).   In COT arteries incubated with NLA, 
MP100 ewes had a lower (P = 0.01) pD2 value compared with MP60 and MP140 ewes, which were 
intermediate (P = 0.09; 6.37 vs. 7.90 and 8.42 ± 0.35 for MP100, MP60, and MP140, respectively).  The 
BK dose response curves for COT arteries incubated with INDO and NLA had similar (P ≥ 0.27) pD2 
values compared to COT arteries with no inhibitor (7.90 and 7.69 vs. 7.76 ± 0.14 for INDO, NLA, and no 
inhibitor, respectively).  The pD2 value for COT arteries with no inhibitor was lower (P = 0.01) compared 
with COT arteries incubated with IBTX (7.76 vs. 8.23 ± 0.10 for no inhibitor and IBTX, respectively).  
Maternal MP did not affect the Emax of the BK dose response curve in COT arteries with no inhibitor (P = 
0.61; Figure 5.5A), with IBTX (P = 0.84; Figure 5.5B), with INDO (P = 0.95; Figure 5.5C), or with NLA (P = 
0.06; Figure 5.5D).   The Emax was similar (P ≥ 0.64) for all dose response curves within the MP60 (Figure 
5.6A) and MP140 ewes (Figure 5.6C), but in MP100 ewes, the Emax was greater (P = 0.01) in COT 
arteries incubated with NLA compared with COT arteries with no inhibitor (Figure 5.6B).  Overall, the BK 
dose response Emax for COT arteries with no incubator was similar (P = 0.11) to the Emax for COT arteries 
incubated with IBTX, INDO, and NLA (Figure 5.4B). 
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Figure 5.6. The effect of dose response curve (DRC) in cotyledonary (COT) arteries 
on the bradykinin (BK) DRC within each dietary treatment.  Ewes were fed diets 
formulated to provide (A) 60% of metabolizable protein (MP) requirements (MP60), 
(B) 100% of MP requirements (MP100), and (C) 140% of MP requirements 
(MP140). The COT arteries were incubated with no inhibitor (NI) or incubated with 
iberiotoxin (IBTX), indomethacin (INDO), or N(omega)-L-arginine methyl ester 
(NLA).  Diets were fed from day 100 to 130 of gestation. †NI is statistically different 
from IBTX, NLA, and INDO (P ≤ 0.05).  *NI is statistically different from IBTX and 
NLA (P ≤ 0.05).  #NI is statistically different from INDO (P ≤ 0.05).   
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Endothelial nitric oxide synthase, GUCY1B3, BKR1, and BKR2 mRNA expression   
The mRNA expression data is expressed as a ratio of the gene of interest to 18s.  Maternal 
metabolizable protein level did not significantly influence the mRNA expression of eNOS (P = 0.54; 1.32, 
1.49, 1.42 ± 0.10 arbitrary units for MP60, MP80, and MP100, respectively), GUCY1B3 (P = 0.47; 1.25, 
1.34, 1.34 ± 0.06 arbitrary units for MP60, MP80, and MP100, respectively), BKR1 (P = 0.28; 1.15, 1.34, 
1.36 ± 0.10 arbitrary units for MP60, MP80, and MP100, respectively), or BKR2 (P = 0.30; 1.32, 1.63, 
1.44 ± 0.14 arbitrary units for MP60, MP80, and MP100, respectively) in the CAR arteries.  Similarly, in 
the COT arteries, maternal metabolizable protein did not significantly influence the mRNA expression of 
eNOS (P = 0.93; 1.24, 1.26, 1.25 ± 0.04 arbitrary units for MP60, MP80, and MP100, respectively), 
GUCY1B3 (P = 0.92; 1.22, 1.20, 1.23 ± 0.16 arbitrary units for MP60, MP80, and MP100, respectively), 
BKR1 (P = 0.71; 1.10, 1.14, 1.13 ± 0.03 arbitrary units for MP60, MP80, and MP100, respectively), or 
BKR2 (P = 0.26; 1.45, 1.34, 1.31 ± 0.06 arbitrary units for MP60, MP80, and MP100, respectively). 
 
Discussion 
 This study aimed to investigate the effects of maternal metabolizable protein level on ewe body 
weight, fetal mass and size, placental characteristics, bradykinin-induced vasorelaxation of maternal and 
fetal placental arteries, the mechanisms of bradykinin-induced vasorelaxation in placental arteries, and 
the mRNA expression of key proteins and receptors in the placental arteries in near term ewes.  This is 
an important study as no data exist on the role of maternal MP in bradykinin-induced vasodilation in 
maternal and fetal placental arteries or the mechanisms responsible for this vasodilation in sheep.   
Limited data exist on the effects of maternal protein level and vascular function.  Brawley et al. 
(2003) found that male offspring from rats fed a low protein diet during gestation had a decreased 
sensitivity to bradykinin in mesenteric arteries.  Maternal protein restriction has also been shown to 
decrease sensitivity to acetylcholine, another endothelium-dependent vasodilator in the uterine artery of 
pregnant rats (Itoh et al., 2002), in the mesenteric arteries of virgin and pregnant rats (Koumentaki et al., 
2002), in mesenteric arteries of pregnant female offspring (Torrens et al., 2002), and in mesenteric 
arteries of male offspring (Brawley et al., 2003).  While the results from these rodent studies are 
interesting, it is difficult to compare the data to the current study.  None of these studies examined the 
 123 
 
effect of a maternal protein level on placental arteries, and some of the studies were measuring vascular 
responses in the offspring rather than the dam (Itoh et al., 2002; Torrens et al., 2002; Brawley et al., 
2003).  Further, while both acetylcholine and bradykinin elicit vasorelaxation via endothelium-dependent 
pathways, studying vascular responses to acetylcholine does not give any indication how these arteries 
would respond to bradykinin.  Wirth et al. (1996) studied vascular responses to acetylcholine and 
bradykinin in spontaneously hypertensive rats and control rats and found that the hypertensive rats had 
impaired responses to bradykinin throughout life, but that impairments to acetylcholine-relaxation were 
only observed in elderly rats.  Wirth et al. (1996) concluded that vascular dysfunction may be more closely 
related to impaired bradykinin-induced vasorelaxation than with acetylcholine-induced responses.  This 
makes the current study very important as it, along with Lekatz (Chapter 3), are the first to study the 
effects of maternal protein level on bradykinin-induced vascular responses in placental arteries in sheep.  
 Lekatz (Chapter 3) found that despite no negative effects of restricting maternal MP on fetal or 
placental measurements, the vascular function of placental arteries were altered.  Ewes restricted to 60 or 
80% of MP from day 100 to 130 of gestation had fetal placental arteries that were more sensitive to BK-
induced vasodilation.  In the current study, there was an overall treatment effect on the BK dose response 
curve in fetal placental arteries, but when the means were separated, no significant differences existed.  
However, the pD2 value of the BK dose response curve in fetal placental arteries was lower in ewes 
receiving 100% of MP requirements compared to ewes that were receiving either 60 or 140% of MP 
requirements.  This means that there was a leftward shift of the BK dose response curve in the MP60 and 
MP140 ewes, which indicates these ewes had fetal placental vessels that were more sensitive to BK-
induced vasodilation compared with ewes meeting MP requirements during late gestation.  
Currently, the exact mechanism of bradykinin-induced vasorelaxation in placental arteries of 
sheep is unknown.  Further, how maternal MP level might affect these mechanisms is also unknown.  
This novel study is important since understanding how bradykinin elicits vasorelaxation in placental 
arteries may lead to potential therapeutics for compromised pregnancies.   
Bradykinin is an endothelium-dependent vasorelaxant. Endothelium-dependent vasorelaxants 
elicit vasodilation through one of three mechanisms including nitric oxide (NO; Ignarro et al., 1987; 
Furchgott, 1988; Moncada et al., 1991; Lamontagne et al., 1992), endothelium-derived hyperpolarizing 
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factor (EDHF; Beny and Brunet, 1988; Chen et al., 1988; Feletou and Vanhoutte, 1988; Tayler et al., 
1988) and prostacyclin (PGI2; Lamontagne et al., 1992) pathways.  In order to study which pathway is 
responsible for bradykinin-induced relaxation in maternal and fetal placental arteries in sheep, each of 
these pathways needs to be blocked before obtaining a bradykinin dose response curve.  Iberiotoxin 
(IBTX) is a selective inhibitor of the high-conductance calcium-activated potassium channels and, 
therefore, was used to inhibit the EDHF pathway.  Indomethacin, a cyclooxygenase inhibitor, was used to 
block the PGI2 pathway, and N(omega)-L-arginine methyl ester (NLA) an inhibitor of nitric oxide synthase 
(NOS) was used to block the NO pathway.  The resulting BK dose response curves were compared to a 
BK dose response curve in the absence of an inhibitor.  It appears that in maternal placental arteries, 
bradykinin-induced vasodilation is mediated by both EDHF and NO, but not by PGI2. Interestingly, the 
data from the fetal placental arteries indicates that a novel pathway may be responsible for bradykinin-
induced vasodilation in fetal placental arteries in sheep.   
In the maternal placental arteries, there was no treatment by dose interaction on the vascular 
responses to the BK dose response curves in the presence of inhibitors (IBTX, INDO, and NLA).  The pD2 
values of the BK dose response curve with no inhibitor (NI) and with INDO were similar.  Further the 
maximal response to BK was similar between the NI and INDO dose response curves.  The similar pD2 
and Emax values for NI and INDO indicate that indomethacin does not prevent bradykinin-induced 
vasorelaxation in maternal placental arteries, and perhaps bradykinin does not elicit vasorelaxation 
through the PGI2 pathway in maternal placental arteries.   
Pregnant sheep have elevated levels of prostaglandins and a high venous-arterial concentration 
difference of prostaglandins exists across the gravid uterus of sheep (Mitchell et al., 1980).  Further, the 
uterine vascular bed has been shown to produce various prostaglandins (Terragno, et al., 1974).  
Magness et al. (1985) demonstrated that the pregnant uterine artery of sheep is capable of producing 
PGI2.  In addition, uterine artery endothelial cells from pregnant sheep have higher protein expression of 
cyclooxygenase-I and increased prostacyclin production compared with uterine artery endothelial cells 
from nonpregnant sheep (Jobe et al., 2013).  Prostacyclin levels were not measured in the current study, 
but despite the possibility of increased PGI2 during late gestation, it does not appear that bradykinin 
induces vasorelaxation of the maternal placental arteries via release of prostacyclin.   This is in 
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agreement with Chaudhuri et al. (1993) who investigated the role of both NO and PGI2 in maintaining low 
vascular tone of the umbilical artery and vein in humans.  Results from the Chaudhuri et al. (1993) study 
indicate that NO is more important than PGI2 for maintaining low vascular tone of feto-placental arteries.  
When maternal placental vessels were subjected to IBTX and NLA, the curves showed a 
rightward shift compared to the no inhibitor curve, which means that both IBTX and NLA did prevent 
bradykinin-induced vasorelaxation in maternal placental arteries, indicating that both EDHF and NO are 
important for bradykinin-induced vasorelaxation in maternal placental arteries in sheep.   
Placental endothelial NO synthase specific activity and NO production is increased in pregnancy 
in sheep (Kwon et al., 2004; Vonnahme et al., 2005).  Inhibition of NOS by NLA in late pregnant sheep 
decreases uterine venous NO second messenger cGMP levels (Rosenfeld et al., 1996) and uterine blood 
flow (Miller et al., 1999).  Therefore, vasodilation during the last three months is partly mediated through 
the rise in NO production.  It is not surprising that inhibiting NOS in near term sheep attenuates maternal 
placental arterial response to bradykinin.   
In the fetal placental arteries, there was no treatment by dose interaction on the vascular 
responses to the BK dose response curves in the presence of inhibitors (IBTX, INDO, and NLA).  
Interestingly, none of the inhibitors used prevented vasorelaxation in the fetal placental arteries; all of the 
dose response curves had similar Emax values.  The observed relaxation in the fetal placental arteries is 
likely due to an EDHF that is not inhibited by IBTX.  Indeed, data regarding EDHF-type responses are 
continually growing, both in the number of studies and in complexity.  These EDHF-type responses may 
be mediated by several factors or pathways depending on the type of vasculature, the species, and the 
physiological environment (reviewed in Luksha et al., 2009).  Luksha et al. (2010) investigated the 
potential role of epoxyeicosatrienoic acids, which are metabolites of arachidonic acid through the 
CYP2C9 pathway, hydrogen peroxide, and communication between gap junctions as EDHF-type 
responses in human myometrial arteries.  Results from the Luksha et al. (2010) study show that the 
myometrial arteries relaxed in the presence of NO and PGI2 inhibitors, but that the combination of NO, 
PGI2, and hydrogen peroxide inhibitors attenuated the bradykinin response.  Similarly, inhibiting NO, 
PGI2, and gap junction communication (with 18-a-glycyrrhetinic acid) also decreased arterial response to 
bradykinin.   Baragatti et al. (2007) observed relaxation of the mouse ductus arteriosus in response to 
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bradykinin despite inhibiting K+ channels, prostaglandins, and NO.  This laboratory hypothesized that 
hydrogen sulfide might manifest itself once the classical active relaxants were inhibited (Baragatti et al., 
2013).  Indeed, only after inhibiting the ductus arteriosus with a cocktail to block prostaglandins, NO, K+ 
channels, and enzymes responsible for hydrogen sulfide production, was bradykinin-induced relaxation 
prevented (Baragatti et al., 2013).  Hydrogen sulfide is a relatively newly described endothelium-
dependent relaxing factor, but there is evidence to support its role in mediating vascular tone (reviewed in 
Wang, 2009).  The data of Lukska et al. (2010) and Baragatti et al. (2007; 2013) indicate that there are 
endothelium-dependent relaxants other than the classical vasorelaxants (NO and PGI2) that are 
important for controlling vascular relaxation.  In the current study, fetal placental arteries relaxed despite 
blocking K+ channels, cyclooxygenase 1 and 2, and nitric oxide synthase, which is likely due to an EDHF-
type vasorelaxant.  Further studies are needed to determine exactly what mechanism is responsible for 
this vasorelaxation in fetal placental arteries.   
It is interesting to note that in the current study, the maternal and fetal placental arteries 
responded to bradykinin through different mechanisms.  This is important when considering possible 
therapeutics for compromised pregnancies.  Care should be taken to address what vascular beds are the 
target of such therapeutics, as the two vasculature systems are mediated by different mechanisms.   
The mRNA expression of the BK receptors 1 and 2 (BKR1 and BKR2) was analyzed in the 
present study.  Because one of the mechanisms of BK-induced relaxation involves nitric oxide, the mRNA 
of eNOS and it’s receptor soluble guanylate cyclase was also analyzed.  The mRNA expression of all 
genes investigated was similar among all treatments in both maternal and fetal placental arteries.  This is 
similar to Lekatz (Chapter 3), where maternal MP restriction did alter mRNA expression of these genes.  
Lekatz (Chapter 3), observed an overall treatment effect on the maternal and fetal placental arterial 
response to BK.  Because of those findings, one might expect to see differences among the three MP 
diets in mRNA expression of BK receptors 1 and 2 in these arteries; however, this was not the case.  This 
is important because it stresses the importance of vascular function studies rather than focusing only on 
mRNA expression data.  
Maternal MP did not impact ewe BW at slaughter or the percentage change from day 100 in ewe 
body weight at slaughter.  Lekatz (Chapter 3) found that restricting MP to 60% of the requirements from 
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day 100 to 130 of gestation reduced the percentage change in BW at day 130 compared with ewes 
meeting 100% of MP requirements; however, ewes from both groups had similar BW at slaughter.  In the 
current study, there was a treatment by day of gestation interaction for ewe BW throughout gestation; 
however, when the means were separated, substantial differences were not revealed (P > 0.05). Van 
Emon et al. (2013), fed similar diets to a larger group of ewes (n = 169) and found that at lambing, ewe 
BW increased linearly as MP in the diet increased.  It is possible that a linear effect on ewe BW and the 
percentage change in ewe BW would have been observed in the current study if a larger sample size was 
used or if the ewes were fed the diets through gestation.   
Maternal undernutrition has been shown to cause fetal growth restriction in sheep (Charlton and 
Johengen, 1985; Holst et al., 1986; Faichney and White, 1987; Holst et al., 1992; Bloomfield et al., 2000; 
Vonnahme et al., 2003; Scheaffer et al., 2004; Lekatz et al., 2010a, 2010b; Lemley et al., 2012).  In the 
current study, maternal MP level did not alter fetal weight, fetal CCR, or fetal abdominal girth, which 
indicates that fetal mass and size is more dependent on the overall amount of calories received rather 
than the level of MP in the maternal diet.  This is similar to Lekatz (Chapter 3), where MP was restricted to 
60 or 80% of requirements during late gestation without impacting fetal growth measurements.  When 
isocaloric diets that differed in the level of MP were fed to ewes from day 100 to lambing, there was no 
difference in lamb birth weight (Van Emon et al., 2013), which indicates that even if the MP treatments 
are fed through lambing, there are no negative effects on fetal weight.  Also of importance, decreasing the 
MP level to 60% or increasing the MP to 140% of NRC requirements did not alter the percentage of 
assisted births or the percentage of lambs requiring treatment for illness at birth, which also indicates that 
decreasing MP level during gestation does not have negative effects on birthing or neonatal health and 
that increasing MP level does not have any additional benefit to birthing or neonatal health (Van Emon et 
al., 2013).   
 Maternal nutrient restriction in sheep has also been linked to altered placental weight in some 
studies (Charlton and Johengen, 1985; Faichney and White, 1987; McCrabb et al., 1991, 1992a, 1992b; 
Heasman et al, 1998; McMullen et al., 2005) but not in others (Vonnahme et al., 2003; Scheaffer et al., 
2004; Holst et al., 1992; Bloomfield et al., 2000; Lemley et al., 2012; Lekatz et al., 2010a, 2010b). It is 
likely that the effects of maternal nutrition on placental characteristics vary among studies due to the 
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timing and severity of nutrient restriction.  In the current study, maternal MP level from day 100 to 130 of 
gestation did not alter total placentome weight, placentome number, CAR weight, or COT weight.  
Further, fetal membrane weight, fetal fluid volume, and the fetal weight to placental weight ratio did not 
differ among treatments in the present study.  This again indicates that not meeting or exceeding MP 
requirements during gestation does not impact placental measurements.  The placental data from the 
current study mirrors the results from Lekatz (Chapter 3), where ewes were fed 60 or 80% of MP 
requirements without altering placental characteristics by day 130.   
 This novel study investigates the mechanisms of bradykinin-induced vasodilation in the maternal 
and fetal placental arteries in near term sheep.  There are three important findings from this study.  First, 
bradykinin-induced vasorelaxation in the maternal arteries appears to be partly due to both an EDHF 
involved with K+ channels and nitric oxide, but not a result of PGI2.  Second, fetal placental arteries 
relaxed in the presence of inhibitors for K+ channels, nitric oxide synthase, and cyclooxygenase, which 
indicates there is an endothelium-dependent mechanism that has not yet been characterized in fetal 
placental arteries.  Further studies are needed to investigate what this EDHF-type response might be.  
Finally, the maternal and fetal placental vasculature beds respond to bradykinin through different 
mechanisms.  This becomes important when considering possible future therapeutics for compromised 
pregnancies.  
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CHAPTER 6. GENERAL CONCLUSIONS AND FUTURE DIRECTIONS 
 
General conclusions 
 
 To my knowledge, very limited data exist on the effects of maternal metabolizable protein level on 
placental vascular function in the ewe.  Because maternal nutrition during gestation has been linked to 
IUGR (Chandler et al., 1985; Barker et al., 1990; Barker et al., 1993; Wallace et al., 2001; Carr et al., 
2012; Lemley et al., 2012), and because blood flow across the placenta is so important for normal fetal 
growth and development (Ford, 1995; Meschia, 1983; Redmer et al., 2004; Reynolds et al., 2005; 
Reynolds et al., 2006; Vonnahme et al., 2013), it is critical to understand how maternal protein levels 
might alter placental arteriole function.   
 These results indicate that while restricting or increasing maternal metabolizable protein during 
late gestation does not impair fetal or placental growth at day 130 of gestation, it may alter placental 
arterial function, particularly of the fetal placental arteries.   Such adaptations to the placental 
cardiovascular system may play a part in programming of the fetal cardiovascular system and potential 
cardiovascular diseases later in life (Dahri et al., 1991; Langley et al., 1994; Ozaki et al., 2001; Itoh et al., 
2002; Koumentaki et al., 2002; Torrens et al., 2002; Brawley et al., 2003).  
 Currently there are no good therapeutics for IUGR, and this is mainly due to a lack of knowledge 
on the mechanisms of IUGR.  The results from this dissertation indicate that bradykinin-induced 
vasodilation of the maternal and fetal placental arteries is achieved through different pathways.  This 
information is important when developing therapeutics for compromised pregnancies.   
 Overall, these studies indicate that maternal protein level during late gestation likely plays a key 
role in the function of the placental vascular system.  Further, the maternal and fetal placental vascular 
beds should be viewed as two separate systems since the vasodilatory mechanisms of the arteries are 
likely mediated through different pathways.  
Future directions 
 The data in these studies contribute to the small number of studies regarding the role of maternal 
metabolizable protein level during gestation on placental function in sheep; however, it is important to 
remember that vascular function measurements were obtained at one time point, day 130 of gestation.  
Future studies should be designed to gather vascular reactivity data in sheep at different time points 
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throughout gestation.  Also, the protein studies presented in this dissertation focus on maternal diet 
during late gestation (day 100 to 130 of gestation).  By this time, the placenta has reached its maximal 
size (Stegeman, 1974); therefore, studies investigating the effect of maternal protein level in sheep during 
early gestation may result in more dramatic vascular function alterations.  For this reason, similar studies 
focusing on maternal protein level earlier in pregnancy are warranted.   
 Chapter 5 provides novel information on how bradykinin-induced vasodilation is mediated in the 
placental arteries.  Given this information, future studies should be designed to better pinpoint the 
mechanism involved.  For example, rather than incubating arterial rings with only one inhibitor, 
combinations of two or more inhibitors should be used to more exactly detect how big of a role each of 
the endothelium-dependent pathways has in placental vasorelaxation.  Because the fetal placental 
arteries relaxed in the presence of all inhibitors tested, future studies are needed to determine what 
endothelial-derived hyperpolarizing like factor is mediating vasodilation of the fetal placental arteries.  In 
addition, studies involving the use of bradykinin receptor 2 may be useful to insure that vasodilation is 
resulting from bradykinin binding to this receptor, as classically believed.   
 In summary, these studies contribute to the knowledge of maternal protein restriction during late 
gestation in ewes and provide information on the mechanisms regulating bradykinin-induced vasodilation 
in the ovine placenta arteries.  The results are interesting and open the door for future studies including 
ones that are designed for multiple tissue collections.  Another future step should include feeding different 
levels of metabolizable protein during different times of gestation, particularly earlier in gestation when 
placental development is rapid.  Finally, additional studies to better understand the mechanisms 
bradykinin-induced vasodilation in the placental arteries are needed if future therapeutics for 
compromised pregnancies will target the placental vascular beds. 
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